/*! For license information please see main.665f88dc.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function u(e,t){return e.indexOf(t)}function c(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function p(e){return e.length}function f(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,b=0,y=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function P(){return g=y>0?c(_,--y):0,v--,10===g&&(v=1,h--),g}function T(){return g=y<b?c(_,y++):0,v++,10===g&&(v=1,h++),g}function k(){return c(_,y)}function C(){return y}function x(e,t){return d(_,e,t)}function F(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function A(e){return h=v=1,b=p(_=e),y=0,[]}function E(e){return _="",e}function N(e){return s(x(y-1,O(91===e?e+2:40===e?e+1:e)))}function R(e){for(;(g=k())&&g<33;)T();return F(e)>2||F(g)>3?"":" "}function M(e,t){for(;--t&&T()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return x(e,C()+(t<6&&32==k()&&32==T()))}function O(e){for(;T();)switch(g){case e:return y;case 34:case 39:34!==e&&39!==e&&O(g);break;case 40:41===e&&O(e);break;case 92:T()}return y}function L(e,t){for(;T()&&e+g!==57&&(e+g!==84||47!==k()););return"/*"+x(t,y-1)+"*"+o(47===e?e:T())}function D(e){for(;!F(k());)T();return x(e,y)}var z="-ms-",I="-moz-",Z="-webkit-",j="comm",V="rule",B="decl",W="@keyframes";function U(e,t){for(var n="",r=f(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function H(e,t,n,r){switch(e.type){case"@import":case B:return e.return=e.return||e.value;case j:return"";case W:return e.return=e.value+"{"+U(e.children,r)+"}";case V:e.value=e.props.join(",")}return p(n=U(e.children,r))?e.return=e.value+"{"+n+"}":""}function J(e,t){switch(function(e,t){return(((t<<2^c(e,0))<<2^c(e,1))<<2^c(e,2))<<2^c(e,3)}(e,t)){case 5103:return Z+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Z+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Z+e+I+e+z+e+e;case 6828:case 4268:return Z+e+z+e+e;case 6165:return Z+e+z+"flex-"+e+e;case 5187:return Z+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Z+e+z+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return Z+e+z+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return Z+e+z+l(e,"shrink","negative")+e;case 5292:return Z+e+z+l(e,"basis","preferred-size")+e;case 6060:return Z+"box-"+l(e,"-grow","")+Z+e+z+l(e,"grow","positive")+e;case 4554:return Z+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,Z+"$1"),/(image-set)/,Z+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,Z+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Z+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,Z+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(p(e)-1-t>6)switch(c(e,t+1)){case 109:if(45!==c(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+I+(108==c(e,t+3)?"$3":"$2-$3"))+e;case 115:return~u(e,"stretch")?J(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==c(e,t+1))break;case 6444:switch(c(e,p(e)-3-(~u(e,"!important")&&10))){case 107:return l(e,":",":"+Z)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Z+(45===c(e,14)?"inline-":"")+"box$3$1"+Z+"$2$3$1"+z+"$2box$3")+e}break;case 5936:switch(c(e,t+11)){case 114:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Z+e+z+e+e}return e}function $(e){return E(G("",null,null,null,[""],e=A(e),0,[0],e))}function G(e,t,n,r,a,i,s,c,d){for(var f=0,h=0,v=s,b=0,y=0,g=0,_=1,w=1,S=1,x=0,F="",A=a,E=i,O=r,z=F;w;)switch(g=x,x=T()){case 40:if(108!=g&&58==z.charCodeAt(v-1)){-1!=u(z+=l(N(x),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:z+=N(x);break;case 9:case 10:case 13:case 32:z+=R(g);break;case 92:z+=M(C()-1,7);continue;case 47:switch(k()){case 42:case 47:m(K(L(T(),C()),t,n),d);break;default:z+="/"}break;case 123*_:c[f++]=p(z)*S;case 125*_:case 59:case 0:switch(x){case 0:case 125:w=0;case 59+h:y>0&&p(z)-v&&m(y>32?Q(z+";",r,n,v-1):Q(l(z," ","")+";",r,n,v-2),d);break;case 59:z+=";";default:if(m(O=q(z,t,n,f,h,a,c,F,A=[],E=[],v),i),123===x)if(0===h)G(z,t,O,O,A,i,v,c,E);else switch(b){case 100:case 109:case 115:G(e,O,O,r&&m(q(e,O,O,0,0,a,c,F,a,A=[],v),E),a,E,v,c,r?A:E);break;default:G(z,O,O,O,[""],E,0,c,E)}}f=h=y=0,_=S=1,F=z="",v=s;break;case 58:v=1+p(z),y=g;default:if(_<1)if(123==x)--_;else if(125==x&&0==_++&&125==P())continue;switch(z+=o(x),x*_){case 38:S=h>0?1:(z+="\f",-1);break;case 44:c[f++]=(p(z)-1)*S,S=1;break;case 64:45===k()&&(z+=N(T())),b=k(),h=v=p(F=z+=D(C())),x++;break;case 45:45===g&&2==p(z)&&(_=0)}}return i}function q(e,t,n,r,o,i,u,c,p,m,h){for(var v=o-1,b=0===o?i:[""],y=f(b),g=0,_=0,S=0;g<r;++g)for(var P=0,T=d(e,v+1,v=a(_=u[g])),k=e;P<y;++P)(k=s(_>0?b[P]+" "+T:l(T,/&\f/g,b[P])))&&(p[S++]=k);return w(e,t,n,0===o?V:c,p,m,h)}function K(e,t,n){return w(e,t,n,j,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,B,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,a=0;r=a,a=k(),38===r&&12===a&&(t[n]=1),!F(a);)T();return x(e,y)},X=function(e,t){return E(function(e,t){var n=-1,r=44;do{switch(F(r)){case 0:38===r&&12===k()&&(t[n]=1),e[n]+=Y(y-1,t,n);break;case 2:e[n]+=N(r);break;case 4:if(44===r){e[++n]=58===k()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=T());return e}(A(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var u=0;u<i.length;u++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[u]):i[u]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case B:e.return=J(e.value,e.length);break;case W:return U([S(e,{value:l(e.value,"@","@"+Z)})],r);case V:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return U([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return U([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,z+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var u,c,d=[H,(c=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&c(e)})],p=function(e){var t=f(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){u=n,U($(e?e+"{"+t.styles+"}":t.styles),p),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},u=function(e){return null!=e&&"boolean"!==typeof e},c=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return f={name:t,styles:n,next:f},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function p(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return f={name:n.name,styles:n.styles,next:f},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)f={name:r.name,styles:r.styles,next:f},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=p(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":u(i)&&(r+=c(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=p(e,t,i);switch(o){case"animation":case"animationName":r+=c(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)u(i[l])&&(r+=c(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=f,o=n(e);return f=a,p(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var f,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";f=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=p(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=p(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,u="";null!==(l=m.exec(o));)u+="-"+l[1];return{name:r(o)+u,styles:o,next:f}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return Z}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function u(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var c=n(2065),d={black:"#000",white:"#fff"},p={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},f={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},b={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},y={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,c.$n)(e.main,a):"dark"===t&&(e.dark=(0,c._j)(e.main,o)))}function P(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,u=e.tonalOffset,P=void 0===u?.2:u,T=(0,a.Z)(e,g),k=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),C=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:f[200],light:f[50],dark:f[400]}:{main:f[500],light:f[300],dark:f[700]}}(n),x=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),F=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[700],light:b[500],dark:b[900]}}(n),A=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[800],light:y[500],dark:y[900]}}(n),E=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function N(e){return(0,c.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var R=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,u=e.darkShade,c=void 0===u?700:u;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,P),S(t,"dark",c,P),t.contrastText||(t.contrastText=N(t.main)),t},M={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:R({color:k,name:"primary"}),secondary:R({color:C,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:R({color:x,name:"error"}),warning:R({color:E,name:"warning"}),info:R({color:F,name:"info"}),success:R({color:A,name:"success"}),grey:p,contrastThreshold:l,getContrastText:N,augmentColor:R,tonalOffset:P},M[n]),T)}var T=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var k={textTransform:"uppercase"},C='"Roboto", "Helvetica", "Arial", sans-serif';function x(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?C:o,l=n.fontSize,u=void 0===l?14:l,c=n.fontWeightLight,d=void 0===c?300:c,p=n.fontWeightRegular,f=void 0===p?400:p,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,b=void 0===v?700:v,y=n.htmlFontSize,g=void 0===y?16:y,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,T);var P=u/14,x=w||function(e){return"".concat(e/g*P,"rem")},F=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:x(t),lineHeight:n},s===C?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},A={h1:F(d,96,1.167,-1.5),h2:F(d,60,1.2,-.5),h3:F(f,48,1.167,0),h4:F(f,34,1.235,.25),h5:F(f,24,1.334,0),h6:F(h,20,1.6,.15),subtitle1:F(f,16,1.75,.15),subtitle2:F(h,14,1.57,.1),body1:F(f,16,1.5,.15),body2:F(f,14,1.43,.15),button:F(h,14,1.75,.4,k),caption:F(f,12,1.66,.4),overline:F(f,12,2.66,1,k)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:x,fontFamily:s,fontSize:u,fontWeightLight:d,fontWeightRegular:f,fontWeightMedium:h,fontWeightBold:b},A),S,{clone:!1})}function F(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var A=["none",F(0,2,1,-1,0,1,1,0,0,1,3,0),F(0,3,1,-2,0,2,2,0,0,1,5,0),F(0,3,3,-2,0,3,4,0,0,1,8,0),F(0,2,4,-1,0,4,5,0,0,1,10,0),F(0,3,5,-1,0,5,8,0,0,1,14,0),F(0,3,5,-1,0,6,10,0,0,1,18,0),F(0,4,5,-2,0,7,10,1,0,2,16,1),F(0,5,5,-3,0,8,10,1,0,3,14,2),F(0,5,6,-3,0,9,12,1,0,3,16,2),F(0,6,6,-3,0,10,14,1,0,4,18,3),F(0,6,7,-4,0,11,15,1,0,4,20,3),F(0,7,8,-4,0,12,17,2,0,5,22,4),F(0,7,8,-4,0,13,19,2,0,5,24,4),F(0,7,9,-4,0,14,21,2,0,5,26,4),F(0,8,9,-5,0,15,22,2,0,6,28,5),F(0,8,10,-5,0,16,24,2,0,6,30,5),F(0,8,11,-5,0,17,26,2,0,6,32,5),F(0,9,11,-5,0,18,28,2,0,7,34,6),F(0,9,12,-6,0,19,29,2,0,7,36,6),F(0,10,13,-6,0,20,31,3,0,8,38,7),F(0,10,13,-6,0,21,33,3,0,8,40,7),F(0,10,14,-6,0,22,35,3,0,8,42,7),F(0,11,14,-7,0,23,36,3,0,9,44,8),F(0,11,15,-7,0,24,38,3,0,9,46,8)],E=["duration","easing","delay"],N={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},R={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function M(e){return"".concat(Math.round(e),"ms")}function O(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function L(e){var t=(0,r.Z)({},N,e.easing),n=(0,r.Z)({},R,e.duration);return(0,r.Z)({getAutoHeightDuration:O,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,u=r.delay,c=void 0===u?0:u;(0,a.Z)(r,E);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:M(i)," ").concat(l," ").concat("string"===typeof c?c:M(c))})).join(",")}},e,{easing:t,duration:n})}var D={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},z=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function I(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,c=void 0===l?{}:l,d=e.transitions,p=void 0===d?{}:d,f=e.typography,m=void 0===f?{}:f,h=(0,a.Z)(e,z);if(e.vars)throw new Error((0,o.Z)(18));var v=P(c),b=(0,s.Z)(e),y=(0,i.Z)(b,{mixins:u(b.breakpoints,n),palette:v,shadows:A.slice(),typography:x(v,m),transitions:L(p),zIndex:(0,r.Z)({},D)});y=(0,i.Z)(y,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,i.Z)(e,t)}),y)}var Z=I},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return P},isMuiElement:function(){return T},ownerDocument:function(){return C},ownerWindow:function(){return x},requirePropFactory:function(){return F},setRef:function(){return A},unstable_ClassNameGenerator:function(){return j},unstable_useEnhancedEffect:function(){return E},unstable_useId:function(){return O},unsupportedProp:function(){return L},useControlled:function(){return D},useEventCallback:function(){return z.Z},useForkRef:function(){return I.Z},useIsFocusVisible:function(){return Z.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),u=n(3366),c=n(8182),d=n(4419),p=n(5513),f=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),b=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],y=(0,f.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,u,c,d,p,f,m,h,v,b,y=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=y.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=y.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=y.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=y.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(u=y.typography)||null==(c=u.pxToRem)?void 0:c.call(u,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(p=(y.vars||y).palette)||null==(f=p[g.color])?void 0:f.main)?d:{action:null==(m=(y.vars||y).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(y.vars||y).palette)||null==(b=v.action)?void 0:b.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,p.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,f=n.component,m=void 0===f?"svg":f,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,P=void 0!==S&&S,T=n.titleAccess,k=n.viewBox,C=void 0===k?"0 0 24 24":k,x=(0,u.Z)(n,b),F=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:P,viewBox:C}),A={};P||(A.viewBox=C);var E=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(F);return(0,v.jsxs)(y,(0,i.Z)({as:m,className:(0,c.Z)(E.root,o),focusable:"false",color:w,"aria-hidden":!T||void 0,role:T?"img":void 0,ref:t},A,x,{ownerState:F,children:[r,T?(0,v.jsx)("title",{children:T}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var P=function(e,t){return function(){return null}};var T=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function k(e){return e&&e.ownerDocument||document}var C=k;var x=function(e){return k(e).defaultView||window};var F=function(e,t){return function(){return null}},A=n(2971).Z,E=n(5721).Z,N=n(885),R=0;var M=l.useId;var O=function(e){if(void 0!==M){var t=M();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,N.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(R+=1))}),[r]),o}(e)};var L=function(e,t,n,r,a){return null};var D=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,N.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},z=n(6702),I=n(792),Z=n(2763),j={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function u(){o=!1}function c(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var p=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",u,!0),t.addEventListener("pointerdown",u,!0),t.addEventListener("touchstart",u,!0),t.addEventListener("visibilitychange",c,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),u=n(5438),c=n(9140),d=n(2561),p=s,f=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?p:f},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,u.hC)(t,n,r);(0,d.L)((function(){return(0,u.My)(t,n,r)}));return null},b=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var p=h(t,n,s),f=p||m(d),b=!f("as");return function(){var y=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==y[0]||void 0===y[0].raw)g.push.apply(g,y);else{0,g.push(y[0][0]);for(var _=y.length,w=1;w<_;w++)g.push(y[w],y[0][w])}var S=(0,l.w)((function(e,t,n){var a=b&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var y in h={},e)h[y]=e[y];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,u.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,c.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=b&&void 0===p?m(a):f,S={};for(var P in e)b&&"as"===P||w(P)&&(S[P]=e[P]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=p,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},y=b.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){y[e]=y(e)}));var g=y;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return c},VO:function(){return a},W8:function(){return s},dt:function(){return u},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function u(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function c(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return u},_j:function(){return c},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},u="rgb",c=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(u+="a",c.push(t[3])),i({type:u,values:c})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function u(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function c(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return T},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),u=n(7312),c=["variant"];function d(e){return 0===e.length}function p(e){var t=e.variant,n=(0,o.Z)(e,c),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,u.Z)(e[t]):"".concat(d(r)?t:(0,u.Z)(t)).concat((0,u.Z)(e[t].toString()))})),r}var f=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function b(e){return 0===Object.keys(e).length}function y(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=p(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],u=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return u&&u.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[p(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var P=(0,l.Z)();function T(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?P:t,l=e.rootShouldForwardProp,u=void 0===l?S:l,c=e.slotShouldForwardProp,d=void 0===c?S:c,p=e.styleFunctionSx,T=void 0===p?f.Z:p,k=function(e){var t=b(e.theme)?n:e.theme;return T((0,i.Z)({},e,{theme:t}))};return k.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,c=t.name,p=t.slot,f=t.skipVariantsResolver,P=t.skipSx,T=t.overridesResolver,C=(0,o.Z)(t,m),x=void 0!==f?f:p&&"Root"!==p||!1,F=P||!1;var A=S;"Root"===p?A=u:p?A=d:y(e)&&(A=void 0);var E=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:A,label:l},C)),N=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var u=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:b(r)?n:r},a))}:e})):[],d=e;c&&T&&u.push((function(e){var t=b(e.theme)?n:e.theme,r=g(c,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),T(e,o)}return null})),c&&!x&&u.push((function(e){var t=b(e.theme)?n:e.theme;return w(e,_(c,t),t,c)})),F||u.push(k);var p=u.length-s.length;if(Array.isArray(e)&&p>0){var f=new Array(p).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(f))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(f))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:b(r)?n:r},a))});var m=E.apply(void 0,[d].concat((0,r.Z)(u)));return m};return E.withConfig&&(N.withConfig=E.withConfig),N}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,u=e.step,c=void 0===u?5:u,d=(0,a.Z)(e,s),p=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),f=Object.keys(p);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-c/100).concat(l,")")}function v(e,t){var r=f.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[f[r]]?n[f[r]]:t)-c/100).concat(l,")")}return(0,r.Z)({keys:f,values:p,up:m,down:h,between:v,only:function(e){return f.indexOf(e)+1<f.length?v(e,f[f.indexOf(e)+1]):m(e)},not:function(e){var t=f.indexOf(e);return 0===t?m(f[1]):t===f.length-1?h(f[t]):v(e,f[f.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var u={borderRadius:4},c=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,c.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var p=["breakpoints","palette","spacing","shape"];var f=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,c=e.spacing,f=e.shape,m=void 0===f?{}:f,h=(0,a.Z)(e,p),v=l(n),b=d(c),y=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:b,shape:(0,r.Z)({},u,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,o.Z)(e,t)}),y)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return G}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var u=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),c=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(u,c,d,p,f,m,h,v,b,y,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),P=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};P.propTypes={},P.filterProps=["gap"];var T=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["columnGap"];var k=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["rowGap"];var C=o(P,T,k,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),x=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),F=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),A=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function E(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var N=(0,r.Z)({prop:"width",transform:E}),R=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||E(t)}}))}return null};R.filterProps=["maxWidth"];var M=(0,r.Z)({prop:"minWidth",transform:E}),O=(0,r.Z)({prop:"height",transform:E}),L=(0,r.Z)({prop:"maxHeight",transform:E}),D=(0,r.Z)({prop:"minHeight",transform:E}),z=((0,r.Z)({prop:"size",cssProperty:"width",transform:E}),(0,r.Z)({prop:"size",cssProperty:"height",transform:E}),o(N,R,M,O,L,D,(0,r.Z)({prop:"boxSizing"}))),I=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),j=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),V=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),B=(0,r.Z)({prop:"letterSpacing"}),W=(0,r.Z)({prop:"textTransform"}),U=(0,r.Z)({prop:"lineHeight"}),H=(0,r.Z)({prop:"textAlign"}),J=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),I,Z,j,V,B,U,H,W),$={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:C.filterProps,positions:x.filterProps,palette:F.filterProps,shadows:A.filterProps,sizing:z.filterProps,spacing:i.ZP.filterProps,typography:J.filterProps},G={borders:_,display:w,flexbox:S,grid:C,positions:x,palette:F,shadows:A,sizing:z,spacing:i.ZP,typography:J},q=Object.keys($).reduce((function(e,t){return $[t].forEach((function(n){e[n]=G[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},u={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},c=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!u[e])return[e];e=u[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],c=l[o]||"";return Array.isArray(c)?c.map((function(e){return i+e})):[i+c]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],p=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],f=[].concat(d,p);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function b(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(c(n),r),i=e[n];return(0,a.k9)(e,i,o)}function y(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return b(e,t,r,n)})).reduce(i.Z,{})}function g(e){return y(e,d)}function _(e){return y(e,p)}function w(e){return y(e,f)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=p,w.propTypes={},w.filterProps=f;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,u=e.themeKey,c=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,u)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,c,e);return e===n&&"string"===typeof e&&(n=s(d,c,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function u(e){var o=e||{},c=o.sx,d=o.theme,p=void 0===d?{}:d;if(!c)return null;function f(e){var o=e;if("function"===typeof e)o=e(p);else if("object"!==typeof e)return e;if(!o)return null;var c=(0,i.W8)(p.breakpoints),d=Object.keys(c),f=c;return Object.keys(o).forEach((function(e){var c=l(o[e],p);if(null!==c&&void 0!==c)if("object"===typeof c)if(t[e])f=(0,a.Z)(f,n(e,c,p));else{var d=(0,i.k9)({theme:p},c,(function(t){return(0,r.Z)({},e,t)}));s(d,c)?f[e]=u({sx:c,theme:p}):f=(0,a.Z)(f,d)}else f=(0,a.Z)(f,n(e,c,p))})),(0,i.L7)(d,f)}return Array.isArray(c)?c.map(f):f(c)}return u}();u.filterProps=["sx"],t.Z=u},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return c}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},u=(0,r.Z)();var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:u;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var u=t[o];if(u.removed){if(u.value=e.join(r.slice(l,l+u.count)),l+=u.count,o&&t[o-1].added){var c=t[o-1];t[o-1]=t[o],t[o]=c}}else{if(!u.added&&a){var d=n.slice(s,s+u.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),u.value=e.join(d)}else u.value=e.join(n.slice(s,s+u.count));s+=u.count,u.added||(l+=u.count)}}var p=t[i-1];return i>1&&"string"===typeof p.value&&(p.added||p.removed)&&e.equals("",p.value)&&(t[i-2].value+=p.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,u=e.length,c=1,d=l+u,p=[{newPos:-1,components:[]}],f=this.extractCommon(p[0],t,e,0);if(p[0].newPos+1>=l&&f+1>=u)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*c;a<=c;a+=2){var o=void 0,d=p[a-1],f=p[a+1],m=(f?f.newPos:0)-a;d&&(p[a-1]=void 0);var h=d&&d.newPos+1<l,v=f&&0<=m&&m<u;if(h||v){if(!h||v&&d.newPos<f.newPos?(o=r(f),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=u)return s(n(i,o.components,t,e,i.useLongestToken));p[a]=o}else p[a]=void 0}c++}if(o)!function e(){setTimeout((function(){if(c>d)return o();m()||e()}),0)}();else for(;c<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,u=new t;function c(e,t,n){return n=i(n,{ignoreWhitespace:!0}),u.diff(e,t,n)}function d(e,t,n){return u.diff(e,t,n)}u.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},u.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var p=new t;function f(e,t,n){return p.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return p.diff(e,t,r)}p.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var b=new t;function y(e,t,n){return b.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||P()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function P(){throw new TypeError("Invalid attempt to spread non-iterable instance")}b.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var T=Object.prototype.toString,k=new t;function C(e,t,n){return k.diff(e,t,n)}function x(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===T.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=x(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=x(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}k.useLongestToken=!0,k.tokenize=p.tokenize,k.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(x(e,null,null,a),a,"  ")},k.equals=function(e,n){return t.prototype.equals.call(k,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var F=new t;function A(e,t,n){return F.diff(e,t,n)}function E(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var u=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(u))break;if(/^@@/.test(u))e.hunks.push(l());else{if(u&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(u));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var u=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==u&&"-"!==u&&" "!==u&&"\\"!==u)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===u?s++:"-"===u?l++:" "===u&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function N(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function R(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=E(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},u=0,c=n.fuzzFactor||0,d=0,p=0;function f(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++u>c)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,b=0,y=p+h.oldStart-1,g=N(y,d,v);void 0!==b;b=g())if(f(h,y+b)){h.offset=p+=b;break}if(void 0===b)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],P=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,P<0&&(P=0);for(var T=0;T<S.lines.length;T++){var k=S.lines[T],C=k.length>0?k[0]:" ",x=k.length>0?k.substr(1):k,F=S.linedelimiters[T];if(" "===C)P++;else if("-"===C)o.splice(P,1),i.splice(P,1);else if("+"===C)o.splice(P,0,x),i.splice(P,0,F),P++;else if("\\"===C){var A=S.lines[T-1]?S.lines[T-1][0]:null;"+"===A?r=!0:"-"===A&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var R=0;R<o.length-1;R++)o[R]=o[R]+i[R];return o.join("")}function M(e,t){"string"===typeof e&&(e=E(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=R(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function O(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=f(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var u=[],c=0,d=0,p=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!c){var f=s[e-1];c=m,d=h,f&&(p=i.context>0?l(f.lines.slice(-i.context)):[],c-=p.length,d-=p.length)}(o=p).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(c)if(a.length<=2*i.context&&e<s.length-2){var v;(v=p).push.apply(v,_(l(a)))}else{var b,y=Math.min(a.length,i.context);(b=p).push.apply(b,_(l(a.slice(0,y))));var g={oldStart:c,oldLines:m-c+y,newStart:d,newLines:h-d+y,lines:p};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),P=0==a.length&&p.length>g.oldLines;!w&&P&&p.splice(g.oldLines,0,"\\ No newline at end of file"),(w||P)&&S||p.push("\\ No newline at end of file")}u.push(g),c=0,d=0,p=[]}m+=a.length,h+=a.length}},b=0;b<s.length;b++)v(b);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:u}}function L(e,t,n,r,a,o,i){var s=O(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var u=0;u<s.hunks.length;u++){var c=s.hunks[u];l.push("@@ -"+c.oldStart+","+c.oldLines+" +"+c.newStart+","+c.newLines+" @@"),l.push.apply(l,c.lines)}return l.join("\n")+"\n"}function D(e,t,n,r,a,o){return L(e,e,t,n,r,a,o)}function z(e,t){return e.length===t.length&&I(e,t)}function I(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function Z(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function j(e,t,n){e=V(e,n),t=V(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(B(e)?B(t)?(r.oldFileName=W(r,e.oldFileName,t.oldFileName),r.newFileName=W(r,e.newFileName,t.newFileName),r.oldHeader=W(r,e.oldHeader,t.oldHeader),r.newHeader=W(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},u=t.hunks[o]||{oldStart:1/0};if(U(l,u))r.hunks.push(H(l,i)),a++,s+=l.newLines-l.oldLines;else if(U(u,l))r.hunks.push(H(u,s)),o++,i+=u.newLines-u.oldLines;else{var c={oldStart:Math.min(l.oldStart,u.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,u.oldStart+s),newLines:0,lines:[]};J(c,l.oldStart,l.lines,u.oldStart,u.lines),o++,a++,r.hunks.push(c)}}return r}function V(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return E(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return O(void 0,void 0,t,e)}return e}function B(e){return e.newFileName&&e.newFileName!==e.oldFileName}function W(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function U(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function H(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function J(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var u;(u=e.lines).push.apply(u,_(Y(o)))}else if("+"===l[0]&&" "===s[0]){var c;(c=e.lines).push.apply(c,_(Y(i)))}else"-"===s[0]&&" "===l[0]?G(e,o,i):"-"===l[0]&&" "===s[0]?G(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Y(o),Y(i));else $(e,o,i)}Q(e,o),Q(e,i),Z(e)}function $(e,t,n){var r=Y(t),a=Y(n);if(ee(r)&&ee(a)){var o,i;if(I(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(I(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(z(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function G(e,t,n,r){var a,o=Y(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}F.tokenize=function(e){return e.slice()},F.join=F.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=c,e.diffWordsWithSpace=d,e.diffLines=f,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=y,e.diffJson=C,e.diffArrays=A,e.structuredPatch=O,e.createTwoFilesPatch=L,e.createPatch=D,e.applyPatch=R,e.applyPatches=M,e.parsePatch=E,e.merge=j,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=x,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return Z},css:function(){return z},cx:function(){return R},flush:function(){return E},getRegisteredStyles:function(){return O},hydrate:function(){return N},injectGlobal:function(){return L},keyframes:function(){return D},merge:function(){return M},sheet:function(){return I}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,u,p){for(var f,m,h,v,_,S=0,P=0,T=0,k=0,C=0,R=0,O=h=f=0,D=0,z=0,I=0,Z=0,j=l.length,V=j-1,B="",W="",U="",H="";D<j;){if(m=l.charCodeAt(D),D===V&&0!==P+k+T+S&&(0!==P&&(m=47===P?10:47),k=T=S=0,j++,V++),0===P+k+T+S){if(D===V&&(0<z&&(B=B.replace(d,"")),0<B.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:B+=l.charAt(D)}m=59}switch(m){case 123:for(f=(B=B.trim()).charCodeAt(0),h=1,Z=++D;D<j;){switch(m=l.charCodeAt(D)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(D+1)){case 42:case 47:e:{for(O=D+1;O<V;++O)switch(l.charCodeAt(O)){case 47:if(42===m&&42===l.charCodeAt(O-1)&&D+2!==O){D=O+1;break e}break;case 10:if(47===m){D=O+1;break e}}D=O}}break;case 91:m++;case 40:m++;case 34:case 39:for(;D++<V&&l.charCodeAt(D)!==m;);}if(0===h)break;D++}if(h=l.substring(Z,D),0===f&&(f=(B=B.replace(c,"").trim()).charCodeAt(0)),64===f){switch(0<z&&(B=B.replace(d,"")),m=B.charCodeAt(1)){case 100:case 109:case 115:case 45:z=r;break;default:z=N}if(Z=(h=t(r,z,h,m,p+1)).length,0<M&&(_=s(3,h,z=n(N,B,I),r,F,x,Z,m,p,u),B=z.join(""),void 0!==_&&0===(Z=(h=_.trim()).length)&&(m=0,h="")),0<Z)switch(m){case 115:B=B.replace(w,i);case 100:case 109:case 45:h=B+"{"+h+"}";break;case 107:h=(B=B.replace(b,"$1 $2"))+"{"+h+"}",h=1===E||2===E&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=B+h,112===u&&(W+=h,h="")}else h=""}else h=t(r,n(r,B,I),h,u,p+1);U+=h,h=I=z=O=f=0,B="",m=l.charCodeAt(++D);break;case 125:case 59:if(1<(Z=(B=(0<z?B.replace(d,""):B).trim()).length))switch(0===O&&(f=B.charCodeAt(0),45===f||96<f&&123>f)&&(Z=(B=B.replace(" ",":")).length),0<M&&void 0!==(_=s(1,B,r,e,F,x,W.length,u,p,u))&&0===(Z=(B=_.trim()).length)&&(B="\0\0"),f=B.charCodeAt(0),m=B.charCodeAt(1),f){case 0:break;case 64:if(105===m||99===m){H+=B+l.charAt(D);break}default:58!==B.charCodeAt(Z-1)&&(W+=a(B,f,m,B.charCodeAt(2)))}I=z=O=f=0,B="",m=l.charCodeAt(++D)}}switch(m){case 13:case 10:47===P?P=0:0===1+f&&107!==u&&0<B.length&&(z=1,B+="\0"),0<M*L&&s(0,B,r,e,F,x,W.length,u,p,u),x=1,F++;break;case 59:case 125:if(0===P+k+T+S){x++;break}default:switch(x++,v=l.charAt(D),m){case 9:case 32:if(0===k+S+P)switch(C){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===k+P+S&&(z=I=1,v="\f"+v);break;case 108:if(0===k+P+S+A&&0<O)switch(D-O){case 2:112===C&&58===l.charCodeAt(D-3)&&(A=C);case 8:111===R&&(A=R)}break;case 58:0===k+P+S&&(O=D);break;case 44:0===P+T+k+S&&(z=1,v+="\r");break;case 34:case 39:0===P&&(k=k===m?0:0===k?m:k);break;case 91:0===k+P+T&&S++;break;case 93:0===k+P+T&&S--;break;case 41:0===k+P+S&&T--;break;case 40:if(0===k+P+S){if(0===f)if(2*C+3*R===533);else f=1;T++}break;case 64:0===P+T+k+S+O+h&&(h=1);break;case 42:case 47:if(!(0<k+S+T))switch(P){case 0:switch(2*m+3*l.charCodeAt(D+1)){case 235:P=47;break;case 220:Z=D,P=42}break;case 42:47===m&&42===C&&Z+2!==D&&(33===l.charCodeAt(Z+2)&&(W+=l.substring(Z,D+1)),v="",P=0)}}0===P&&(B+=v)}R=C,C=m,D++}if(0<(Z=W.length)){if(z=r,0<M&&(void 0!==(_=s(2,W,z,e,F,x,Z,u,p,u))&&0===(W=_).length))return H+W+U;if(W=z.join(",")+"{"+W+"}",0!==E*A){switch(2!==E||o(W,2)||(A=0),A){case 111:W=W.replace(g,":-moz-$1")+W;break;case 112:W=W.replace(y,"::-webkit-input-$1")+W.replace(y,"::-moz-$1")+W.replace(y,":-ms-input-$1")+W}A=0}}return H+W+U}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var u=0;u<i;++u)t[l++]=r(e[u]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===E||2===E&&o(l,1)?"-webkit-"+l+l:l}if(0===E||2===E&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(C,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return f.test(i)?i.replace(p,":-webkit-")+i.replace(p,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(P,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(P,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===k.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),O(2!==t?r:r.replace(T,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,c){for(var d,p=0,f=t;p<M;++p)switch(d=R[p].call(u,e,f,n,r,a,o,i,s,l,c)){case void 0:case!1:case!0:case null:break;default:f=d}if(f!==t)return f}function l(e){return void 0!==(e=e.prefix)&&(O=null,e?"function"!==typeof e?E=1:(E=2,O=e):E=0),l}function u(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<M){var a=s(-1,n,r,r,F,x,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(N,r,n,0,0);return 0<M&&(void 0!==(a=s(-2,o,r,r,F,x,o.length,0,0,0))&&(o=a)),"",A=0,x=F=1,o}var c=/^\0+/g,d=/[\0\r\f]/g,p=/: */g,f=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,b=/@(k\w+)\s*(\S*)\s*/,y=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,P=/-self|flex-/g,T=/[^]*?(:[rp][el]a[\w-]+)[^]*/,k=/stretch|:\s*\w+\-(?:conte|avail)/,C=/([^-])(image-set\()/,x=1,F=1,A=0,E=1,N=[],R=[],M=0,O=null,L=0;return u.use=function e(t){switch(t){case void 0:case null:M=R.length=0;break;default:if("function"===typeof t)R[M++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else L=0|!!t}return e},u.set=l,void 0!==e&&l(e),u},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,u,c,d,p){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===c)return t+o;break;case 3:switch(c){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===p?o:"")}case-2:t.split("/*|*/}").forEach(i)}},u=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,u={};i=e.container||document.head;var c,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){u[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),c=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(p.inserted[a]=!0)};var p={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:u,registered:{},insert:c};return p};var c=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var p=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},f=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},b=p((function(e){return h(e)?e:e.replace(f,"-$&").toLowerCase()})),y=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=b(o)+":"+y(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=b(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=b(o)+":"+y(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:c(a)+l,styles:a,next:_}};function P(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var T=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function k(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function C(e,t,n){var r=[],a=P(e,r,n);return r.length<2?n:a+t(r)}var x=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},F=function(e){var t=u(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return T(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return C(t.registered,n,x(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);k(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return k(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:P.bind(null,t.registered),merge:C.bind(null,t.registered,n)}},A=F(),E=A.flush,N=A.hydrate,R=A.cx,M=A.merge,O=A.getRegisteredStyles,L=A.injectGlobal,D=A.keyframes,z=A.css,I=A.sheet,Z=A.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var u=Object.defineProperty,c=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=f(n);a&&a!==m&&e(t,a,r)}var i=c(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var b=i[v];if(!o[b]&&(!r||!r[b])&&(!h||!h[b])&&(!s||!s[b])){var y=p(n,b);try{u(t,b,y)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,u=n?Symbol.for("react.context"):60110,c=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,p=n?Symbol.for("react.forward_ref"):60112,f=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,b=n?Symbol.for("react.block"):60121,y=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case c:case d:case o:case s:case i:case f:return e;default:switch(e=e&&e.$$typeof){case u:case p:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=c,t.ConcurrentMode=d,t.ContextConsumer=u,t.ContextProvider=l,t.Element=r,t.ForwardRef=p,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=f,t.isAsyncMode=function(e){return S(e)||w(e)===c},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===u},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===p},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===f},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===f||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===u||e.$$typeof===p||e.$$typeof===y||e.$$typeof===g||e.$$typeof===_||e.$$typeof===b)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);u.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),u.propTypes=l.propTypes,t.default=u},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),u=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,u=n.uFEFF,c=t&&"function"===typeof r?r():r,d=new Blob([u?"\ufeff":"",(0,l.toCSV)(c,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,u=t.children,c=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),p="undefined"===typeof window?"":this.buildURI(n,l,r,o,c);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:p,onClick:this.handleClick()}),u)}}]),t}(s.default.Component);c.defaultProps=u.defaultProps,c.propTypes=u.propTypes,t.default=c},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return u(t,e)}))}));return[n].concat(r(i))},u=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},c=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return c(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},p=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},f=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return f(e,t,n,r);if(i(e))return p(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),u="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,c=window.URL||window.webkitURL;return"undefined"===typeof c.createObjectURL?u:c.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var u=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,c){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===c&&(c=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),p=c,f=c,m=[],h=0,v=[],b=[],y=function e(t,a,s,c,m){return u(t).map((function(t,y){var g={},_={};if(!(b.includes(a+"-"+y)||m&&0!==y)){if(s||c)if(v.includes(h)||v.push(h),c){f+=1,g.lineNumber=f,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(u(w.value)[y]){var S=e(w.value,a,!0,!1,!0)[0].right,P=S.value,T=S.lineNumber,k=S.type;if(b.push(a+1+"-"+y),_.lineNumber=T,_.type=k,n)_.value=P;else{var C=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,P,r);_.value=C.right,g.value=C.left}}}else p+=1,_.lineNumber=p,_.type=o.ADDED,_.value=t;else f+=1,p+=1,g.lineNumber=f,g.type=o.DEFAULT,g.value=t,_.lineNumber=p,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,y(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,u=n(2813),c=n(5781),d=c.default||c;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var p=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(u.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,u){var c,d,p,f,m,h=r+"-"+e,v=u+"-"+l,b=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),y=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(c={},c[n.styles.emptyGutter]=!e,c[n.styles.diffAdded]=y,c[n.styles.diffRemoved]=g,c[n.styles.highlightedGutter]=b,c))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=y,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=b,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=y,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=b,p))},a.createElement("pre",null,y&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=y,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=b,f))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,u=l.hideLineNumbers,c=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),p=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),f=!c&&!u;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!u&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=f,s))}),f?a.createElement(a.Fragment,null,a.createElement("td",null),p):a.createElement(a.Fragment,null,p,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,u=e.linesOffset,c=s.computeLineInformation(t,r,i,l,u),d=c.lineInformation,p=c.diffLines,f=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=p[0],i=r-t;if(n.props.showDiffOnly&&(i===-f&&(m=[],p.shift()),e.left.type===s.DiffType.DEFAULT&&(i>f||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===f&&m.length>0){var u=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(u,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,u=t.rightTitle,c=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var p=n.renderDiff(),f=d?2:3,m=d?2:4,h=(l||u)&&a.createElement("tr",null,a.createElement("td",{colSpan:c?f:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),c&&a.createElement("td",{colSpan:f,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},u)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=c,e))},a.createElement("tbody",null,h,p))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=p},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,u,c,d;void 0===t&&(t=!1);var p=e.variables,f=void 0===p?{}:p,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},f.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},f.dark||{})},v=t?h.dark:h.light,b=o.css({width:"100%",label:"content"}),y=o.css(((n={})["."+b]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),P=o.css({color:v.gutterColor,label:"line-number"}),T=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+P]={color:v.removedGutterColor},s.label="diff-removed",s)),k=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+P]={color:v.addedGutterColor},l.label="diff-added",l)),C=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),x=o.css({background:v.wordAddedBackground,label:"word-added"}),F=o.css({background:v.wordRemovedBackground,label:"word-removed"}),A=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),E=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),N=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),R=o.css(((u={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+k]={pre:{color:v.addedColor}},u["&."+T]={pre:{color:v.removedColor}},u)),M=o.css(((c={background:v.highlightBackground,label:"highlighted-line"})["."+x+", ."+F]={backgroundColor:"initial"},c)),O=o.css({label:"highlighted-gutter"}),L=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+k]={background:v.addedGutterBackground},d["&."+T]={background:v.removedGutterBackground},d["&."+O]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),D=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),z={diffContainer:g,diffRemoved:T,diffAdded:k,splitView:y,marker:R,highlightedGutter:O,highlightedLine:M,gutter:L,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:C,wordAdded:x,wordRemoved:F,codeFoldGutter:A,codeFold:E,emptyGutter:D,emptyLine:N,lineNumber:P,contentText:w,content:b,codeFoldContent:_,titleBlock:S},I=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(z).reduce((function(e,t){var n;return r({},e,((n={})[t]=I[t]?o.cx(z[t],I[t]):z[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){u(e,t),u(e+"Capture",t)}function u(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var c=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,p=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,f={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var b=/[\-:]([a-z])/g;function y(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(f,e)&&(p.test(e)?m[e]=!0:(f[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),P=Symbol.for("react.fragment"),T=Symbol.for("react.strict_mode"),k=Symbol.for("react.profiler"),C=Symbol.for("react.provider"),x=Symbol.for("react.context"),F=Symbol.for("react.forward_ref"),A=Symbol.for("react.suspense"),E=Symbol.for("react.suspense_list"),N=Symbol.for("react.memo"),R=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var M=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var O=Symbol.iterator;function L(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=O&&e[O]||e["@@iterator"])?e:null}var D,z=Object.assign;function I(e){if(void 0===D)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);D=t&&t[1]||""}return"\n"+D+e}var Z=!1;function j(e,t){if(!e||Z)return"";Z=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var r=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){r=u}e.call(t.prototype)}else{try{throw Error()}catch(u){r=u}e()}}catch(u){if(u&&r&&"string"===typeof u.stack){for(var a=u.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{Z=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?I(e):""}function V(e){switch(e.tag){case 5:return I(e.type);case 16:return I("Lazy");case 13:return I("Suspense");case 19:return I("SuspenseList");case 0:case 2:case 15:return e=j(e.type,!1);case 11:return e=j(e.type.render,!1);case 1:return e=j(e.type,!0);default:return""}}function B(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case P:return"Fragment";case S:return"Portal";case k:return"Profiler";case T:return"StrictMode";case A:return"Suspense";case E:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case x:return(e.displayName||"Context")+".Consumer";case C:return(e._context.displayName||"Context")+".Provider";case F:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case N:return null!==(t=e.displayName||null)?t:B(e.type)||"Memo";case R:t=e._payload,e=e._init;try{return B(e(t))}catch(n){}}return null}function W(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return B(t);case 8:return t===T?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function U(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function H(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function J(e){e._valueTracker||(e._valueTracker=function(e){var t=H(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function $(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=H(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function G(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return z({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=U(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=U(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,U(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&G(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+U(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return z({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:U(n)}}function oe(e,t){var n=U(t.value),r=U(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ue,ce,de=(ce=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ue=ue||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ue.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ce(e,t)}))}:ce);function pe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var fe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||fe.hasOwnProperty(e)&&fe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(fe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),fe[t]=fe[e]}))}));var be=z({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function ye(e,t){if(t){if(be[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,Pe=null,Te=null;function ke(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function Ce(e){Pe?Te?Te.push(e):Te=[e]:Pe=e}function xe(){if(Pe){var e=Pe,t=Te;if(Te=Pe=null,ke(e),t)for(e=0;e<t.length;e++)ke(t[e])}}function Fe(e,t){return e(t)}function Ae(){}var Ee=!1;function Ne(e,t,n){if(Ee)return e(t,n);Ee=!0;try{return Fe(e,t,n)}finally{Ee=!1,(null!==Pe||null!==Te)&&(Ae(),xe())}}function Re(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Me=!1;if(c)try{var Oe={};Object.defineProperty(Oe,"passive",{get:function(){Me=!0}}),window.addEventListener("test",Oe,Oe),window.removeEventListener("test",Oe,Oe)}catch(ce){Me=!1}function Le(e,t,n,r,a,o,i,s,l){var u=Array.prototype.slice.call(arguments,3);try{t.apply(n,u)}catch(c){this.onError(c)}}var De=!1,ze=null,Ie=!1,Ze=null,je={onError:function(e){De=!0,ze=e}};function Ve(e,t,n,r,a,o,i,s,l){De=!1,ze=null,Le.apply(je,arguments)}function Be(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function We(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ue(e){if(Be(e)!==e)throw Error(o(188))}function He(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=Be(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return Ue(a),e;if(i===r)return Ue(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?Je(e):null}function Je(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=Je(e);if(null!==t)return t;e=e.sibling}return null}var $e=a.unstable_scheduleCallback,Ge=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Ye=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ut=64,ct=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function pt(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function ft(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ut;return 0===(4194240&(ut<<=1))&&(ut=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function bt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function yt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,Pt,Tt,kt,Ct=!1,xt=[],Ft=null,At=null,Et=null,Nt=new Map,Rt=new Map,Mt=[],Ot="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Lt(e,t){switch(e){case"focusin":case"focusout":Ft=null;break;case"dragenter":case"dragleave":At=null;break;case"mouseover":case"mouseout":Et=null;break;case"pointerover":case"pointerout":Nt.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Rt.delete(t.pointerId)}}function Dt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function zt(e){var t=ya(e.target);if(null!==t){var n=Be(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=We(n)))return e.blockedOn=t,void kt(e.priority,(function(){Pt(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function It(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function Zt(e,t,n){It(e)&&n.delete(t)}function jt(){Ct=!1,null!==Ft&&It(Ft)&&(Ft=null),null!==At&&It(At)&&(At=null),null!==Et&&It(Et)&&(Et=null),Nt.forEach(Zt),Rt.forEach(Zt)}function Vt(e,t){e.blockedOn===t&&(e.blockedOn=null,Ct||(Ct=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,jt)))}function Bt(e){function t(t){return Vt(t,e)}if(0<xt.length){Vt(xt[0],e);for(var n=1;n<xt.length;n++){var r=xt[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Ft&&Vt(Ft,e),null!==At&&Vt(At,e),null!==Et&&Vt(Et,e),Nt.forEach(t),Rt.forEach(t),n=0;n<Mt.length;n++)(r=Mt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Mt.length&&null===(n=Mt[0]).blockedOn;)zt(n),null===n.blockedOn&&Mt.shift()}var Wt=_.ReactCurrentBatchConfig,Ut=!0;function Ht(e,t,n,r){var a=gt,o=Wt.transition;Wt.transition=null;try{gt=1,$t(e,t,n,r)}finally{gt=a,Wt.transition=o}}function Jt(e,t,n,r){var a=gt,o=Wt.transition;Wt.transition=null;try{gt=4,$t(e,t,n,r)}finally{gt=a,Wt.transition=o}}function $t(e,t,n,r){if(Ut){var a=qt(e,t,n,r);if(null===a)Ur(e,t,r,Gt,n),Lt(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Ft=Dt(Ft,e,t,n,r,a),!0;case"dragenter":return At=Dt(At,e,t,n,r,a),!0;case"mouseover":return Et=Dt(Et,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return Nt.set(o,Dt(Nt.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Rt.set(o,Dt(Rt.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(Lt(e,r),4&t&&-1<Ot.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Ur(e,t,r,Gt,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Ur(e,t,r,null,n)}}var Gt=null;function qt(e,t,n,r){if(Gt=null,null!==(e=ya(e=we(r))))if(null===(t=Be(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=We(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Gt=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return z(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,un={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},cn=an(un),dn=z({},un,{view:0,detail:0}),pn=an(dn),fn=z({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:kn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(fn),hn=an(z({},fn,{dataTransfer:0})),vn=an(z({},dn,{relatedTarget:0})),bn=an(z({},un,{animationName:0,elapsedTime:0,pseudoElement:0})),yn=z({},un,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(yn),_n=an(z({},un,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Pn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Tn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=Pn[e])&&!!t[e]}function kn(){return Tn}var Cn=z({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:kn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),xn=an(Cn),Fn=an(z({},fn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),An=an(z({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:kn})),En=an(z({},un,{propertyName:0,elapsedTime:0,pseudoElement:0})),Nn=z({},fn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Rn=an(Nn),Mn=[9,13,27,32],On=c&&"CompositionEvent"in window,Ln=null;c&&"documentMode"in document&&(Ln=document.documentMode);var Dn=c&&"TextEvent"in window&&!Ln,zn=c&&(!On||Ln&&8<Ln&&11>=Ln),In=String.fromCharCode(32),Zn=!1;function jn(e,t){switch(e){case"keyup":return-1!==Mn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Vn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Bn=!1;var Wn={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Un(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Wn[e.type]:"textarea"===t}function Hn(e,t,n,r){Ce(r),0<(t=Jr(t,"onChange")).length&&(n=new cn("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Jn=null,$n=null;function Gn(e){Ir(e,0)}function qn(e){if($(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(c){var Yn;if(c){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){Jn&&(Jn.detachEvent("onpropertychange",nr),$n=Jn=null)}function nr(e){if("value"===e.propertyName&&qn($n)){var t=[];Hn(t,$n,e,we(e)),Ne(Gn,t)}}function rr(e,t,n){"focusin"===e?(tr(),$n=n,(Jn=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn($n)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function ur(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function cr(e,t){var n,r=ur(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=ur(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function pr(){for(var e=window,t=G();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=G((e=t.contentWindow).document)}return t}function fr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=pr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&fr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=cr(n,o);var i=cr(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=c&&"documentMode"in document&&11>=document.documentMode,vr=null,br=null,yr=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==G(r)||("selectionStart"in(r=vr)&&fr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},yr&&lr(yr,r)||(yr=r,0<(r=Jr(br,"onSelect")).length&&(t=new cn("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},Pr={},Tr={};function kr(e){if(Pr[e])return Pr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Tr)return Pr[e]=n[t];return e}c&&(Tr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var Cr=kr("animationend"),xr=kr("animationiteration"),Fr=kr("animationstart"),Ar=kr("transitionend"),Er=new Map,Nr="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Rr(e,t){Er.set(e,t),l(t,[e])}for(var Mr=0;Mr<Nr.length;Mr++){var Or=Nr[Mr];Rr(Or.toLowerCase(),"on"+(Or[0].toUpperCase()+Or.slice(1)))}Rr(Cr,"onAnimationEnd"),Rr(xr,"onAnimationIteration"),Rr(Fr,"onAnimationStart"),Rr("dblclick","onDoubleClick"),Rr("focusin","onFocus"),Rr("focusout","onBlur"),Rr(Ar,"onTransitionEnd"),u("onMouseEnter",["mouseout","mouseover"]),u("onMouseLeave",["mouseout","mouseover"]),u("onPointerEnter",["pointerout","pointerover"]),u("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Lr="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Dr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Lr));function zr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,u){if(Ve.apply(this,arguments),De){if(!De)throw Error(o(198));var c=ze;De=!1,ze=null,Ie||(Ie=!0,Ze=c)}}(r,t,void 0,e),e.currentTarget=null}function Ir(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,u=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;zr(a,s,u),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,u=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;zr(a,s,u),o=l}}}if(Ie)throw e=Ze,Ie=!1,Ze=null,e}function Zr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Wr(t,e,2,!1),n.add(r))}function jr(e,t,n){var r=0;t&&(r|=4),Wr(n,e,r,t)}var Vr="_reactListening"+Math.random().toString(36).slice(2);function Br(e){if(!e[Vr]){e[Vr]=!0,i.forEach((function(t){"selectionchange"!==t&&(Dr.has(t)||jr(t,!1,e),jr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Vr]||(t[Vr]=!0,jr("selectionchange",!1,t))}}function Wr(e,t,n,r){switch(Kt(t)){case 1:var a=Ht;break;case 4:a=Jt;break;default:a=$t}n=a.bind(null,t,n,e),a=void 0,!Me||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Ur(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ya(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Ne((function(){var r=o,a=we(n),i=[];e:{var s=Er.get(e);if(void 0!==s){var l=cn,u=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=xn;break;case"focusin":u="focus",l=vn;break;case"focusout":u="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=An;break;case Cr:case xr:case Fr:l=bn;break;case Ar:l=En;break;case"scroll":l=pn;break;case"wheel":l=Rn;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=Fn}var c=0!==(4&t),d=!c&&"scroll"===e,p=c?null!==s?s+"Capture":null:s;c=[];for(var f,m=r;null!==m;){var h=(f=m).stateNode;if(5===f.tag&&null!==h&&(f=h,null!==p&&(null!=(h=Re(m,p))&&c.push(Hr(m,h,f)))),d)break;m=m.return}0<c.length&&(s=new l(s,u,null,n,a),i.push({event:s,listeners:c}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(u=n.relatedTarget||n.fromElement)||!ya(u)&&!u[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(u=(u=n.relatedTarget||n.toElement)?ya(u):null)&&(u!==(d=Be(u))||5!==u.tag&&6!==u.tag)&&(u=null)):(l=null,u=r),l!==u)){if(c=mn,h="onMouseLeave",p="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(c=Fn,h="onPointerLeave",p="onPointerEnter",m="pointer"),d=null==l?s:_a(l),f=null==u?s:_a(u),(s=new c(h,m+"leave",l,n,a)).target=d,s.relatedTarget=f,h=null,ya(a)===r&&((c=new c(p,m+"enter",u,n,a)).target=f,c.relatedTarget=d,h=c),d=h,l&&u)e:{for(p=u,m=0,f=c=l;f;f=$r(f))m++;for(f=0,h=p;h;h=$r(h))f++;for(;0<m-f;)c=$r(c),m--;for(;0<f-m;)p=$r(p),f--;for(;m--;){if(c===p||null!==p&&c===p.alternate)break e;c=$r(c),p=$r(p)}c=null}else c=null;null!==l&&Gr(i,s,l,c,!1),null!==u&&null!==d&&Gr(i,d,u,c,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Un(s))if(Qn)v=ir;else{v=ar;var b=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Hn(i,v,n,a):(b&&b(e,s,r),"focusout"===e&&(b=s._wrapperState)&&b.controlled&&"number"===s.type&&ee(s,"number",s.value)),b=r?_a(r):window,e){case"focusin":(Un(b)||"true"===b.contentEditable)&&(vr=b,br=r,yr=null);break;case"focusout":yr=br=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var y;if(On)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Bn?jn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(zn&&"ko"!==n.locale&&(Bn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Bn&&(y=en()):(Yt="value"in(Qt=a)?Qt.value:Qt.textContent,Bn=!0)),0<(b=Jr(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:b}),y?g.data=y:null!==(y=Vn(n))&&(g.data=y))),(y=Dn?function(e,t){switch(e){case"compositionend":return Vn(t);case"keypress":return 32!==t.which?null:(Zn=!0,In);case"textInput":return(e=t.data)===In&&Zn?null:e;default:return null}}(e,n):function(e,t){if(Bn)return"compositionend"===e||!On&&jn(e,t)?(e=en(),Xt=Yt=Qt=null,Bn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return zn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Jr(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=y))}Ir(i,t)}))}function Hr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Jr(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Re(e,n))&&r.unshift(Hr(e,o,a)),null!=(o=Re(e,t))&&r.push(Hr(e,o,a))),e=e.return}return r}function $r(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Gr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,u=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==u&&(s=u,a?null!=(l=Re(n,o))&&i.unshift(Hr(n,l,s)):a||null!=(l=Re(n,o))&&i.push(Hr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Bt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Bt(t)}function ua(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ca(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),pa="__reactFiber$"+da,fa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ba="__reactHandles$"+da;function ya(e){var t=e[pa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[pa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ca(e);null!==e;){if(n=e[pa])return n;e=ca(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[pa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[fa]||null}var Sa=[],Pa=-1;function Ta(e){return{current:e}}function ka(e){0>Pa||(e.current=Sa[Pa],Sa[Pa]=null,Pa--)}function Ca(e,t){Pa++,Sa[Pa]=e.current,e.current=t}var xa={},Fa=Ta(xa),Aa=Ta(!1),Ea=xa;function Na(e,t){var n=e.type.contextTypes;if(!n)return xa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Ra(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Ma(){ka(Aa),ka(Fa)}function Oa(e,t,n){if(Fa.current!==xa)throw Error(o(168));Ca(Fa,t),Ca(Aa,n)}function La(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,W(e)||"Unknown",a));return z({},n,r)}function Da(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||xa,Ea=Fa.current,Ca(Fa,e),Ca(Aa,Aa.current),!0}function za(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=La(e,t,Ea),r.__reactInternalMemoizedMergedChildContext=e,ka(Aa),ka(Fa),Ca(Fa,e)):ka(Aa),Ca(Aa,n)}var Ia=null,Za=!1,ja=!1;function Va(e){null===Ia?Ia=[e]:Ia.push(e)}function Ba(){if(!ja&&null!==Ia){ja=!0;var e=0,t=gt;try{var n=Ia;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}Ia=null,Za=!1}catch(a){throw null!==Ia&&(Ia=Ia.slice(e+1)),$e(Xe,Ba),a}finally{gt=t,ja=!1}}return null}var Wa=[],Ua=0,Ha=null,Ja=0,$a=[],Ga=0,qa=null,Ka=1,Qa="";function Ya(e,t){Wa[Ua++]=Ja,Wa[Ua++]=Ha,Ha=e,Ja=t}function Xa(e,t,n){$a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Ya(e,1),Xa(e,1,0))}function to(e){for(;e===Ha;)Ha=Wa[--Ua],Wa[Ua]=null,Ja=Wa[--Ua],Wa[Ua]=null;for(;e===qa;)qa=$a[--Ga],$a[Ga]=null,Qa=$a[--Ga],$a[Ga]=null,Ka=$a[--Ga],$a[Ga]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Nu(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ua(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Nu(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function uo(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ua(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function co(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function po(e){if(e!==no)return!1;if(!ao)return co(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw fo(),Error(o(418));for(;t;)io(e,t),t=ua(t.nextSibling)}if(co(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ua(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ua(e.stateNode.nextSibling):null;return!0}function fo(){for(var e=ro;e;)e=ua(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function bo(e,t){if(e&&e.defaultProps){for(var n in t=z({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var yo=Ta(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function Po(e){var t=yo.current;ka(yo),e._currentValue=t}function To(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function ko(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function Co(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var xo=null;function Fo(e){null===xo?xo=[e]:xo.push(e)}function Ao(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Fo(t)):(n.next=a.next,a.next=n),t.interleaved=n,Eo(e,r)}function Eo(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var No=!1;function Ro(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Mo(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Oo(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Lo(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Fl)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,Eo(e,n)}return null===(a=r.interleaved)?(t.next=t,Fo(r)):(t.next=a.next,a.next=t),r.interleaved=t,Eo(e,n)}function Do(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}function zo(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Io(e,t,n,r){var a=e.updateQueue;No=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,u=l.next;l.next=null,null===i?o=u:i.next=u,i=l;var c=e.alternate;null!==c&&((s=(c=c.updateQueue).lastBaseUpdate)!==i&&(null===s?c.firstBaseUpdate=u:s.next=u,c.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,c=u=l=null,s=o;;){var p=s.lane,f=s.eventTime;if((r&p)===p){null!==c&&(c=c.next={eventTime:f,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(p=t,f=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(f,d,p);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(p="function"===typeof(m=h.payload)?m.call(f,d,p):m)||void 0===p)break e;d=z({},d,p);break e;case 2:No=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(p=a.effects)?a.effects=[s]:p.push(s))}else f={eventTime:f,lane:p,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===c?(u=c=f,l=d):c=c.next=f,i|=p;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(p=s).next,p.next=null,a.lastBaseUpdate=p,a.shared.pending=null}}if(null===c&&(l=d),a.baseState=l,a.firstBaseUpdate=u,a.lastBaseUpdate=c,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);Dl|=i,e.lanes=i,e.memoizedState=d}}function Zo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var jo=(new r.Component).refs;function Vo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:z({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Bo={isMounted:function(e){return!!(e=e._reactInternals)&&Be(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Oo(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Lo(e,o,a))&&(nu(t,e,a,r),Do(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Oo(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Lo(e,o,a))&&(nu(t,e,a,r),Do(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=eu(),r=tu(e),a=Oo(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Lo(e,a,r))&&(nu(t,e,r,n),Do(t,e,r))}};function Wo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Uo(e,t,n){var r=!1,a=xa,o=t.contextType;return"object"===typeof o&&null!==o?o=Co(o):(a=Ra(t)?Ea:Fa.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Na(e,a):xa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Bo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Ho(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Bo.enqueueReplaceState(t,t.state,null)}function Jo(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=jo,Ro(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=Co(o):(o=Ra(t)?Ea:Fa.current,a.context=Na(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Vo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Bo.enqueueReplaceState(a,a.state,null),Io(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function $o(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===jo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Go(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Mu(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=zu(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function u(e,t,n,r){var o=n.type;return o===P?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===R&&qo(o)===t.type)?((r=a(t,n.props)).ref=$o(e,t,n),r.return=e,r):((r=Ou(n.type,n.key,n.props,null,e.mode,r)).ref=$o(e,t,n),r.return=e,r)}function c(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Iu(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Lu(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function p(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=zu(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Ou(t.type,t.key,t.props,null,e.mode,n)).ref=$o(e,null,t),n.return=e,n;case S:return(t=Iu(t,e.mode,n)).return=e,t;case R:return p(e,(0,t._init)(t._payload),n)}if(te(t)||L(t))return(t=Lu(t,e.mode,n,null)).return=e,t;Go(e,t)}return null}function f(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?u(e,t,n,r):null;case S:return n.key===a?c(e,t,n,r):null;case R:return f(e,t,(a=n._init)(n._payload),r)}if(te(n)||L(n))return null!==a?null:d(e,t,n,r,null);Go(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case R:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||L(r))return d(t,e=e.get(n)||null,r,a,null);Go(t,r)}return null}function h(a,o,s,l){for(var u=null,c=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var b=f(a,d,s[h],l);if(null===b){null===d&&(d=v);break}e&&d&&null===b.alternate&&t(a,d),o=i(b,o,h),null===c?u=b:c.sibling=b,c=b,d=v}if(h===s.length)return n(a,d),ao&&Ya(a,h),u;if(null===d){for(;h<s.length;h++)null!==(d=p(a,s[h],l))&&(o=i(d,o,h),null===c?u=d:c.sibling=d,c=d);return ao&&Ya(a,h),u}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===c?u=v:c.sibling=v,c=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Ya(a,h),u}function v(a,s,l,u){var c=L(l);if("function"!==typeof c)throw Error(o(150));if(null==(l=c.call(l)))throw Error(o(151));for(var d=c=null,h=s,v=s=0,b=null,y=l.next();null!==h&&!y.done;v++,y=l.next()){h.index>v?(b=h,h=null):b=h.sibling;var g=f(a,h,y.value,u);if(null===g){null===h&&(h=b);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?c=g:d.sibling=g,d=g,h=b}if(y.done)return n(a,h),ao&&Ya(a,v),c;if(null===h){for(;!y.done;v++,y=l.next())null!==(y=p(a,y.value,u))&&(s=i(y,s,v),null===d?c=y:d.sibling=y,d=y);return ao&&Ya(a,v),c}for(h=r(a,h);!y.done;v++,y=l.next())null!==(y=m(h,a,v,y.value,u))&&(e&&null!==y.alternate&&h.delete(null===y.key?v:y.key),s=i(y,s,v),null===d?c=y:d.sibling=y,d=y);return e&&h.forEach((function(e){return t(a,e)})),ao&&Ya(a,v),c}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===P&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var u=i.key,c=o;null!==c;){if(c.key===u){if((u=i.type)===P){if(7===c.tag){n(r,c.sibling),(o=a(c,i.props.children)).return=r,r=o;break e}}else if(c.elementType===u||"object"===typeof u&&null!==u&&u.$$typeof===R&&qo(u)===c.type){n(r,c.sibling),(o=a(c,i.props)).ref=$o(r,c,i),o.return=r,r=o;break e}n(r,c);break}t(r,c),c=c.sibling}i.type===P?((o=Lu(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Ou(i.type,i.key,i.props,null,r.mode,l)).ref=$o(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(c=i.key;null!==o;){if(o.key===c){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Iu(i,r.mode,l)).return=r,r=o}return s(r);case R:return e(r,o,(c=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(L(i))return v(r,o,i,l);Go(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=zu(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Yo=Ko(!1),Xo={},ei=Ta(Xo),ti=Ta(Xo),ni=Ta(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(Ca(ni,t),Ca(ti,e),Ca(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}ka(ei),Ca(ei,t)}function oi(){ka(ei),ka(ti),ka(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(Ca(ti,e),Ca(ei,n))}function si(e){ti.current===e&&(ka(ei),ka(ti))}var li=Ta(0);function ui(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ci=[];function di(){for(var e=0;e<ci.length;e++)ci[e]._workInProgressVersionPrimary=null;ci.length=0}var pi=_.ReactCurrentDispatcher,fi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,bi=null,yi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function Pi(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ti(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,pi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,bi=vi=null,t.updateQueue=null,pi.current=us,e=n(r,a)}while(gi)}if(pi.current=is,t=null!==vi&&null!==vi.next,mi=0,bi=vi=hi=null,yi=!1,t)throw Error(o(300));return e}function ki(){var e=0!==_i;return _i=0,e}function Ci(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===bi?hi.memoizedState=bi=e:bi=bi.next=e,bi}function xi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===bi?hi.memoizedState:bi.next;if(null!==t)bi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===bi?hi.memoizedState=bi=e:bi=bi.next=e}return bi}function Fi(e,t){return"function"===typeof t?t(e):t}function Ai(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,u=null,c=i;do{var d=c.lane;if((mi&d)===d)null!==u&&(u=u.next={lane:0,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),r=c.hasEagerState?c.eagerState:e(r,c.action);else{var p={lane:d,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null};null===u?(l=u=p,s=r):u=u.next=p,hi.lanes|=d,Dl|=d}c=c.next}while(null!==c&&c!==i);null===u?s=r:u.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=u,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,Dl|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Ei(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Ni(){}function Ri(e,t){var n=hi,r=xi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Ui(Li.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==bi&&1&bi.memoizedState.tag){if(n.flags|=2048,Zi(9,Oi.bind(null,n,r,a,t),void 0,null),null===Al)throw Error(o(349));0!==(30&mi)||Mi(n,t,a)}return a}function Mi(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Oi(e,t,n,r){t.value=n,t.getSnapshot=r,Di(t)&&zi(e)}function Li(e,t,n){return n((function(){Di(t)&&zi(e)}))}function Di(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function zi(e){var t=Eo(e,1);null!==t&&nu(t,e,1,-1)}function Ii(e){var t=Ci();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Fi,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Zi(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function ji(){return xi().memoizedState}function Vi(e,t,n,r){var a=Ci();hi.flags|=e,a.memoizedState=Zi(1|t,n,void 0,void 0===r?null:r)}function Bi(e,t,n,r){var a=xi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&Pi(r,i.deps))return void(a.memoizedState=Zi(t,n,o,r))}hi.flags|=e,a.memoizedState=Zi(1|t,n,o,r)}function Wi(e,t){return Vi(8390656,8,e,t)}function Ui(e,t){return Bi(2048,8,e,t)}function Hi(e,t){return Bi(4,2,e,t)}function Ji(e,t){return Bi(4,4,e,t)}function $i(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Gi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4,4,$i.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Pi(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Pi(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,Dl|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=fi.transition;fi.transition={};try{e(!1),t()}finally{gt=n,fi.transition=r}}function es(){return xi().memoizedState}function ts(e,t,n){var r=tu(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Ao(e,t,n,r))){nu(n,e,r,eu()),os(n,t,r)}}function ns(e,t,n){var r=tu(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Fo(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(u){}null!==(n=Ao(e,t,a,r))&&(nu(n,e,r,a=eu()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=yi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}var is={readContext:Co,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:Co,useCallback:function(e,t){return Ci().memoizedState=[e,void 0===t?null:t],e},useContext:Co,useEffect:Wi,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Vi(4194308,4,$i.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Vi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Vi(4,2,e,t)},useMemo:function(e,t){var n=Ci();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=Ci();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},Ci().memoizedState=e},useState:Ii,useDebugValue:qi,useDeferredValue:function(e){return Ci().memoizedState=e},useTransition:function(){var e=Ii(!1),t=e[0];return e=Xi.bind(null,e[1]),Ci().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=Ci();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===Al)throw Error(o(349));0!==(30&mi)||Mi(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Wi(Li.bind(null,r,i,e),[e]),r.flags|=2048,Zi(9,Oi.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=Ci(),t=Al.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:Co,useCallback:Ki,useContext:Co,useEffect:Ui,useImperativeHandle:Gi,useInsertionEffect:Hi,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ai,useRef:ji,useState:function(){return Ai(Fi)},useDebugValue:qi,useDeferredValue:function(e){return Yi(xi(),vi.memoizedState,e)},useTransition:function(){return[Ai(Fi)[0],xi().memoizedState]},useMutableSource:Ni,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1},us={readContext:Co,useCallback:Ki,useContext:Co,useEffect:Ui,useImperativeHandle:Gi,useInsertionEffect:Hi,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ei,useRef:ji,useState:function(){return Ei(Fi)},useDebugValue:qi,useDeferredValue:function(e){var t=xi();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Ei(Fi)[0],xi().memoizedState]},useMutableSource:Ni,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1};function cs(e,t){try{var n="",r=t;do{n+=V(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function ps(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var fs="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Oo(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Ul||(Ul=!0,Hl=r),ps(0,t)},n}function hs(e,t,n){(n=Oo(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){ps(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){ps(0,t),"function"!==typeof r&&(null===Jl?Jl=new Set([this]):Jl.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new fs;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=ku.bind(null,e,t,n),t.then(e,e))}function bs(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function ys(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Oo(-1,1)).tag=2,Lo(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Yo(t,null,n,r):Qo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return ko(t,a),r=Ti(e,t,n,r,o,a),n=ki(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Us(e,t,a))}function Ps(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Ru(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Ou(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Ts(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Us(e,t,a)}return t.flags|=1,(e=Mu(o,r)).ref=t.ref,e.return=t,t.child=e}function Ts(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Us(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return xs(e,t,n,r,a)}function ks(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},Ca(Ml,Rl),Rl|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,Ca(Ml,Rl),Rl|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,Ca(Ml,Rl),Rl|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,Ca(Ml,Rl),Rl|=r;return ws(e,t,a,n),t.child}function Cs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function xs(e,t,n,r,a){var o=Ra(n)?Ea:Fa.current;return o=Na(t,o),ko(t,a),n=Ti(e,t,n,r,o,a),r=ki(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Us(e,t,a))}function Fs(e,t,n,r,a){if(Ra(n)){var o=!0;Da(t)}else o=!1;if(ko(t,a),null===t.stateNode)Ws(e,t),Uo(t,n,r),Jo(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,u=n.contextType;"object"===typeof u&&null!==u?u=Co(u):u=Na(t,u=Ra(n)?Ea:Fa.current);var c=n.getDerivedStateFromProps,d="function"===typeof c||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==u)&&Ho(t,i,r,u),No=!1;var p=t.memoizedState;i.state=p,Io(t,r,i,a),l=t.memoizedState,s!==r||p!==l||Aa.current||No?("function"===typeof c&&(Vo(t,n,c,r),l=t.memoizedState),(s=No||Wo(t,n,s,r,p,l,u))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=u,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Mo(e,t),s=t.memoizedProps,u=t.type===t.elementType?s:bo(t.type,s),i.props=u,d=t.pendingProps,p=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=Co(l):l=Na(t,l=Ra(n)?Ea:Fa.current);var f=n.getDerivedStateFromProps;(c="function"===typeof f||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||p!==l)&&Ho(t,i,r,l),No=!1,p=t.memoizedState,i.state=p,Io(t,r,i,a);var m=t.memoizedState;s!==d||p!==m||Aa.current||No?("function"===typeof f&&(Vo(t,n,f,r),m=t.memoizedState),(u=No||Wo(t,n,u,r,p,m,l)||!1)?(c||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=u):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),r=!1)}return As(e,t,n,r,o,a)}function As(e,t,n,r,a,o){Cs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&za(t,n,!1),Us(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&za(t,n,!0),t.child}function Es(e){var t=e.stateNode;t.pendingContext?Oa(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Oa(0,t.context,!1),ai(e,t.containerInfo)}function Ns(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Rs,Ms,Os,Ls={dehydrated:null,treeContext:null,retryLane:0};function Ds(e){return{baseLanes:e,cachePool:null,transitions:null}}function zs(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),Ca(li,1&i),null===e)return uo(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=Du(l,a,0,null),e=Lu(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=Ds(n),t.memoizedState=Ls,e):Is(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Zs(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=Du({mode:"visible",children:r.children},a,0,null),(i=Lu(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=Ds(s),t.memoizedState=Ls,i);if(0===(1&t.mode))return Zs(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Zs(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Al)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,Eo(e,a),nu(r,e,a,-1))}return hu(),Zs(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=xu.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ua(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&($a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Is(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var u={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=u,t.deletions=null):(a=Mu(i,u)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Mu(r,s):(s=Lu(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?Ds(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Ls,a}return e=(s=e.child).sibling,a=Mu(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Is(e,t){return(t=Du({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Zs(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Is(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function js(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),To(e.return,t,n)}function Vs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Bs(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&js(e,n,t);else if(19===e.tag)js(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(Ca(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ui(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Vs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ui(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Vs(t,!0,n,null,o);break;case"together":Vs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Ws(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Us(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),Dl|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Mu(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Mu(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Hs(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Js(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function $s(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Js(t),null;case 1:case 17:return Ra(t.type)&&Ma(),Js(t),null;case 3:return r=t.stateNode,oi(),ka(Aa),ka(Fa),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(po(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(iu(oo),oo=null))),Js(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Ms(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return Js(t),null}if(e=ri(ei.current),po(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[pa]=t,r[fa]=i,e=0!==(1&t.mode),n){case"dialog":Zr("cancel",r),Zr("close",r);break;case"iframe":case"object":case"embed":Zr("load",r);break;case"video":case"audio":for(a=0;a<Lr.length;a++)Zr(Lr[a],r);break;case"source":Zr("error",r);break;case"img":case"image":case"link":Zr("error",r),Zr("load",r);break;case"details":Zr("toggle",r);break;case"input":K(r,i),Zr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Zr("invalid",r);break;case"textarea":ae(r,i),Zr("invalid",r)}for(var l in ye(n,i),a=null,i)if(i.hasOwnProperty(l)){var u=i[l];"children"===l?"string"===typeof u?r.textContent!==u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",u]):"number"===typeof u&&r.textContent!==""+u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",""+u]):s.hasOwnProperty(l)&&null!=u&&"onScroll"===l&&Zr("scroll",r)}switch(n){case"input":J(r),X(r,i,!0);break;case"textarea":J(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[pa]=t,e[fa]=r,Rs(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Zr("cancel",e),Zr("close",e),a=r;break;case"iframe":case"object":case"embed":Zr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Lr.length;a++)Zr(Lr[a],e);a=r;break;case"source":Zr("error",e),a=r;break;case"img":case"image":case"link":Zr("error",e),Zr("load",e),a=r;break;case"details":Zr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Zr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=z({},r,{value:void 0}),Zr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Zr("invalid",e)}for(i in ye(n,a),u=a)if(u.hasOwnProperty(i)){var c=u[i];"style"===i?ve(e,c):"dangerouslySetInnerHTML"===i?null!=(c=c?c.__html:void 0)&&de(e,c):"children"===i?"string"===typeof c?("textarea"!==n||""!==c)&&pe(e,c):"number"===typeof c&&pe(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=c&&"onScroll"===i&&Zr("scroll",e):null!=c&&g(e,i,c,l))}switch(n){case"input":J(e),X(e,r,!1);break;case"textarea":J(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+U(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Js(t),null;case 6:if(e&&null!=t.stateNode)Os(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),po(t)){if(r=t.stateNode,n=t.memoizedProps,r[pa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[pa]=t,t.stateNode=r}return Js(t),null;case 13:if(ka(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))fo(),mo(),t.flags|=98560,i=!1;else if(i=po(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[pa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Js(t),i=!1}else null!==oo&&(iu(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Ol&&(Ol=3):hu())),null!==t.updateQueue&&(t.flags|=4),Js(t),null);case 4:return oi(),null===e&&Br(t.stateNode.containerInfo),Js(t),null;case 10:return Po(t.type._context),Js(t),null;case 19:if(ka(li),null===(i=t.memoizedState))return Js(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Hs(i,!1);else{if(0!==Ol||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ui(e))){for(t.flags|=128,Hs(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return Ca(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Bl&&(t.flags|=128,r=!0,Hs(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ui(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Hs(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return Js(t),null}else 2*Qe()-i.renderingStartTime>Bl&&1073741824!==n&&(t.flags|=128,r=!0,Hs(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,Ca(li,r?1&n|2:1&n),t):(Js(t),null);case 22:case 23:return du(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Rl)&&(Js(t),6&t.subtreeFlags&&(t.flags|=8192)):Js(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Gs(e,t){switch(to(t),t.tag){case 1:return Ra(t.type)&&Ma(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),ka(Aa),ka(Fa),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(ka(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return ka(li),null;case 4:return oi(),null;case 10:return Po(t.type._context),null;case 22:case 23:return du(),null;default:return null}}Rs=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Ms=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=z({},a,{value:void 0}),r=z({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(c in ye(n,r),n=null,a)if(!r.hasOwnProperty(c)&&a.hasOwnProperty(c)&&null!=a[c])if("style"===c){var l=a[c];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==c&&"children"!==c&&"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&"autoFocus"!==c&&(s.hasOwnProperty(c)?i||(i=[]):(i=i||[]).push(c,null));for(c in r){var u=r[c];if(l=null!=a?a[c]:void 0,r.hasOwnProperty(c)&&u!==l&&(null!=u||null!=l))if("style"===c)if(l){for(o in l)!l.hasOwnProperty(o)||u&&u.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in u)u.hasOwnProperty(o)&&l[o]!==u[o]&&(n||(n={}),n[o]=u[o])}else n||(i||(i=[]),i.push(c,n)),n=u;else"dangerouslySetInnerHTML"===c?(u=u?u.__html:void 0,l=l?l.__html:void 0,null!=u&&l!==u&&(i=i||[]).push(c,u)):"children"===c?"string"!==typeof u&&"number"!==typeof u||(i=i||[]).push(c,""+u):"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&(s.hasOwnProperty(c)?(null!=u&&"onScroll"===c&&Zr("scroll",e),i||l===u||(i=[])):(i=i||[]).push(c,u))}n&&(i=i||[]).push("style",n);var c=i;(t.updateQueue=c)&&(t.flags|=4)}},Os=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Tu(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Tu(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[pa],delete t[fa],delete t[ha],delete t[va],delete t[ba])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function ul(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(ul(e,t,n),e=e.sibling;null!==e;)ul(e,t,n),e=e.sibling}var cl=null,dl=!1;function pl(e,t,n){for(n=n.child;null!==n;)fl(e,t,n),n=n.sibling}function fl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=cl,a=dl;cl=null,pl(e,t,n),dl=a,null!==(cl=r)&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):cl.removeChild(n.stateNode));break;case 18:null!==cl&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Bt(e)):la(cl,n.stateNode));break;case 4:r=cl,a=dl,cl=n.stateNode.containerInfo,dl=!0,pl(e,t,n),cl=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}pl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Tu(n,t,s)}pl(e,t,n);break;case 21:pl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,pl(e,t,n),Ks=r):pl(e,t,n);break;default:pl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Fu.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:cl=l.stateNode,dl=!1;break e;case 3:case 4:cl=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===cl)throw Error(o(160));fl(i,s,a),cl=null,dl=!1;var u=a.alternate;null!==u&&(u.return=null),a.return=null}catch(c){Tu(a,t,c)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),bl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Tu(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Tu(e,e.return,v)}}break;case 1:hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{pe(a,"")}catch(v){Tu(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,u=e.updateQueue;if(e.updateQueue=null,null!==u)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var c=ge(l,i);for(s=0;s<u.length;s+=2){var d=u[s],p=u[s+1];"style"===d?ve(a,p):"dangerouslySetInnerHTML"===d?de(a,p):"children"===d?pe(a,p):g(a,d,p,c)}switch(l){case"input":Y(a,i);break;case"textarea":oe(a,i);break;case"select":var f=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):f!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[fa]=i}catch(v){Tu(e,e.return,v)}}break;case 6:if(hl(t,e),bl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Tu(e,e.return,v)}}break;case 3:if(hl(t,e),bl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Bt(t.containerInfo)}catch(v){Tu(e,e.return,v)}break;case 4:default:hl(t,e),bl(e);break;case 13:hl(t,e),bl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Vl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(c=Ks)||d,hl(t,e),Ks=c):hl(t,e),bl(e),8192&r){if(c=null!==e.memoizedState,(e.stateNode.isHidden=c)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(p=Ys=d;null!==Ys;){switch(m=(f=Ys).child,f.tag){case 0:case 11:case 14:case 15:nl(4,f,f.return);break;case 1:Xs(f,f.return);var h=f.stateNode;if("function"===typeof h.componentWillUnmount){r=f,n=f.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Tu(r,n,v)}}break;case 5:Xs(f,f.return);break;case 22:if(null!==f.memoizedState){wl(p);continue}}null!==m?(m.return=f,Ys=m):wl(p)}d=d.sibling}e:for(d=null,p=e;;){if(5===p.tag){if(null===d){d=p;try{a=p.stateNode,c?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=p.stateNode,s=void 0!==(u=p.memoizedProps.style)&&null!==u&&u.hasOwnProperty("display")?u.display:null,l.style.display=he("display",s))}catch(v){Tu(e,e.return,v)}}}else if(6===p.tag){if(null===d)try{p.stateNode.nodeValue=c?"":p.memoizedProps}catch(v){Tu(e,e.return,v)}}else if((22!==p.tag&&23!==p.tag||null===p.memoizedState||p===e)&&null!==p.child){p.child.return=p,p=p.child;continue}if(p===e)break e;for(;null===p.sibling;){if(null===p.return||p.return===e)break e;d===p&&(d=null),p=p.return}d===p&&(d=null),p.sibling.return=p.return,p=p.sibling}}break;case 19:hl(t,e),bl(e),4&r&&ml(e);case 21:}}function bl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(pe(a,""),r.flags&=-33),ul(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Tu(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function yl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var a=Ys,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var u=Ks;if(qs=i,(Ks=l)&&!u)for(Ys=a;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Ys=l):Sl(a);for(;null!==o;)Ys=o,gl(o,t,n),o=o.sibling;Ys=a,qs=s,Ks=u}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Ys=o):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:bo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Zo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Zo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var u=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":u.autoFocus&&n.focus();break;case"img":u.src&&(n.src=u.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var c=t.alternate;if(null!==c){var d=c.memoizedState;if(null!==d){var p=d.dehydrated;null!==p&&Bt(p)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(f){Tu(t,t.return,f)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function Sl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Tu(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Tu(t,a,l)}}var o=t.return;try{al(t)}catch(l){Tu(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Tu(t,i,l)}}}catch(l){Tu(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var Pl,Tl=Math.ceil,kl=_.ReactCurrentDispatcher,Cl=_.ReactCurrentOwner,xl=_.ReactCurrentBatchConfig,Fl=0,Al=null,El=null,Nl=0,Rl=0,Ml=Ta(0),Ol=0,Ll=null,Dl=0,zl=0,Il=0,Zl=null,jl=null,Vl=0,Bl=1/0,Wl=null,Ul=!1,Hl=null,Jl=null,$l=!1,Gl=null,ql=0,Kl=0,Ql=null,Yl=-1,Xl=0;function eu(){return 0!==(6&Fl)?Qe():-1!==Yl?Yl:Yl=Qe()}function tu(e){return 0===(1&e.mode)?1:0!==(2&Fl)&&0!==Nl?Nl&-Nl:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nu(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));bt(e,n,r),0!==(2&Fl)&&e===Al||(e===Al&&(0===(2&Fl)&&(zl|=n),4===Ol&&su(e,Nl)),ru(e,r),1===n&&0===Fl&&0===(1&t.mode)&&(Bl=Qe()+500,Za&&Ba()))}function ru(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=ft(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=pt(e,e===Al?Nl:0);if(0===r)null!==n&&Ge(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&Ge(n),1===t)0===e.tag?function(e){Za=!0,Va(e)}(lu.bind(null,e)):Va(lu.bind(null,e)),ia((function(){0===(6&Fl)&&Ba()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Au(n,au.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function au(e,t){if(Yl=-1,Xl=0,0!==(6&Fl))throw Error(o(327));var n=e.callbackNode;if(Su()&&e.callbackNode!==n)return null;var r=pt(e,e===Al?Nl:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vu(e,r);else{t=r;var a=Fl;Fl|=2;var i=mu();for(Al===e&&Nl===t||(Wl=null,Bl=Qe()+500,pu(e,t));;)try{yu();break}catch(l){fu(e,l)}So(),kl.current=i,Fl=a,null!==El?t=0:(Al=null,Nl=0,t=Ol)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=ou(e,a))),1===t)throw n=Ll,pu(e,0),su(e,r),ru(e,Qe()),n;if(6===t)su(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vu(e,r))&&(0!==(i=mt(e))&&(r=i,t=ou(e,i))),1===t))throw n=Ll,pu(e,0),su(e,r),ru(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wu(e,jl,Wl);break;case 3:if(su(e,r),(130023424&r)===r&&10<(t=Vl+500-Qe())){if(0!==pt(e,0))break;if(((a=e.suspendedLanes)&r)!==r){eu(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wu.bind(null,e,jl,Wl),t);break}wu(e,jl,Wl);break;case 4:if(su(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Tl(r/1960))-r)){e.timeoutHandle=ra(wu.bind(null,e,jl,Wl),r);break}wu(e,jl,Wl);break;default:throw Error(o(329))}}}return ru(e,Qe()),e.callbackNode===n?au.bind(null,e):null}function ou(e,t){var n=Zl;return e.current.memoizedState.isDehydrated&&(pu(e,t).flags|=256),2!==(e=vu(e,t))&&(t=jl,jl=n,null!==t&&iu(t)),e}function iu(e){null===jl?jl=e:jl.push.apply(jl,e)}function su(e,t){for(t&=~Il,t&=~zl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lu(e){if(0!==(6&Fl))throw Error(o(327));Su();var t=pt(e,0);if(0===(1&t))return ru(e,Qe()),null;var n=vu(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ou(e,r))}if(1===n)throw n=Ll,pu(e,0),su(e,t),ru(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wu(e,jl,Wl),ru(e,Qe()),null}function uu(e,t){var n=Fl;Fl|=1;try{return e(t)}finally{0===(Fl=n)&&(Bl=Qe()+500,Za&&Ba())}}function cu(e){null!==Gl&&0===Gl.tag&&0===(6&Fl)&&Su();var t=Fl;Fl|=1;var n=xl.transition,r=gt;try{if(xl.transition=null,gt=1,e)return e()}finally{gt=r,xl.transition=n,0===(6&(Fl=t))&&Ba()}}function du(){Rl=Ml.current,ka(Ml)}function pu(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==El)for(n=El.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Ma();break;case 3:oi(),ka(Aa),ka(Fa),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:ka(li);break;case 10:Po(r.type._context);break;case 22:case 23:du()}n=n.return}if(Al=e,El=e=Mu(e.current,null),Nl=Rl=t,Ol=0,Ll=null,Il=zl=Dl=0,jl=Zl=null,null!==xo){for(t=0;t<xo.length;t++)if(null!==(r=(n=xo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}xo=null}return e}function fu(e,t){for(;;){var n=El;try{if(So(),pi.current=is,yi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}yi=!1}if(mi=0,bi=vi=hi=null,gi=!1,_i=0,Cl.current=null,null===n||null===n.return){Ol=1,Ll=t,El=null;break}e:{var i=e,s=n.return,l=n,u=t;if(t=Nl,l.flags|=32768,null!==u&&"object"===typeof u&&"function"===typeof u.then){var c=u,d=l,p=d.tag;if(0===(1&d.mode)&&(0===p||11===p||15===p)){var f=d.alternate;f?(d.updateQueue=f.updateQueue,d.memoizedState=f.memoizedState,d.lanes=f.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=bs(s);if(null!==m){m.flags&=-257,ys(m,s,l,0,t),1&m.mode&&vs(i,c,t),u=c;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(u),t.updateQueue=v}else h.add(u);break e}if(0===(1&t)){vs(i,c,t),hu();break e}u=Error(o(426))}else if(ao&&1&l.mode){var b=bs(s);if(null!==b){0===(65536&b.flags)&&(b.flags|=256),ys(b,s,l,0,t),ho(cs(u,l));break e}}i=u=cs(u,l),4!==Ol&&(Ol=2),null===Zl?Zl=[i]:Zl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,zo(i,ms(0,u,t));break e;case 1:l=u;var y=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof y.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Jl||!Jl.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,zo(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_u(n)}catch(_){t=_,El===n&&null!==n&&(El=n=n.return);continue}break}}function mu(){var e=kl.current;return kl.current=is,null===e?is:e}function hu(){0!==Ol&&3!==Ol&&2!==Ol||(Ol=4),null===Al||0===(268435455&Dl)&&0===(268435455&zl)||su(Al,Nl)}function vu(e,t){var n=Fl;Fl|=2;var r=mu();for(Al===e&&Nl===t||(Wl=null,pu(e,t));;)try{bu();break}catch(a){fu(e,a)}if(So(),Fl=n,kl.current=r,null!==El)throw Error(o(261));return Al=null,Nl=0,Ol}function bu(){for(;null!==El;)gu(El)}function yu(){for(;null!==El&&!qe();)gu(El)}function gu(e){var t=Pl(e.alternate,e,Rl);e.memoizedProps=e.pendingProps,null===t?_u(e):El=t,Cl.current=null}function _u(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=$s(n,t,Rl)))return void(El=n)}else{if(null!==(n=Gs(n,t)))return n.flags&=32767,void(El=n);if(null===e)return Ol=6,void(El=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(El=t);El=t=e}while(null!==t);0===Ol&&(Ol=5)}function wu(e,t,n){var r=gt,a=xl.transition;try{xl.transition=null,gt=1,function(e,t,n,r){do{Su()}while(null!==Gl);if(0!==(6&Fl))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===Al&&(El=Al=null,Nl=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||$l||($l=!0,Au(tt,(function(){return Su(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=xl.transition,xl.transition=null;var s=gt;gt=1;var l=Fl;Fl|=4,Cl.current=null,function(e,t){if(ea=Ut,fr(e=pr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,u=-1,c=0,d=0,p=e,f=null;t:for(;;){for(var m;p!==n||0!==a&&3!==p.nodeType||(l=s+a),p!==i||0!==r&&3!==p.nodeType||(u=s+r),3===p.nodeType&&(s+=p.nodeValue.length),null!==(m=p.firstChild);)f=p,p=m;for(;;){if(p===e)break t;if(f===n&&++c===a&&(l=s),f===i&&++d===r&&(u=s),null!==(m=p.nextSibling))break;f=(p=f).parentNode}p=m}n=-1===l||-1===u?null:{start:l,end:u}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Ut=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,b=h.memoizedState,y=t.stateNode,g=y.getSnapshotBeforeUpdate(t.elementType===t.type?v:bo(t.type,v),b);y.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Tu(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Ut=!!ea,ta=ea=null,e.current=n,yl(n,e,a),Ke(),Fl=l,gt=s,xl.transition=i}else e.current=n;if($l&&($l=!1,Gl=e,ql=a),0===(i=e.pendingLanes)&&(Jl=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),ru(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Ul)throw Ul=!1,e=Hl,Hl=null,e;0!==(1&ql)&&0!==e.tag&&Su(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Ba()}(e,t,n,r)}finally{xl.transition=a,gt=r}return null}function Su(){if(null!==Gl){var e=_t(ql),t=xl.transition,n=gt;try{if(xl.transition=null,gt=16>e?16:e,null===Gl)var r=!1;else{if(e=Gl,Gl=null,ql=0,0!==(6&Fl))throw Error(o(331));var a=Fl;for(Fl|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var u=0;u<l.length;u++){var c=l[u];for(Ys=c;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var p=d.child;if(null!==p)p.return=d,Ys=p;else for(;null!==Ys;){var f=(d=Ys).sibling,m=d.return;if(ol(d),d===c){Ys=null;break}if(null!==f){f.return=m,Ys=f;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var b=v.sibling;v.sibling=null,v=b}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var y=i.sibling;if(null!==y){y.return=i.return,Ys=y;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){Tu(l,l.return,S)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(Fl=a,Ba(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,xl.transition=t}}return!1}function Pu(e,t,n){e=Lo(e,t=ms(0,t=cs(n,t),1),1),t=eu(),null!==e&&(bt(e,1,t),ru(e,t))}function Tu(e,t,n){if(3===e.tag)Pu(e,e,n);else for(;null!==t;){if(3===t.tag){Pu(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Jl||!Jl.has(r))){t=Lo(t,e=hs(t,e=cs(n,e),1),1),e=eu(),null!==t&&(bt(t,1,e),ru(t,e));break}}t=t.return}}function ku(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=eu(),e.pingedLanes|=e.suspendedLanes&n,Al===e&&(Nl&n)===n&&(4===Ol||3===Ol&&(130023424&Nl)===Nl&&500>Qe()-Vl?pu(e,0):Il|=n),ru(e,t)}function Cu(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ct,0===(130023424&(ct<<=1))&&(ct=4194304)));var n=eu();null!==(e=Eo(e,t))&&(bt(e,t,n),ru(e,n))}function xu(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),Cu(e,n)}function Fu(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),Cu(e,n)}function Au(e,t){return $e(e,t)}function Eu(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Nu(e,t,n,r){return new Eu(e,t,n,r)}function Ru(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Mu(e,t){var n=e.alternate;return null===n?((n=Nu(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Ou(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Ru(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case P:return Lu(n.children,a,i,t);case T:s=8,a|=8;break;case k:return(e=Nu(12,n,t,2|a)).elementType=k,e.lanes=i,e;case A:return(e=Nu(13,n,t,a)).elementType=A,e.lanes=i,e;case E:return(e=Nu(19,n,t,a)).elementType=E,e.lanes=i,e;case M:return Du(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case C:s=10;break e;case x:s=9;break e;case F:s=11;break e;case N:s=14;break e;case R:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Nu(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Lu(e,t,n,r){return(e=Nu(7,e,r,t)).lanes=n,e}function Du(e,t,n,r){return(e=Nu(22,e,r,t)).elementType=M,e.lanes=n,e.stateNode={isHidden:!1},e}function zu(e,t,n){return(e=Nu(6,e,null,t)).lanes=n,e}function Iu(e,t,n){return(t=Nu(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Zu(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function ju(e,t,n,r,a,o,i,s,l){return e=new Zu(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Nu(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Ro(o),e}function Vu(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Bu(e){if(!e)return xa;e:{if(Be(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Ra(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Ra(n))return La(e,n,t)}return t}function Wu(e,t,n,r,a,o,i,s,l){return(e=ju(n,r,!0,e,0,o,0,s,l)).context=Bu(null),n=e.current,(o=Oo(r=eu(),a=tu(n))).callback=void 0!==t&&null!==t?t:null,Lo(n,o,a),e.current.lanes=a,bt(e,a,r),ru(e,r),e}function Uu(e,t,n,r){var a=t.current,o=eu(),i=tu(a);return n=Bu(n),null===t.context?t.context=n:t.pendingContext=n,(t=Oo(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Lo(a,t,i))&&(nu(e,a,i,o),Do(e,a,i)),i}function Hu(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Ju(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function $u(e,t){Ju(e,t),(e=e.alternate)&&Ju(e,t)}Pl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Aa.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Es(t),mo();break;case 5:ii(t);break;case 1:Ra(t.type)&&Da(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;Ca(yo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(Ca(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?zs(e,t,n):(Ca(li,1&li.current),null!==(e=Us(e,t,n))?e.sibling:null);Ca(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Bs(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),Ca(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,ks(e,t,n)}return Us(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,Ja,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Ws(e,t),e=t.pendingProps;var a=Na(t,Fa.current);ko(t,n),a=Ti(null,t,r,e,a,n);var i=ki();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Ra(r)?(i=!0,Da(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Ro(t),a.updater=Bo,t.stateNode=a,a._reactInternals=t,Jo(t,r,e,n),t=As(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Ws(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Ru(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===F)return 11;if(e===N)return 14}return 2}(r),e=bo(r,e),a){case 0:t=xs(null,t,r,e,n);break e;case 1:t=Fs(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=Ps(null,t,r,bo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,xs(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Fs(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 3:e:{if(Es(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,Mo(e,t),Io(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Ns(e,t,r,n,a=cs(Error(o(423)),t));break e}if(r!==a){t=Ns(e,t,r,n,a=cs(Error(o(424)),t));break e}for(ro=ua(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Yo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Us(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&uo(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),Cs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&uo(t),null;case 13:return zs(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,Ca(yo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Aa.current){t=Us(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var u=l.firstContext;null!==u;){if(u.context===r){if(1===i.tag){(u=Oo(-1,n&-n)).tag=2;var c=i.updateQueue;if(null!==c){var d=(c=c.shared).pending;null===d?u.next=u:(u.next=d.next,d.next=u),c.pending=u}}i.lanes|=n,null!==(u=i.alternate)&&(u.lanes|=n),To(i.return,n,t),l.lanes|=n;break}u=u.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),To(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,ko(t,n),r=r(a=Co(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=bo(r=t.type,t.pendingProps),Ps(e,t,r,a=bo(r.type,a),n);case 15:return Ts(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:bo(r,a),Ws(e,t),t.tag=1,Ra(r)?(e=!0,Da(t)):e=!1,ko(t,n),Uo(t,r,a),Jo(t,r,a,n),As(null,t,r,!0,e,n);case 19:return Bs(e,t,n);case 22:return ks(e,t,n)}throw Error(o(156,t.tag))};var Gu="function"===typeof reportError?reportError:function(e){console.error(e)};function qu(e){this._internalRoot=e}function Ku(e){this._internalRoot=e}function Qu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xu(){}function ec(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Hu(i);s.call(e)}}Uu(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Hu(i);o.call(e)}}var i=Wu(t,r,e,0,null,!1,0,"",Xu);return e._reactRootContainer=i,e[ma]=i.current,Br(8===e.nodeType?e.parentNode:e),cu(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Hu(l);s.call(e)}}var l=ju(e,0,!1,null,0,!1,0,"",Xu);return e._reactRootContainer=l,e[ma]=l.current,Br(8===e.nodeType?e.parentNode:e),cu((function(){Uu(t,l,n,r)})),l}(n,t,e,a,r);return Hu(i)}Ku.prototype.render=qu.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Uu(e,t,null,null)},Ku.prototype.unmount=qu.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;cu((function(){Uu(null,e,null,null)})),t[ma]=null}},Ku.prototype.unstable_scheduleHydration=function(e){if(e){var t=Tt();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Mt.length&&0!==t&&t<Mt[n].priority;n++);Mt.splice(n,0,e),0===n&&zt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(yt(t,1|n),ru(t,Qe()),0===(6&Fl)&&(Bl=Qe()+500,Ba()))}break;case 13:cu((function(){var t=Eo(e,1);if(null!==t){var n=eu();nu(t,e,1,n)}})),$u(e,1)}},St=function(e){if(13===e.tag){var t=Eo(e,134217728);if(null!==t)nu(t,e,134217728,eu());$u(e,134217728)}},Pt=function(e){if(13===e.tag){var t=tu(e),n=Eo(e,t);if(null!==n)nu(n,e,t,eu());$u(e,t)}},Tt=function(){return gt},kt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));$(r),Y(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Fe=uu,Ae=cu;var tc={usingClientEntryPoint:!1,Events:[ga,_a,wa,Ce,xe,uu]},nc={findFiberByHostInstance:ya,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},rc={bundleType:nc.bundleType,version:nc.version,rendererPackageName:nc.rendererPackageName,rendererConfig:nc.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=He(e))?null:e.stateNode},findFiberByHostInstance:nc.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ac=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ac.isDisabled&&ac.supportsFiber)try{at=ac.inject(rc),ot=ac}catch(ce){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tc,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qu(t))throw Error(o(200));return Vu(e,t,null,n)},t.createRoot=function(e,t){if(!Qu(e))throw Error(o(299));var n=!1,r="",a=Gu;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=ju(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Br(8===e.nodeType?e.parentNode:e),new qu(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=He(t))?null:e.stateNode},t.flushSync=function(e){return cu(e)},t.hydrate=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qu(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Gu;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Wu(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Br(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Ku(t)},t.render=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yu(e))throw Error(o(40));return!!e._reactRootContainer&&(cu((function(){ec(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=uu,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yu(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return ec(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function u(e,t,n){var r,o={},u=null,c=null;for(r in void 0!==n&&(u=""+n),void 0!==t.key&&(u=""+t.key),void 0!==t.ref&&(c=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:u,ref:c,props:o,_owner:s.current}}t.Fragment=o,t.jsx=u,t.jsxs=u},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),u=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),p=Symbol.for("react.lazy"),f=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function b(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function y(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}b.prototype.isReactComponent={},b.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},b.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},y.prototype=b.prototype;var _=g.prototype=new y;_.constructor=g,h(_,b.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,P={current:null},T={key:!0,ref:!0,__self:!0,__source:!0};function k(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!T.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var u=Array(l),c=0;c<l;c++)u[c]=arguments[c+2];o.children=u}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:P.current}}function C(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var x=/\/+/g;function F(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function A(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+F(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(x,"$&/")+"/"),A(i,t,a,"",(function(e){return e}))):null!=i&&(C(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(x,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var u=0;u<e.length;u++){var c=o+F(s=e[u],u);l+=A(s,t,a,c,i)}else if(c=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=f&&e[f]||e["@@iterator"])?e:null}(e),"function"===typeof c)for(e=c.call(e),u=0;!(s=e.next()).done;)l+=A(s=s.value,t,a,c=o+F(s,u++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function E(e,t,n){if(null==e)return e;var r=[],a=0;return A(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function N(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var R={current:null},M={transition:null},O={ReactCurrentDispatcher:R,ReactCurrentBatchConfig:M,ReactCurrentOwner:P};t.Children={map:E,forEach:function(e,t,n){E(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return E(e,(function(){t++})),t},toArray:function(e){return E(e,(function(e){return e}))||[]},only:function(e){if(!C(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=b,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=c,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=O,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=P.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(u in t)S.call(t,u)&&!T.hasOwnProperty(u)&&(a[u]=void 0===t[u]&&void 0!==l?l[u]:t[u])}var u=arguments.length-2;if(1===u)a.children=r;else if(1<u){l=Array(u);for(var c=0;c<u;c++)l[c]=arguments[c+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=k,t.createFactory=function(e){var t=k.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:u,render:e}},t.isValidElement=C,t.lazy=function(e){return{$$typeof:p,_payload:{_status:-1,_result:e},_init:N}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=M.transition;M.transition={};try{e()}finally{M.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return R.current.useCallback(e,t)},t.useContext=function(e){return R.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return R.current.useDeferredValue(e)},t.useEffect=function(e,t){return R.current.useEffect(e,t)},t.useId=function(){return R.current.useId()},t.useImperativeHandle=function(e,t,n){return R.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return R.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return R.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return R.current.useMemo(e,t)},t.useReducer=function(e,t,n){return R.current.useReducer(e,t,n)},t.useRef=function(e){return R.current.useRef(e)},t.useState=function(e){return R.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return R.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return R.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],u=s+1,c=e[u];if(0>o(l,n))u<a&&0>o(c,l)?(e[r]=c,e[u]=n,r=u):(e[r]=l,e[s]=n,r=s);else{if(!(u<a&&0>o(c,n)))break e;e[r]=c,e[u]=n,r=u}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var u=[],c=[],d=1,p=null,f=3,m=!1,h=!1,v=!1,b="function"===typeof setTimeout?setTimeout:null,y="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(c);null!==t;){if(null===t.callback)a(c);else{if(!(t.startTime<=e))break;a(c),t.sortIndex=t.expirationTime,n(u,t)}t=r(c)}}function w(e){if(v=!1,_(e),!h)if(null!==r(u))h=!0,M(S);else{var t=r(c);null!==t&&O(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,y(C),C=-1),m=!0;var o=f;try{for(_(n),p=r(u);null!==p&&(!(p.expirationTime>n)||e&&!A());){var i=p.callback;if("function"===typeof i){p.callback=null,f=p.priorityLevel;var s=i(p.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?p.callback=s:p===r(u)&&a(u),_(n)}else a(u);p=r(u)}if(null!==p)var l=!0;else{var d=r(c);null!==d&&O(w,d.startTime-n),l=!1}return l}finally{p=null,f=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var P,T=!1,k=null,C=-1,x=5,F=-1;function A(){return!(t.unstable_now()-F<x)}function E(){if(null!==k){var e=t.unstable_now();F=e;var n=!0;try{n=k(!0,e)}finally{n?P():(T=!1,k=null)}}else T=!1}if("function"===typeof g)P=function(){g(E)};else if("undefined"!==typeof MessageChannel){var N=new MessageChannel,R=N.port2;N.port1.onmessage=E,P=function(){R.postMessage(null)}}else P=function(){b(E,0)};function M(e){k=e,T||(T=!0,P())}function O(e,n){C=b((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,M(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):x=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return f},t.unstable_getFirstCallbackNode=function(){return r(u)},t.unstable_next=function(e){switch(f){case 1:case 2:case 3:var t=3;break;default:t=f}var n=f;f=t;try{return e()}finally{f=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=f;f=e;try{return t()}finally{f=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(c,e),null===r(u)&&e===r(c)&&(v?(y(C),C=-1):v=!0,O(w,o-i))):(e.sortIndex=s,n(u,e),h||m||(h=!0,M(S))),e},t.unstable_shouldYield=A,t.unstable_wrapCallback=function(e){var t=f;return function(){var n=f;f=t;try{return e.apply(this,arguments)}finally{f=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),u=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),u=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),u.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=u.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function c(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=c.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var p=n(184);function f(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,p.jsx)(u,{styles:a})}var m=n(4205);var h=function(e){return(0,p.jsx)(f,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},b=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var y=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},b(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),P=n(7312),T=n(1217),k=n(4419),C=n(8691),x=(0,n(4046).ZP)(),F=n(5080),A=["className","component","disableGutters","fixed","maxWidth","classes"],E=(0,F.Z)(),N=x("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,P.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),R=function(e){return(0,C.Z)({props:e,name:"MuiContainer",defaultTheme:E})},M=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,P.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,k.Z)(i,(function(e){return(0,T.Z)(t,e)}),n)};var O=n(9853),L=n(277),D=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?N:n,o=t.useThemeProps,i=void 0===o?R:o,s=t.componentName,l=void 0===s?"MuiContainer":s,u=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),c=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,c=n.disableGutters,d=void 0!==c&&c,f=n.fixed,m=void 0!==f&&f,h=n.maxWidth,v=void 0===h?"lg":h,b=(0,w.Z)(n,A),y=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=M(y,l);return(0,p.jsx)(u,(0,r.Z)({as:s,ownerState:y,className:(0,S.Z)(g.root,a),ref:t},b))}));return c}({createStyledComponent:(0,L.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,O.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),z=D,I=n(2421),Z=n(104),j=n(2982),V=n(2466),B=n(114),W=["sx"];function U(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){B.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,W)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,j.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,V.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var H=n(886),J=["className","component"];var $=n(5902),G=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?Z.Z:s,u=(0,I.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),c=e.forwardRef((function(e,t){var a=(0,H.Z)(n),s=U(e),l=s.className,c=s.component,d=void 0===c?"div":c,f=(0,w.Z)(s,J);return(0,p.jsx)(u,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},f))}));return c}({defaultTheme:(0,G.Z)(),defaultClassName:"MuiBox-root",generateClassName:$.Z.generate}),K=q,Q=JSON.parse('{"e":16,"C":[{"nctid":"NCT03083665","version_a":1,"version_b":2,"version_a_date":"2017-03-14","version_b_date":"2017-03-17","pom_a":[{"label":"1.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From baseline to 12-weeks Tratement period ]"}],"pom_b":[{"label":"1.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From baseline to 12-weeks Treatment period ]"}],"first_posted":"No date provided","completion_date":"June 30, 2022","primary_completion_date":"June 30, 2022","start_date":"August 22, 2017","last_update_posted":"August 12, 2022"},{"nctid":"NCT03083665","version_a":2,"version_b":3,"version_a_date":"2017-03-17","version_b_date":"2017-04-13","pom_a":[{"label":"1.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From baseline to 12-weeks Treatment period ]"}],"pom_b":[{"label":"1.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From baseline to 12-weeks Treatment period ]Calculated as (seizure frequency Baseline - seizure frequency Treatment) *100/ (seizure frequency Baseline).The higher the values for percent change in partial seizure (PS) frequency, the higher the improvement from Baseline."}],"first_posted":"No date provided","completion_date":"June 30, 2022","primary_completion_date":"June 30, 2022","start_date":"August 22, 2017","last_update_posted":"August 12, 2022"},{"nctid":"NCT03083665","version_a":22,"version_b":23,"version_a_date":"2019-03-21","version_b_date":"2019-04-09","pom_a":[{"label":"1.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From baseline to 12-weeks Treatment period ]Calculated as (seizure frequency Baseline - seizure frequency Treatment) *100/ (seizure frequency Baseline).The higher the values for percent change in partial seizure (PS) frequency, the higher the improvement from Baseline."}],"pom_b":[{"label":"1.","content":"Adverse events (AEs)[ Time Frame: From Screening (Week -8) until Safety Visit (up to Week 18) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"2.","content":"Partial seizure frequency per 28 days during the 12-week Treatment Period[ Time Frame: From Baseline to 12-weeks Treatement Period ]Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures."},{"label":"3.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From Baseline to 12-weeks Tratement Period ]Calculated as (seizure frequency Baseline - seizure frequency Treatment) *100/ (seizure frequency Baseline). The higher the values for percent change in partial seizure (PS) frequency, the higher the improvement from Baseline."}],"first_posted":"No date provided","completion_date":"June 30, 2022","primary_completion_date":"June 30, 2022","start_date":"August 22, 2017","last_update_posted":"August 12, 2022"},{"nctid":"NCT03083665","version_a":81,"version_b":82,"version_a_date":"2022-08-11","version_b_date":"2022-10-06","pom_a":[{"label":"1.","content":"Adverse events (AEs)[ Time Frame: From Screening (Week -8) until Safety Visit (up to Week 18) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"2.","content":"Partial seizure frequency per 28 days during the 12-week Treatment Period[ Time Frame: From Baseline to 12-weeks Treatement Period ]Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures."},{"label":"3.","content":"Percent change in partial seizure frequency during the 12-week Treatment Period[ Time Frame: From Baseline to 12-weeks Tratement Period ]Calculated as (seizure frequency Baseline - seizure frequency Treatment) *100/ (seizure frequency Baseline). The higher the values for percent change in partial seizure (PS) frequency, the higher the improvement from Baseline."}],"pom_b":[{"label":"1.","content":"Incidence of Treatment-Emergent Adverse Events (TEAEs)[ Time Frame: From start of the Treatment Period (Week 2) until Safety Visit (up to Week 18) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"2.","content":"Incidence of Treatment-Emergent AEs (TEAEs) leading to study withdrawal[ Time Frame: From start of the Treatment Period (Week 2) until Safety Visit (up to Week 18) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"3.","content":"Incidence of Treatment-Emergent Serious Adverse Events (SAEs)[ Time Frame: From start of the Treatment Period (Week 2) until Safety Visit (up to Week 18) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"4.","content":"Partial seizure frequency per 28 days during the 12-week Treatment Period[ Time Frame: From Baseline to 12-weeks Treatement Period ]Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures."}],"first_posted":"No date provided","completion_date":"June 30, 2022","primary_completion_date":"June 30, 2022","start_date":"August 22, 2017","last_update_posted":"August 12, 2022"},{"nctid":"NCT02807636","version_a":9,"version_b":10,"version_a_date":"2016-11-08","version_b_date":"2017-02-02","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Assessed by Investigator Using RECIST V1.1[ Time Frame: Baseline up to Disease progression or death, whichever occurred first (up to 33 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Baseline until death due to any cause (up to 33 months) ]"},{"label":"3.","content":"Percentage of Participants with Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0[ Time Frame: Baseline up to 33 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Participants Treated with Atezolizumab Combination Therapy Compared With Placebo Arm[ Time Frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 44 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Baseline until death due to any cause (up to 44 months) ]"},{"label":"3.","content":"Percentage of Participants with Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0[ Time Frame: Baseline up to 44 months ]"}],"first_posted":"No date provided","completion_date":"July 22, 2023","primary_completion_date":"July 22, 2023","start_date":"June 30, 2016","last_update_posted":"July 18, 2022"},{"nctid":"NCT00317642","version_a":16,"version_b":17,"version_a_date":"2007-08-16","version_b_date":"2007-08-29","pom_a":[{"label":"1.","content":"overall survival"}],"pom_b":[{"label":"1.","content":"overall survival[ Time Frame: Duration of study ]"}],"first_posted":"September 15, 2011","completion_date":"January 2012","primary_completion_date":"January 2012","start_date":"August 2006","last_update_posted":"April 14, 2014"},{"nctid":"NCT00317642","version_a":20,"version_b":21,"version_a_date":"2007-12-14","version_b_date":"2007-12-31","pom_a":[{"label":"1.","content":"overall survival[ Time Frame: Duration of study ]"}],"pom_b":[{"label":"1.","content":"overall survival[ Time Frame: Up to 7 years or duration of study ]"}],"first_posted":"September 15, 2011","completion_date":"January 2012","primary_completion_date":"January 2012","start_date":"August 2006","last_update_posted":"April 14, 2014"},{"nctid":"NCT00317642","version_a":33,"version_b":34,"version_a_date":"2011-05-16","version_b_date":"2011-08-11","pom_a":[{"label":"1.","content":"overall survival[ Time Frame: Up to 7 years or duration of study ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Day 1 (randomization) up to approximately 4 years ]Overall survival (OS) for Full Analysis Set (FAS) and for the 2 randomization strata - Participants with CR1 <6 months and Participants with CR1 >=6 months (CR1 = remission after first pre-study induction regimen) - was defined as the number of months from date of randomization until date of death due to any cause."}],"first_posted":"September 15, 2011","completion_date":"January 2012","primary_completion_date":"January 2012","start_date":"August 2006","last_update_posted":"April 14, 2014"},{"nctid":"NCT00317642","version_a":36,"version_b":37,"version_a_date":"2012-05-03","version_b_date":"2012-11-27","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Day 1 (randomization) up to approximately 4 years ]Overall survival (OS) for Full Analysis Set (FAS) and for the 2 randomization strata - Participants with CR1 <6 months and Participants with CR1 >=6 months (CR1 = remission after first pre-study induction regimen) - was defined as the number of months from date of randomization until date of death due to any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)[ Time Frame: Day 1 (randomization) up to approximately 4 years ]Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 calculated strata. OS was defined as the number of months from date of randomization until date of death due to any cause."},{"label":"2.","content":"Overall Survival - Overall and by Randomized Strata (CSR 9-July-12)[ Time Frame: Day 1 (randomization) up to approximately 4 years ]Overall survival (OS) for the Full Analysis Set (FAS) and for the 2 randomized strata. OS was defined as the number of months from date of randomization until date of death due to any cause."}],"first_posted":"September 15, 2011","completion_date":"January 2012","primary_completion_date":"January 2012","start_date":"August 2006","last_update_posted":"April 14, 2014"},{"nctid":"NCT03058094","version_a":2,"version_b":3,"version_a_date":"2017-06-26","version_b_date":"2018-06-28","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: From the date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 24 months. ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: From the date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 24 months. ]To assess the Progression-Free Survival (PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC)."}],"first_posted":"No date provided","completion_date":"January 2020","primary_completion_date":"December 2019","start_date":"December 2018","last_update_posted":"February 4, 2019"},{"nctid":"NCT00655876","version_a":29,"version_b":30,"version_a_date":"2008-11-12","version_b_date":"2008-11-13","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival (failure: death due to any cause)"}],"first_posted":"March 14, 2018","completion_date":"May 20, 2022","primary_completion_date":"April 2015","start_date":"June 2008","last_update_posted":"June 14, 2022"},{"nctid":"NCT00655876","version_a":484,"version_b":485,"version_a_date":"2014-03-28","version_b_date":"2015-03-31","pom_a":[{"label":"1.","content":"Overall survival (failure: death due to any cause)"}],"pom_b":[{"label":"1.","content":"Overall survival (failure: death due to any cause)[ Time Frame: From randomization to the date of death or last follow-up for up to 10 years ]"}],"first_posted":"March 14, 2018","completion_date":"May 20, 2022","primary_completion_date":"April 2015","start_date":"June 2008","last_update_posted":"June 14, 2022"},{"nctid":"NCT00655876","version_a":486,"version_b":487,"version_a_date":"2016-09-28","version_b_date":"2018-02-14","pom_a":[{"label":"1.","content":"Overall survival (failure: death due to any cause)[ Time Frame: From randomization to the date of death or last follow-up for up to 10 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (24-month Rate Reported)[ Time Frame: From randomization to last follow-up. Analysis was planned to occur after at least 281 deaths had been observed. Maximum follow-up at time of analysis was 74.5 months. ]Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur after at least 281 deaths have been observed, unless an early stopping rule was satisfied."}],"first_posted":"March 14, 2018","completion_date":"May 20, 2022","primary_completion_date":"April 2015","start_date":"June 2008","last_update_posted":"June 14, 2022"},{"nctid":"NCT03194646","version_a":49,"version_b":50,"version_a_date":"2021-04-29","version_b_date":"2021-06-21","pom_a":[{"label":"1.","content":"Percentage change in bone mineral density (BMD) of lumbar spine[ Time Frame: One year ]The percentage change in BMD of lumbar spine from baseline to about one year after start of treatment (SoT) in all randomized and treated subjects with measurements at those 2 time points in each treatment group.The study will be continued after the date of primary completion. Study results will be updated once the study is completed, after LPLV."}],"pom_b":[{"label":"1.","content":"Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine[ Time Frame: From baseline to about 1 year after start of treatment ]The percentage change in BMD (measured by dual-energy X-ray absorptiometry (DEXA) scan) of lumbar spine from baseline to about one year after start of treatment (SoT) in all randomized and treated participants with measurements at those 2 time points in each treatment group."}],"first_posted":"August 26, 2021","completion_date":"June 30, 2024","primary_completion_date":"May 10, 2019","start_date":"June 30, 2017","last_update_posted":"September 7, 2022"},{"nctid":"NCT00057564","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2008-03-04","pom_a":[],"pom_b":[{"label":"1.","content":"Compare the efficacy of combination thalidomide and dexamethasone treatments[ Time Frame: Years ]"}],"first_posted":"No date provided","completion_date":"August 2013","primary_completion_date":"April 2006","start_date":"February 2003","last_update_posted":"September 11, 2015"},{"nctid":"NCT00057564","version_a":5,"version_b":6,"version_a_date":"2010-08-27","version_b_date":"2012-09-19","pom_a":[{"label":"1.","content":"Compare the efficacy of combination thalidomide and dexamethasone treatments[ Time Frame: Years ]"}],"pom_b":[{"label":"1.","content":"Time to tumor progression (TTP)[ Time Frame: Up to 3 years ]Time to tumor progression (TTP)"}],"first_posted":"No date provided","completion_date":"August 2013","primary_completion_date":"April 2006","start_date":"February 2003","last_update_posted":"September 11, 2015"},{"nctid":"NCT02606461","version_a":2,"version_b":3,"version_a_date":"2016-02-05","version_b_date":"2016-05-04","pom_a":[{"label":"1.","content":"Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 30 months. ]"},{"label":"2.","content":"Primary analysis of PFS -performed on the intent-to-treat (ITT) population.[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 12 months. ]Phase 2 PFS data will inform adjustment of the Phase 3 sample size"},{"label":"3.","content":"Time to progression (TTP)[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 30 months. ]"},{"label":"4.","content":"Quality of Life as measured by the EORTC QLQ-C30 total score.[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 30 months. ]For EORTC QLQ-C30, the transformed score will be used, calculated according to the EORTC QLQ-C30 Scoring Manual."},{"label":"5.","content":"Quality of Life as measured by the EQ-5D-5L category scores and total score.[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 30 months. ]For the EQ-5D-5L questionnaire, the overall health score will be used."}],"pom_b":[{"label":"1.","content":"Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 30 months. ]"}],"first_posted":"December 7, 2021","completion_date":"December 2021","primary_completion_date":"October 28, 2020","start_date":"January 4, 2016","last_update_posted":"December 7, 2021"},{"nctid":"NCT02606461","version_a":12,"version_b":13,"version_a_date":"2017-05-25","version_b_date":"2017-11-29","pom_a":[{"label":"1.","content":"Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.[ Time Frame: From the date of randomization until the first date of disease progression, per WHO Response Criteria, or death due to any cause; up to approximately 30 months. ]"}],"pom_b":[{"label":"1.","content":"Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.[ Time Frame: From the date of randomization until the first date of disease progression, per RECIST v1.1 Response Criteria, or death due to any cause; up to approximately 30 months. ]"}],"first_posted":"December 7, 2021","completion_date":"December 2021","primary_completion_date":"October 28, 2020","start_date":"January 4, 2016","last_update_posted":"December 7, 2021"},{"nctid":"NCT02606461","version_a":41,"version_b":42,"version_a_date":"2021-04-30","version_b_date":"2021-11-08","pom_a":[{"label":"1.","content":"Assess and compare Progression-free Survival (PFS) of patients with advanced unresectable DDLS treated with selinexor (60 milligrams [mg]) or placebo.[ Time Frame: From the date of randomization until the first date of disease progression, per RECIST v1.1 Response Criteria, or death due to any cause; up to approximately 30 months. ]"}],"pom_b":[{"label":"1.","content":"Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version. 1.1[ Time Frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 56 months) ]Progression-free survival (PFS) was defined as the time from the date of randomization until the first date of IRC-confirmed PD per RECIST version. 1.1, or death due to any cause. PD was defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions."},{"label":"2.","content":"Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1[ Time Frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 56 months) ]Progression-free survival (PFS) was defined as the time from date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions."}],"first_posted":"December 7, 2021","completion_date":"December 2021","primary_completion_date":"October 28, 2020","start_date":"January 4, 2016","last_update_posted":"December 7, 2021"},{"nctid":"NCT00069095","version_a":8,"version_b":9,"version_a_date":"2006-01-18","version_b_date":"2006-02-17","pom_a":[],"pom_b":[{"label":"1.","content":"Efficacy: Non-inferiority of XELOX vs FOLFOX with respect to time to tumor progression or death, and superiority of Avastin vs placebo"}],"first_posted":"January 22, 2016","completion_date":"April 2009","primary_completion_date":"January 2006","start_date":"July 2003","last_update_posted":"October 6, 2016"},{"nctid":"NCT00069095","version_a":32,"version_b":33,"version_a_date":"2007-12-18","version_b_date":"2008-01-18","pom_a":[{"label":"1.","content":"Efficacy: Non-inferiority of XELOX vs FOLFOX with respect to time to tumor progression or death, and superiority of Avastin vs placebo"}],"pom_b":[{"label":"1.","content":"Non-inferiority of XELOX vs FOLFOX, with respect to time to progression or death, and superiority of Avastin vs placebo.[ Time Frame: Event driven ]"}],"first_posted":"January 22, 2016","completion_date":"April 2009","primary_completion_date":"January 2006","start_date":"July 2003","last_update_posted":"October 6, 2016"},{"nctid":"NCT00069095","version_a":60,"version_b":61,"version_a_date":"2012-09-14","version_b_date":"2013-01-30","pom_a":[{"label":"1.","content":"Non-inferiority of XELOX vs FOLFOX, with respect to time to progression or death, and superiority of Avastin vs placebo.[ Time Frame: Event driven ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST)[ Time Frame: Baseline to the 10 Feb 2005 data cut-off (up to 1 year 7 months) ]PFS was defined as the time from randomization to disease progression (PD) or death. All measurable lesions (maximum of 5 per organ and 10 in total, those with the longest diameter and suitability for accurate repeated measurements) were identified as target lesions (TL). A sum of the longest diameter for all TLs was calculated and reported as the baseline sum longest diameter(SLD). All other lesions were identified as non-TLs and recorded at baseline. PD for TLs was defined as \u2265 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Patients with neither PD nor death were censored at the date of the last tumor assessment that confirmed no PD. Patients who underwent surgical resection with curative intent without prior progression were censored at the date of surgery."}],"first_posted":"January 22, 2016","completion_date":"April 2009","primary_completion_date":"January 2006","start_date":"July 2003","last_update_posted":"October 6, 2016"},{"nctid":"NCT00069095","version_a":61,"version_b":62,"version_a_date":"2013-01-30","version_b_date":"2015-12-11","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST)[ Time Frame: Baseline to the 10 Feb 2005 data cut-off (up to 1 year 7 months) ]PFS was defined as the time from randomization to disease progression (PD) or death. All measurable lesions (maximum of 5 per organ and 10 in total, those with the longest diameter and suitability for accurate repeated measurements) were identified as target lesions (TL). A sum of the longest diameter for all TLs was calculated and reported as the baseline sum longest diameter(SLD). All other lesions were identified as non-TLs and recorded at baseline. PD for TLs was defined as \u2265 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Patients with neither PD nor death were censored at the date of the last tumor assessment that confirmed no PD. Patients who underwent surgical resection with curative intent without prior progression were censored at the date of surgery."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4[ Time Frame: Baseline until disease progression or death, approximately 2 years 6 months ]PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated."},{"label":"2.","content":"PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone[ Time Frame: Baseline until disease progression or death, approximately 2 years 6 months ]PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms."}],"first_posted":"January 22, 2016","completion_date":"April 2009","primary_completion_date":"January 2006","start_date":"July 2003","last_update_posted":"October 6, 2016"},{"nctid":"NCT00876486","version_a":1,"version_b":2,"version_a_date":"2009-04-03","version_b_date":"2012-06-10","pom_a":[],"pom_b":[{"label":"1.","content":"Objective Response Rate[ Time Frame: 6 months ]Evaluate the efficacy of Genexol\xae-PM versus Genexol\xae in subjects with recurrent or metastatic breast cancer based on Objective Response Rate."}],"first_posted":"No date provided","completion_date":"November 2013","primary_completion_date":"February 2013","start_date":"December 2008","last_update_posted":"May 1, 2017"},{"nctid":"NCT04099251","version_a":40,"version_b":41,"version_a_date":"2020-11-16","version_b_date":"2021-06-23","pom_a":[{"label":"1.","content":"Recurrence-Free Survival (RFS)[ Time Frame: approxiatemately 51 months ]"},{"label":"2.","content":"Number of other safety biomarkers[ Time Frame: Up to 5 years ]"}],"pom_b":[{"label":"1.","content":"Recurrence-Free Survival (RFS)[ Time Frame: Approximately 68 months ]"}],"first_posted":"No date provided","completion_date":"December 27, 2025","primary_completion_date":"November 11, 2022","start_date":"October 28, 2019","last_update_posted":"September 2, 2022"},{"nctid":"NCT03257267","version_a":9,"version_b":10,"version_a_date":"2019-06-19","version_b_date":"2020-01-11","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Time from randomization up to approximately 32 months ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Time from randomization up to approximately 44 months ]"}],"first_posted":"April 6, 2022","completion_date":"July 9, 2023","primary_completion_date":"March 15, 2021","start_date":"September 5, 2017","last_update_posted":"April 6, 2022"},{"nctid":"NCT03257267","version_a":15,"version_b":16,"version_a_date":"2021-11-12","version_b_date":"2022-03-11","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Time from randomization up to approximately 44 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Time from randomization to the date of death due to any cause (assessed up to 40 months) ]Overall survival was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last known date of contact."}],"first_posted":"April 6, 2022","completion_date":"July 9, 2023","primary_completion_date":"March 15, 2021","start_date":"September 5, 2017","last_update_posted":"April 6, 2022"},{"nctid":"NCT00086580","version_a":2,"version_b":3,"version_a_date":"2005-08-03","version_b_date":"2006-03-29","pom_a":[],"pom_b":[{"label":"1.","content":"FluCAM vs. Fludra"}],"first_posted":"August 11, 2011","completion_date":"June 2010","primary_completion_date":"June 2010","start_date":"July 2004","last_update_posted":"March 13, 2014"},{"nctid":"NCT00086580","version_a":8,"version_b":9,"version_a_date":"2007-07-16","version_b_date":"2007-12-23","pom_a":[{"label":"1.","content":"FluCAM vs. Fludra"}],"pom_b":[{"label":"1.","content":"Compare efficacy of FluCAM (Fludara+Campath) versus Fludara alone based on the time to disease progression for the two treatment groups[ Time Frame: Up to 6 yrs but variable based on time to disease progression ]"}],"first_posted":"August 11, 2011","completion_date":"June 2010","primary_completion_date":"June 2010","start_date":"July 2004","last_update_posted":"March 13, 2014"},{"nctid":"NCT00086580","version_a":9,"version_b":10,"version_a_date":"2007-12-23","version_b_date":"2008-05-07","pom_a":[{"label":"1.","content":"Compare efficacy of FluCAM (Fludara+Campath) versus Fludara alone based on the time to disease progression for the two treatment groups[ Time Frame: Up to 6 yrs but variable based on time to disease progression ]"}],"pom_b":[{"label":"1.","content":"Compare efficacy of FluCAM (Fludara+Campath) versus Fludara alone based on the PFS (Progression Free Survival) for the two treatment groups[ Time Frame: Up to 6 yrs but variable based on time to disease progression ]"}],"first_posted":"August 11, 2011","completion_date":"June 2010","primary_completion_date":"June 2010","start_date":"July 2004","last_update_posted":"March 13, 2014"},{"nctid":"NCT00086580","version_a":15,"version_b":16,"version_a_date":"2011-04-11","version_b_date":"2011-07-18","pom_a":[{"label":"1.","content":"Compare efficacy of FluCAM (Fludara+Campath) versus Fludara alone based on the PFS (Progression Free Survival) for the two treatment groups[ Time Frame: Up to 6 yrs but variable based on time to disease progression ]"}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment[ Time Frame: Up to 6 years ]Progression-free survival was defined as the number of days from the date of randomization to the date of first objective documentation of progressive disease (PD) as determined by the treatment-blinded IRRP, or death due to any cause. Results are expressed in months."}],"first_posted":"August 11, 2011","completion_date":"June 2010","primary_completion_date":"June 2010","start_date":"July 2004","last_update_posted":"March 13, 2014"},{"nctid":"NCT00075478","version_a":12,"version_b":13,"version_a_date":"2006-09-29","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Nonrelapse mortality 1 year post-transplant"}],"first_posted":"May 19, 2014","completion_date":"February 2, 2014","primary_completion_date":"February 2014","start_date":"October 2003","last_update_posted":"May 15, 2017"},{"nctid":"NCT00075478","version_a":53,"version_b":54,"version_a_date":"2009-07-07","version_b_date":"2010-08-04","pom_a":[{"label":"1.","content":"Nonrelapse mortality 1 year post-transplant"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: At 3 years after conditioning ]"}],"first_posted":"May 19, 2014","completion_date":"February 2, 2014","primary_completion_date":"February 2014","start_date":"October 2003","last_update_posted":"May 15, 2017"},{"nctid":"NCT00075478","version_a":56,"version_b":57,"version_a_date":"2011-06-03","version_b_date":"2011-08-19","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: At 3 years after conditioning ]"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: At 3 years after transplant ]"}],"first_posted":"May 19, 2014","completion_date":"February 2, 2014","primary_completion_date":"February 2014","start_date":"October 2003","last_update_posted":"May 15, 2017"},{"nctid":"NCT00075478","version_a":60,"version_b":61,"version_a_date":"2013-08-09","version_b_date":"2014-01-14","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: At 3 years after transplant ]"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: At 3 years after transplant ]A log-rank test at the two-sided 0.05 level of significance will be used."}],"first_posted":"May 19, 2014","completion_date":"February 2, 2014","primary_completion_date":"February 2014","start_date":"October 2003","last_update_posted":"May 15, 2017"},{"nctid":"NCT00075478","version_a":61,"version_b":62,"version_a_date":"2014-01-14","version_b_date":"2014-04-18","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: At 3 years after transplant ]A log-rank test at the two-sided 0.05 level of significance will be used."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: At 3 years after transplant ]A log-rank test at the two-sided 0.05 level of significance will be used."}],"first_posted":"May 19, 2014","completion_date":"February 2, 2014","primary_completion_date":"February 2014","start_date":"October 2003","last_update_posted":"May 15, 2017"},{"nctid":"NCT00075478","version_a":62,"version_b":63,"version_a_date":"2014-04-18","version_b_date":"2014-07-14","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: At 3 years after transplant ]A log-rank test at the two-sided 0.05 level of significance will be used."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: 3 years after transplant ]Percentage of patients surviving as estimated by Kaplan-Meier."}],"first_posted":"May 19, 2014","completion_date":"February 2, 2014","primary_completion_date":"February 2014","start_date":"October 2003","last_update_posted":"May 15, 2017"},{"nctid":"NCT03257033","version_a":1,"version_b":2,"version_a_date":"2017-08-17","version_b_date":"2018-02-19","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: 3 Years ]To compare the Progression Free Survival of intra-arterial delivery of gemcitabine using the RenovoCath\u2122 device vs. continuation of IV gemcitabine and nab-paclitaxel following induction therapy with gemcitabine and nab-paclitaxel and radiation treatment for locally advanced pancreatic adenocarcinoma. Disease response and progression will be assessed according to RECIST 1.1."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: 3 Years ]OS from time of randomization will be calculated using the Kaplan-Meier method and compared between the test and control groups using the stratified Log-Rank Test"}],"first_posted":"No date provided","completion_date":"September 2023","primary_completion_date":"September 2022","start_date":"March 12, 2018","last_update_posted":"February 25, 2022"},{"nctid":"NCT00509444","version_a":2,"version_b":3,"version_a_date":"2008-05-05","version_b_date":"2010-06-23","pom_a":[{"label":"1.","content":"The difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization."}],"pom_b":[{"label":"1.","content":"The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization."}],"first_posted":"No date provided","completion_date":"December 2010","primary_completion_date":"December 2010","start_date":"October 2006","last_update_posted":"April 20, 2017"},{"nctid":"NCT00002995","version_a":16,"version_b":17,"version_a_date":"2012-05-19","version_b_date":"2014-02-12","pom_a":[],"pom_b":[{"label":"1.","content":"Failure-free survival"}],"first_posted":"No date provided","completion_date":"January 2011","primary_completion_date":"September 2006","start_date":"August 1997","last_update_posted":"February 14, 2014"},{"nctid":"NCT00492544","version_a":4,"version_b":5,"version_a_date":"2007-08-27","version_b_date":"2007-12-20","pom_a":[{"label":"1.","content":"HPV-16/18 antibody titres and seroconversion status 1m after last vaccination; Occurrence and intensity of solicited symptoms within 7 days after vaccination"}],"pom_b":[{"label":"1.","content":"HPV-16 and HPV-18 antibody titres and seroconversion status[ Time Frame: Assessed at Day 0 and Month 7 ]"},{"label":"2.","content":"Occurrence and intensity of solicited local and general symptoms[ Time Frame: Within 7 days after each and any vaccination ]"}],"first_posted":"December 21, 2009","completion_date":"March 28, 2008","primary_completion_date":"March 28, 2008","start_date":"July 2, 2007","last_update_posted":"September 4, 2018"},{"nctid":"NCT00492544","version_a":9,"version_b":10,"version_a_date":"2009-08-20","version_b_date":"2009-11-12","pom_a":[{"label":"1.","content":"HPV-16 and HPV-18 antibody titres and seroconversion status[ Time Frame: Assessed at Day 0 and Month 7 ]"},{"label":"2.","content":"Occurrence and intensity of solicited local and general symptoms[ Time Frame: Within 7 days after each and any vaccination ]"}],"pom_b":[{"label":"1.","content":"Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies[ Time Frame: One month post Dose 3 (Month 7) ]Seroconversion is defined as the appearance of anti-HPV-16 and/or anti-HPV-18 antibodies (i.e. antibody titer \u2265 cut-off value) in the sera of subjects seronegative before vaccination.Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies."},{"label":"2.","content":"Anti-HPV-16 and Anti-HPV-18 Antibody Titers[ Time Frame: Before vaccination (PRE) and one month post Dose 3 (Month 7) ]Titers are given as geometric mean titers (GMTs) calculated on all subjects."},{"label":"3.","content":"Number of Subjects Reporting Solicited Local Symptoms[ Time Frame: During the 7-day (Days 0-6) period following each vaccination ]Solicited local symptoms assessed include pain, redness and swelling."},{"label":"4.","content":"Number of Subjects Reporting Solicited General Symptoms[ Time Frame: During the 7-day (Days 0-6) period following each vaccination ]Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria."}],"first_posted":"December 21, 2009","completion_date":"March 28, 2008","primary_completion_date":"March 28, 2008","start_date":"July 2, 2007","last_update_posted":"September 4, 2018"},{"nctid":"NCT00136487","version_a":1,"version_b":2,"version_a_date":"2005-08-26","version_b_date":"2005-12-19","pom_a":[{"label":"1.","content":"- To evaluate the biologic activity of celecoxib by comparing the proportion of men with a post-treatment PSADT greater than or equal to 200% pre-treatment PSADT in the celecoxib-treated group compared to the placebo-treated group."}],"pom_b":[{"label":"1.","content":"To evaluate the biologic activity of celecoxib by comparing the proportion of men with a post-treatment PSA doubling time (PSADT) greater than or equal to 200% pre-treatment PSADT in the celecoxib-treated group compared to the placebo-treated group"}],"first_posted":"No date provided","completion_date":"September 2006","primary_completion_date":"September 2006","start_date":"October 2002","last_update_posted":"December 9, 2009"},{"nctid":"NCT03920293","version_a":21,"version_b":22,"version_a_date":"2022-03-11","version_b_date":"2022-05-03","pom_a":[{"label":"1.","content":"Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26[ Time Frame: Baseline, Week 26 ]To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the MG-ADL profile."}],"pom_b":[{"label":"1.","content":"Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26[ Time Frame: Baseline, Week 26 ]The MG-ADL is an 8-point questionnaire that focused on relevant symptoms and functional performance of activities of daily living in participants with MG. The 8 items of the MGADL questionnaire were derived from symptom-based components of the original 13-item QMG scale to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response was graded 0 (normal) to 3 (most severe). The range of total MG-ADL score was 0 to 24. A decrease in score indicated improvement. Estimates were based on Mixed Effect Repeated Measures (MMRM) that included treatment group, stratification factor region, and MG-ADL total score at baseline, study visit, and study visit by treatment group interaction."}],"first_posted":"May 26, 2022","completion_date":"December 31, 2023","primary_completion_date":"May 11, 2021","start_date":"March 26, 2019","last_update_posted":"May 26, 2022"},{"nctid":"NCT00532194","version_a":1,"version_b":2,"version_a_date":"2007-09-19","version_b_date":"2011-12-20","pom_a":[{"label":"1.","content":"Stage 1: Safety[ Time Frame: May 2008 ]"},{"label":"2.","content":"Stage 2: Progression-free survival[ Time Frame: May 2010 ]"},{"label":"3.","content":"Stage 3: Overall survival[ Time Frame: Oct 2013 ]"}],"pom_b":[{"label":"1.","content":"Stage 1: Safety[ Time Frame: Dec 2009 ]"},{"label":"2.","content":"Stage 2: Progression-free survival[ Time Frame: Dec 2012 ]"}],"first_posted":"No date provided","completion_date":"December 2016","primary_completion_date":"April 2013","start_date":"July 2007","last_update_posted":"September 23, 2015"},{"nctid":"NCT00532194","version_a":2,"version_b":3,"version_a_date":"2011-12-20","version_b_date":"2015-03-11","pom_a":[{"label":"1.","content":"Stage 1: Safety[ Time Frame: Dec 2009 ]"},{"label":"2.","content":"Stage 2: Progression-free survival[ Time Frame: Dec 2012 ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: Apr 2013 ]"}],"first_posted":"No date provided","completion_date":"December 2016","primary_completion_date":"April 2013","start_date":"July 2007","last_update_posted":"September 23, 2015"},{"nctid":"NCT00751036","version_a":8,"version_b":9,"version_a_date":"2009-11-18","version_b_date":"2011-03-14","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: Median progression free survival (time when half of the patients have progressed) The measurements will be done bi-monthly. ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: every 6 weeks in the first 6 months and every 8 weeks thereafter ]"}],"first_posted":"March 26, 2014","completion_date":"August 2012","primary_completion_date":"August 2012","start_date":"June 2009","last_update_posted":"March 26, 2014"},{"nctid":"NCT00751036","version_a":14,"version_b":15,"version_a_date":"2012-05-16","version_b_date":"2013-03-22","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: every 6 weeks in the first 6 months and every 8 weeks thereafter ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: every 6 weeks in the first 6 months and every 8 weeks thereafter ]Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions."}],"first_posted":"March 26, 2014","completion_date":"August 2012","primary_completion_date":"August 2012","start_date":"June 2009","last_update_posted":"March 26, 2014"},{"nctid":"NCT00751036","version_a":17,"version_b":18,"version_a_date":"2013-08-07","version_b_date":"2014-02-25","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: every 6 weeks in the first 6 months and every 8 weeks thereafter ]Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: 24 months ]Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions."}],"first_posted":"March 26, 2014","completion_date":"August 2012","primary_completion_date":"August 2012","start_date":"June 2009","last_update_posted":"March 26, 2014"},{"nctid":"NCT01131312","version_a":3,"version_b":4,"version_a_date":"2010-12-08","version_b_date":"2011-02-15","pom_a":[{"label":"1.","content":"Cumulative detection of pathology QC histologically confirmed CIN3 (cervical precancer) over the 2 years of the trial."}],"pom_b":[],"first_posted":"November 20, 2018","completion_date":"February 5, 2009","primary_completion_date":"February 5, 2009","start_date":"February 20, 2008","last_update_posted":"November 20, 2018"},{"nctid":"NCT01131312","version_a":15,"version_b":16,"version_a_date":"2013-02-20","version_b_date":"2013-05-23","pom_a":[],"pom_b":[{"label":"1.","content":"Cumulative detection of pathology QC histologically confirmed CIN3 (cervical precancer) over the 2 years of the trial."}],"first_posted":"November 20, 2018","completion_date":"February 5, 2009","primary_completion_date":"February 5, 2009","start_date":"February 20, 2008","last_update_posted":"November 20, 2018"},{"nctid":"NCT01131312","version_a":34,"version_b":35,"version_a_date":"2017-06-30","version_b_date":"2017-07-18","pom_a":[{"label":"1.","content":"Cumulative detection of pathology QC histologically confirmed CIN3 (cervical precancer) over the 2 years of the trial."}],"pom_b":[{"label":"1.","content":"Detection of CIN III[ Time Frame: 2 years ]"}],"first_posted":"November 20, 2018","completion_date":"February 5, 2009","primary_completion_date":"February 5, 2009","start_date":"February 20, 2008","last_update_posted":"November 20, 2018"},{"nctid":"NCT01131312","version_a":39,"version_b":40,"version_a_date":"2017-10-05","version_b_date":"2018-10-22","pom_a":[{"label":"1.","content":"Detection of CIN III[ Time Frame: 2 years ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III)[ Time Frame: up to 2 years ]A cervical exam, pap test, human papilloma virus (HPV) deoxyribonucleic acid (DNA) test, and/or colposcopy was performed to detect whether or not a participant had CINIII. CINIII is defined as moderate or severe dysplasia or abnormal cells located on the cervix that can lead to cancer."}],"first_posted":"November 20, 2018","completion_date":"February 5, 2009","primary_completion_date":"February 5, 2009","start_date":"February 20, 2008","last_update_posted":"November 20, 2018"},{"nctid":"NCT02578680","version_a":38,"version_b":39,"version_a_date":"2017-02-22","version_b_date":"2017-06-05","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: Up to 24 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: Up to 24 months ]"}],"first_posted":"November 28, 2018","completion_date":"February 8, 2023","primary_completion_date":"November 8, 2017","start_date":"January 15, 2016","last_update_posted":"August 17, 2022"},{"nctid":"NCT02578680","version_a":39,"version_b":40,"version_a_date":"2017-06-05","version_b_date":"2017-11-17","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: Up to 24 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: Up to 24 months ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 24 months ]"}],"first_posted":"November 28, 2018","completion_date":"February 8, 2023","primary_completion_date":"November 8, 2017","start_date":"January 15, 2016","last_update_posted":"August 17, 2022"},{"nctid":"NCT02578680","version_a":45,"version_b":46,"version_a_date":"2018-05-21","version_b_date":"2018-10-29","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: Up to 24 months ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 24 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months) ]PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Through Database Cutoff Date of 08-Nov-2017 (Up to approximately 21 months) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS is presented."}],"first_posted":"November 28, 2018","completion_date":"February 8, 2023","primary_completion_date":"November 8, 2017","start_date":"January 15, 2016","last_update_posted":"August 17, 2022"},{"nctid":"NCT04674683","version_a":2,"version_b":3,"version_a_date":"2021-01-11","version_b_date":"2021-11-23","pom_a":[{"label":"1.","content":"Primary Outcome[ Time Frame: From enrollment until disease progression or unacceptable toxicity, assessed up to 48 months ]Objective Response Rate (ORR) defined as the percentage of patients enrolled in each study arm with a best response of Complete Response (CR) or Partial Response (PR) as determined by the blinded independent review committee (BIRC)."},{"label":"2.","content":"Primary Outcome[ Time Frame: From date of randomization to the earliest date of documented progressive disease (PD), assessed up to 48 months ]Progression-free Survival (PFS) defined as the time from the date of randomization to the first date of documented disease progression."}],"pom_b":[{"label":"1.","content":"Primary Outcome[ Time Frame: From date of randomization until disease progression or unacceptable toxicity, assessed up to 48 months ]Objective Response Rate (ORR) defined as the percentage of patients enrolled in each study arm with a best response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as determined by the blinded independent review committee (BIRC)."},{"label":"2.","content":"Primary Outcome[ Time Frame: From date of randomization to the earliest date of documented progressive disease (PD), assessed up to 48 months ]Progression-free Survival (PFS) defined as the time from the date of randomization to the first date of documented disease progression as determined by BIRC, or the date of death due to any cause, whichever occurs first."}],"first_posted":"No date provided","completion_date":"October 2025","primary_completion_date":"December 2024","start_date":"August 12, 2021","last_update_posted":"August 31, 2022"},{"nctid":"NCT00169845","version_a":1,"version_b":2,"version_a_date":"2005-09-09","version_b_date":"2011-02-11","pom_a":[{"label":"1.","content":"Second primary cancers"}],"pom_b":[{"label":"1.","content":"Second primary cancers[ Time Frame: Immediatly and 1 month after radiation therapy, every 6 months during the 3 years following the end of radiation therapy, and then once a year until June 30, 2003 ]"}],"first_posted":"No date provided","completion_date":"March 2018","primary_completion_date":"June 2003","start_date":"October 1994","last_update_posted":"March 14, 2018"},{"nctid":"NCT00169845","version_a":6,"version_b":7,"version_a_date":"2015-09-01","version_b_date":"2016-10-17","pom_a":[{"label":"1.","content":"Second primary cancers[ Time Frame: Immediatly and 1 month after radiation therapy, every 6 months during the 3 years following the end of radiation therapy, and then once a year until June 30, 2003 ]"}],"pom_b":[{"label":"1.","content":"Second primary cancers[ Time Frame: Immediately and 1 month after radiation therapy, every 6 months during the 3 years following the end of radiation therapy, and then once a year until June 30, 2003 ]"}],"first_posted":"No date provided","completion_date":"March 2018","primary_completion_date":"June 2003","start_date":"October 1994","last_update_posted":"March 14, 2018"},{"nctid":"NCT03199885","version_a":9,"version_b":10,"version_a_date":"2018-02-02","version_b_date":"2018-02-15","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 5 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no prior trastuzumab; prior trastuzumab and no pertuzumab; prior trastuzumab and pertuzumab), estrogen receptor status (positive; negative), and disease sites (any visceral without brain metastasis; non-visceral only without brain me"}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 5 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no prior trastuzumab; prior trastuzumab and no pertuzumab; prior trastuzumab and pertuzumab), estrogen receptor status (positive; negative), and disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"first_posted":"No date provided","completion_date":"January 31, 2023","primary_completion_date":"January 31, 2023","start_date":"March 12, 2019","last_update_posted":"September 2, 2022"},{"nctid":"NCT03199885","version_a":12,"version_b":13,"version_a_date":"2018-06-11","version_b_date":"2018-07-09","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 5 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no prior trastuzumab; prior trastuzumab and no pertuzumab; prior trastuzumab and pertuzumab), estrogen receptor status (positive; negative), and disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 7 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no prior trastuzumab; prior trastuzumab and no pertuzumab; prior trastuzumab and pertuzumab), estrogen receptor status (positive; negative), and disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"first_posted":"No date provided","completion_date":"January 31, 2023","primary_completion_date":"January 31, 2023","start_date":"March 12, 2019","last_update_posted":"September 2, 2022"},{"nctid":"NCT03199885","version_a":376,"version_b":377,"version_a_date":"2021-06-18","version_b_date":"2021-07-02","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 7 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no prior trastuzumab; prior trastuzumab and no pertuzumab; prior trastuzumab and pertuzumab), estrogen receptor status (positive; negative), and disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 7 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no; yes), estrogen receptor status (positive; negative), disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis), and choice of taxane (paclitaxel; docetaxel). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"first_posted":"No date provided","completion_date":"January 31, 2023","primary_completion_date":"January 31, 2023","start_date":"March 12, 2019","last_update_posted":"September 2, 2022"},{"nctid":"NCT03199885","version_a":500,"version_b":501,"version_a_date":"2022-08-05","version_b_date":"2022-08-24","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease assessed up to 7 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no; yes), estrogen receptor status (positive; negative), disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis), and choice of taxane (paclitaxel; docetaxel). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: The time from randomization to the first documented progressive disease every 6 months, assessed up to 8 years ]Will be determined using the current Response Evaluation Criteria in Solid Tumors 1.1 criteria. Analysis will be based on the intent to treat population. The stratified log-rank test will be used to compare the progression free survival between the two treatment arms with the following stratification factors: prior neoadjuvant or adjuvant therapy with trastuzumab (no; yes), estrogen receptor status (positive; negative), disease sites (any visceral without brain metastasis; non-visceral only without brain metastasis; brain metastasis), and choice of taxane (paclitaxel; docetaxel). The Kaplan-Meier estimates will be calculated by treatment arms. Stratified Cox proportional hazards models to estimate the hazard ratio."}],"first_posted":"No date provided","completion_date":"January 31, 2023","primary_completion_date":"January 31, 2023","start_date":"March 12, 2019","last_update_posted":"September 2, 2022"},{"nctid":"NCT00033735","version_a":6,"version_b":7,"version_a_date":"2008-07-23","version_b_date":"2012-12-20","pom_a":[],"pom_b":[{"label":"1.","content":"Survival of Irofulven vs. 5-FU[ Time Frame: 28 day cycle or until disease progression ]"}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"June 2003","start_date":"January 2000","last_update_posted":"December 24, 2012"},{"nctid":"NCT00052962","version_a":3,"version_b":4,"version_a_date":"2012-02-27","version_b_date":"2012-10-16","pom_a":[],"pom_b":[{"label":"1.","content":"Demonstrate Whether Use of Continuous Peritoneal Perfusion (CHPP) is Able to Improve the Progression Free Survival of Patients With Low Grade Gastrointestinal Adenocarcinomas and Peritoneal Carcinomatosis Compared to Patients Who do Not[ Time Frame: 2003-2008 ]CHPP is administered as a heated cisplatin solution delivered to the abdomen through a catheter (plastic tube), washed through the abdomen for 90 minutes, and then drained out of the body through another catheter.Progression is defined as imageable tumor nodules or increasing ascites persistent on two serial computed tomography (CT) scans."}],"first_posted":"November 19, 2012","completion_date":"September 2008","primary_completion_date":"September 2008","start_date":"January 2003","last_update_posted":"November 22, 2012"},{"nctid":"NCT00052962","version_a":4,"version_b":5,"version_a_date":"2012-10-16","version_b_date":"2012-11-16","pom_a":[{"label":"1.","content":"Demonstrate Whether Use of Continuous Peritoneal Perfusion (CHPP) is Able to Improve the Progression Free Survival of Patients With Low Grade Gastrointestinal Adenocarcinomas and Peritoneal Carcinomatosis Compared to Patients Who do Not[ Time Frame: 2003-2008 ]CHPP is administered as a heated cisplatin solution delivered to the abdomen through a catheter (plastic tube), washed through the abdomen for 90 minutes, and then drained out of the body through another catheter.Progression is defined as imageable tumor nodules or increasing ascites persistent on two serial computed tomography (CT) scans."}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: 2003-2008 ]CHPP is administered as a heated cisplatin solution delivered to the abdomen through a catheter (plastic tube), washed through the abdomen for 90 minutes, and then drained out of the body through another catheter.Progression is defined as imageable tumor nodules or increasing ascites persistent on two serial computed tomography (CT) scans."}],"first_posted":"November 19, 2012","completion_date":"September 2008","primary_completion_date":"September 2008","start_date":"January 2003","last_update_posted":"November 22, 2012"},{"nctid":"NCT00128661","version_a":11,"version_b":12,"version_a_date":"2007-03-07","version_b_date":"2007-05-16","pom_a":[],"pom_b":[{"label":"1.","content":"Histopathologically confirmed, incident CIN2+ associated with an HPV16 or HPV18 infection"}],"first_posted":"May 2, 2012","completion_date":"December 31, 2010","primary_completion_date":"December 31, 2010","start_date":"June 30, 2004","last_update_posted":"March 8, 2019"},{"nctid":"NCT00128661","version_a":29,"version_b":30,"version_a_date":"2011-11-01","version_b_date":"2012-04-05","pom_a":[{"label":"1.","content":"Histopathologically confirmed, incident CIN2+ associated with an HPV16 or HPV18 infection"}],"pom_b":[{"label":"1.","content":"Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.[ Time Frame: From Month 6 up to Month 48 ]CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer.Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained.Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type."}],"first_posted":"May 2, 2012","completion_date":"December 31, 2010","primary_completion_date":"December 31, 2010","start_date":"June 30, 2004","last_update_posted":"March 8, 2019"},{"nctid":"NCT00128661","version_a":31,"version_b":32,"version_a_date":"2012-05-24","version_b_date":"2019-02-12","pom_a":[{"label":"1.","content":"Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.[ Time Frame: From Month 6 up to Month 48 ]CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer.Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained.Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type."}],"pom_b":[{"label":"1.","content":"Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.[ Time Frame: From Month 6 up to Month 48 ]CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer. Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained. Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type."}],"first_posted":"May 2, 2012","completion_date":"December 31, 2010","primary_completion_date":"December 31, 2010","start_date":"June 30, 2004","last_update_posted":"March 8, 2019"},{"nctid":"NCT02364557","version_a":22,"version_b":23,"version_a_date":"2021-05-27","version_b_date":"2021-09-22","pom_a":[{"label":"1.","content":"Progression-free survival (failure: progression or death due to any cause) (Phase II-R)[ Time Frame: From the date of randomization to the date of first PFS failure or last follow-up; assessed up to 3 years ]Progression-free survival will be estimated by the Kaplan-Meier method, with progression defined as: progression of initial/treated metastases (using the revised Response Evaluation Criteria in Solid Tumors [RECIST] guideline), appearance of new metastases, or death due to any cause. The distribution of PFS estimates between the two arms will be compared using the log rank test."},{"label":"2.","content":"Overall survival (failure: death due to any cause) (Phase III)[ Time Frame: From the date of randomization to the date of death or last follow-up; assessed up to 8 years ]Overall survival will be estimated by the Kaplan-Meier method. The distribution of OS estimates between the two arms will be compared using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) (failure: progression or death due to any cause) (Phase II-R)[ Time Frame: From the date of randomization to the date of first PFS failure or last follow-up ]Progression-free survival will be estimated by the Kaplan-Meier method, with progression defined as: progression of initial/treated metastases (using the revised Response Evaluation Criteria in Solid Tumors [RECIST] guideline), appearance of new metastases, or death due to any cause. The distribution of PFS estimates between the two arms will be compared using the log rank test."},{"label":"2.","content":"Overall survival (OS) (failure: death due to any cause) (Phase III)[ Time Frame: From the date of randomization to the date of death or last follow-up ]Overall survival will be estimated by the Kaplan-Meier method. The distribution of OS estimates between the two arms will be compared using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS."}],"first_posted":"No date provided","completion_date":"December 31, 2022","primary_completion_date":"December 31, 2022","start_date":"December 24, 2014","last_update_posted":"September 28, 2021"},{"nctid":"NCT00193856","version_a":4,"version_b":5,"version_a_date":"2006-10-26","version_b_date":"2007-05-13","pom_a":[{"label":"1.","content":"Biochemical Failure"},{"label":"2.","content":"Survival"}],"pom_b":[{"label":"1.","content":"PSA relapse free survival[ Time Frame: Two main endpoint analyses are planned when five and ten years have elapsed from treatment of the last patient registered on the trial. ]"}],"first_posted":"No date provided","completion_date":"August 2017","primary_completion_date":"August 2017","start_date":"October 2003","last_update_posted":"October 12, 2017"},{"nctid":"NCT00193856","version_a":9,"version_b":10,"version_a_date":"2009-09-29","version_b_date":"2012-06-21","pom_a":[{"label":"1.","content":"PSA relapse free survival[ Time Frame: Two main endpoint analyses are planned when five and ten years have elapsed from treatment of the last patient registered on the trial. ]"}],"pom_b":[{"label":"1.","content":"Prostate cancer-specific mortality.[ Time Frame: Two main endpoint analyses are planned when five and ten years have elapsed from treatment of the last patient registered on the trial. ]"}],"first_posted":"No date provided","completion_date":"August 2017","primary_completion_date":"August 2017","start_date":"October 2003","last_update_posted":"October 12, 2017"},{"nctid":"NCT00193856","version_a":11,"version_b":12,"version_a_date":"2013-08-07","version_b_date":"2013-10-09","pom_a":[{"label":"1.","content":"Prostate cancer-specific mortality.[ Time Frame: Two main endpoint analyses are planned when five and ten years have elapsed from treatment of the last patient registered on the trial. ]"}],"pom_b":[{"label":"1.","content":"Prostate cancer-specific mortality.[ Time Frame: Two main endpoint analyses are planned when 6.5 and 10 years have elapsed from randomisation of the last participant ]"}],"first_posted":"No date provided","completion_date":"August 2017","primary_completion_date":"August 2017","start_date":"October 2003","last_update_posted":"October 12, 2017"},{"nctid":"NCT00556322","version_a":3,"version_b":4,"version_a_date":"2007-12-18","version_b_date":"2008-01-18","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Event driven ]"}],"first_posted":"February 23, 2015","completion_date":"June 2012","primary_completion_date":"June 2012","start_date":"March 2006","last_update_posted":"February 23, 2015"},{"nctid":"NCT00556322","version_a":83,"version_b":84,"version_a_date":"2014-03-03","version_b_date":"2015-02-04","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Event driven ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010)[ Time Frame: Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 or Death and Every 12 Weeks until Death or Data Cut off (07 September 2010) up to 52 months ]Overall survival (OS) was determined from the date of randomization to the date of death irrespective of the cause of death."},{"label":"2.","content":"Duration of Overall Survival in All Participants (Data Cutoff 07 September 2010)[ Time Frame: Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 and Every 12 Weeks until Death or Until Data Cut off (07 September 2010) up to 52 months ]OS was determined from the date of randomization to the date of death irrespective of the cause of death. Kaplan-Meier estimates were used for analysis."},{"label":"3.","content":"Probable Percentage of Participants Remaining Alive at 1 Year[ Time Frame: 1 Year ]OS was determined from the date of randomization to the date of death irrespective of the cause of death. Kaplan-Meier estimates were used for analysis."}],"first_posted":"February 23, 2015","completion_date":"June 2012","primary_completion_date":"June 2012","start_date":"March 2006","last_update_posted":"February 23, 2015"},{"nctid":"NCT00667251","version_a":47,"version_b":48,"version_a_date":"2011-03-04","version_b_date":"2011-08-04","pom_a":[{"label":"1.","content":"Progression-free survival"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: Jun 2013 ]"}],"first_posted":"June 18, 2014","completion_date":"July 27, 2022","primary_completion_date":"August 1, 2012","start_date":"October 7, 2008","last_update_posted":"August 2, 2022"},{"nctid":"NCT00667251","version_a":49,"version_b":50,"version_a_date":"2011-10-28","version_b_date":"2011-11-25","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: Jun 2013 ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: 4 years ]"}],"first_posted":"June 18, 2014","completion_date":"July 27, 2022","primary_completion_date":"August 1, 2012","start_date":"October 7, 2008","last_update_posted":"August 2, 2022"},{"nctid":"NCT00667251","version_a":66,"version_b":67,"version_a_date":"2013-06-07","version_b_date":"2014-06-17","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: 4 years ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival[ Time Frame: From randomization to RECIST V 1.0 progression or death assessed up to 39 months. ]Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions"}],"first_posted":"June 18, 2014","completion_date":"July 27, 2022","primary_completion_date":"August 1, 2012","start_date":"October 7, 2008","last_update_posted":"August 2, 2022"},{"nctid":"NCT02819518","version_a":62,"version_b":63,"version_a_date":"2018-05-07","version_b_date":"2019-04-19","pom_a":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE)[ Time Frame: Up to 44 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE[ Time Frame: Up to 41 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 41 months ]"},{"label":"4.","content":"Part 2: PFS - Participants With PD-L1 Positive Tumors[ Time Frame: Up to 41 months ]"},{"label":"5.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 41 months ]"},{"label":"6.","content":"Part 2: OS - Participants With PD-L1 Positive Tumors[ Time Frame: Up to 41 months ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE)[ Time Frame: Up to 41 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE[ Time Frame: Up to 41 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 41 months ]"},{"label":"4.","content":"Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors[ Time Frame: Up to 41 months ]"},{"label":"5.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 41 months ]"},{"label":"6.","content":"Part 2: OS - Participants With PD-L1 Positive Tumors[ Time Frame: Up to 41 months ]"}],"first_posted":"July 5, 2022","completion_date":"November 15, 2023","primary_completion_date":"June 15, 2021","start_date":"July 27, 2016","last_update_posted":"July 25, 2022"},{"nctid":"NCT02819518","version_a":64,"version_b":65,"version_a_date":"2019-04-24","version_b_date":"2019-08-30","pom_a":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE)[ Time Frame: Up to 41 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE[ Time Frame: Up to 41 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 41 months ]"},{"label":"4.","content":"Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors[ Time Frame: Up to 41 months ]"},{"label":"5.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 41 months ]"},{"label":"6.","content":"Part 2: OS - Participants With PD-L1 Positive Tumors[ Time Frame: Up to 41 months ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE)[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE[ Time Frame: Up to 45 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"4.","content":"Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors[ Time Frame: Up to 45 months ]"},{"label":"5.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"6.","content":"Part 2: OS - Participants With PD-L1 Positive Tumors[ Time Frame: Up to 45 months ]"}],"first_posted":"July 5, 2022","completion_date":"November 15, 2023","primary_completion_date":"June 15, 2021","start_date":"July 27, 2016","last_update_posted":"July 25, 2022"},{"nctid":"NCT02819518","version_a":65,"version_b":66,"version_a_date":"2019-08-30","version_b_date":"2019-10-24","pom_a":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE)[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE[ Time Frame: Up to 45 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"4.","content":"Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors[ Time Frame: Up to 45 months ]"},{"label":"5.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"6.","content":"Part 2: OS - Participants With PD-L1 Positive Tumors[ Time Frame: Up to 45 months ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE - All Participants[ Time Frame: Up to 45 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"4.","content":"Part 2: PFS - Participants with Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) \u22651 Tumors[ Time Frame: Up to 45 months ]"},{"label":"5.","content":"Part 2: PFS - Participants with PD-L1 CPS \u226510 Tumors[ Time Frame: Up to 45 months ]"},{"label":"6.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"7.","content":"Part 2: OS - Participants with PD-L1 CPS \u22651 Tumors[ Time Frame: Up to 45 months ]"},{"label":"8.","content":"Part 2: OS - Participants with PD-L1 CPS \u226510 Tumors[ Time Frame: Up to 45 months ]"}],"first_posted":"July 5, 2022","completion_date":"November 15, 2023","primary_completion_date":"June 15, 2021","start_date":"July 27, 2016","last_update_posted":"July 25, 2022"},{"nctid":"NCT02819518","version_a":70,"version_b":71,"version_a_date":"2021-11-21","version_b_date":"2022-06-08","pom_a":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experience an Adverse Event (AE) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE - All Participants[ Time Frame: Up to 45 months ]"},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"4.","content":"Part 2: PFS - Participants with Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) \u22651 Tumors[ Time Frame: Up to 45 months ]"},{"label":"5.","content":"Part 2: PFS - Participants with PD-L1 CPS \u226510 Tumors[ Time Frame: Up to 45 months ]"},{"label":"6.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to 45 months ]"},{"label":"7.","content":"Part 2: OS - Participants with PD-L1 CPS \u22651 Tumors[ Time Frame: Up to 45 months ]"},{"label":"8.","content":"Part 2: OS - Participants with PD-L1 CPS \u226510 Tumors[ Time Frame: Up to 45 months ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants[ Time Frame: Up to approximately 39 months ]An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment."},{"label":"2.","content":"Part 1: Percentage of Participants Who Discontinued Study Drug Due to an AE - All Participants[ Time Frame: Up to approximately 39 months ]An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment."},{"label":"3.","content":"Part 2: Progression-Free Survival (PFS) - All Participants[ Time Frame: Up to approximately 53 months ]Progression-free survival was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on assessments by blinded independent central review (BICR) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD."},{"label":"4.","content":"Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) \u22651 Tumors[ Time Frame: Up to approximately 53 months ]Progression-free survival was defined as the time from randomization to the first documented PD per RECIST 1.1 based on assessments by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD."},{"label":"5.","content":"Part 2: PFS - Participants With PD-L1 CPS \u226510 Tumors[ Time Frame: Up to approximately 53 months ]Progression-free survival was defined as the time from randomization to the first documented PD per RECIST 1.1 based on assessments by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD."},{"label":"6.","content":"Part 2: Overall Survival (OS) - All Participants[ Time Frame: Up to approximately 53 months ]Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up."},{"label":"7.","content":"Part 2: OS - Participants With PD-L1 CPS \u22651 Tumors[ Time Frame: Up to approximately 53 months ]Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up."},{"label":"8.","content":"Part 2: OS - Participants With PD-L1 CPS \u226510 Tumors[ Time Frame: Up to approximately 53 months ]Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up."}],"first_posted":"July 5, 2022","completion_date":"November 15, 2023","primary_completion_date":"June 15, 2021","start_date":"July 27, 2016","last_update_posted":"July 25, 2022"},{"nctid":"NCT00908531","version_a":4,"version_b":5,"version_a_date":"2015-02-13","version_b_date":"2019-04-25","pom_a":[{"label":"1.","content":"Invasive disease-free survival[ Time Frame: 2020 ]"}],"pom_b":[{"label":"1.","content":"pCR[ Time Frame: At four months ]Complete response rate"},{"label":"2.","content":"Clinical tumor response[ Time Frame: At four months ]Ultrasound"}],"first_posted":"No date provided","completion_date":"December 1, 2013","primary_completion_date":"December 1, 2013","start_date":"May 2009","last_update_posted":"April 29, 2019"},{"nctid":"NCT03553836","version_a":86,"version_b":87,"version_a_date":"2020-09-23","version_b_date":"2020-10-12","pom_a":[{"label":"1.","content":"Recurrence-free Survival (RFS)[ Time Frame: Up to 4 Years ]RFS is defined as the time from randomization to any of the following events: recurrence of melanoma at any site (local, in-transit or regional lymph nodes or distant recurrence) per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 for immune-based therapeutics (iRECIST 1.1) or death due to any cause."}],"pom_b":[{"label":"1.","content":"Recurrence-free Survival (RFS)[ Time Frame: Up to 4 Years ]RFS is defined as the time from randomization to any of the following events: recurrence of melanoma at any site (local, in-transit or regional lymph nodes or distant recurrence) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause."}],"first_posted":"June 24, 2022","completion_date":"October 12, 2033","primary_completion_date":"June 21, 2021","start_date":"September 12, 2018","last_update_posted":"June 24, 2022"},{"nctid":"NCT03553836","version_a":91,"version_b":92,"version_a_date":"2021-08-23","version_b_date":"2022-05-26","pom_a":[{"label":"1.","content":"Recurrence-free Survival (RFS)[ Time Frame: Up to 4 Years ]RFS is defined as the time from randomization to any of the following events: recurrence of melanoma at any site (local, in-transit or regional lymph nodes or distant recurrence) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause."}],"pom_b":[{"label":"1.","content":"Recurrence-free Survival (RFS)[ Time Frame: Up to ~32.7 months ]RFS was defined as the time from randomization to any of the following events: recurrence of melanoma at any site (local, in-transit or regional lymph nodes or distant recurrence) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. Per protocol, final analysis for this primary outcome measure was performed using the initial pembrolizumab or placebo treatment with a protocol-specified analysis data cut-off date of June-21-2021."}],"first_posted":"June 24, 2022","completion_date":"October 12, 2033","primary_completion_date":"June 21, 2021","start_date":"September 12, 2018","last_update_posted":"June 24, 2022"},{"nctid":"NCT01500083","version_a":8,"version_b":9,"version_a_date":"2013-09-18","version_b_date":"2014-10-10","pom_a":[{"label":"1.","content":"Number of adverse events in patients in Canada with iNHL that has progressed during or following treatment with a rituximab regimen[ Time Frame: Up to 266 days ]"},{"label":"2.","content":"Number of adverse events in patients in Canada with previously untreated CLL[ Time Frame: Up to 266 days ]"}],"pom_b":[{"label":"1.","content":"Number of Adverse Events[ Time Frame: Up to 266 days ]"}],"first_posted":"October 16, 2014","completion_date":"June 2013","primary_completion_date":"June 2013","start_date":"March 2012","last_update_posted":"August 14, 2017"},{"nctid":"NCT00117598","version_a":3,"version_b":4,"version_a_date":"2005-08-07","version_b_date":"2005-09-16","pom_a":[],"pom_b":[{"label":"1.","content":"Progression free survival"},{"label":"2.","content":"Time to response"},{"label":"3.","content":"Duration of response"},{"label":"4.","content":"Time to treatment failure"},{"label":"5.","content":"Time to next treatment"},{"label":"6.","content":"Time to tumor progression"},{"label":"7.","content":"Overall survival"}],"first_posted":"March 6, 2012","completion_date":"January 2011","primary_completion_date":"August 2007","start_date":"May 2005","last_update_posted":"March 30, 2015"},{"nctid":"NCT00117598","version_a":7,"version_b":8,"version_a_date":"2006-09-21","version_b_date":"2006-10-02","pom_a":[{"label":"1.","content":"Progression free survival"},{"label":"2.","content":"Time to response"},{"label":"3.","content":"Duration of response"},{"label":"4.","content":"Time to treatment failure"},{"label":"5.","content":"Time to next treatment"},{"label":"6.","content":"Time to tumor progression"},{"label":"7.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Progression free survival"}],"first_posted":"March 6, 2012","completion_date":"January 2011","primary_completion_date":"August 2007","start_date":"May 2005","last_update_posted":"March 30, 2015"},{"nctid":"NCT00117598","version_a":9,"version_b":10,"version_a_date":"2007-05-31","version_b_date":"2007-12-19","pom_a":[{"label":"1.","content":"Progression free survival"}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: Duration of trial ]"}],"first_posted":"March 6, 2012","completion_date":"January 2011","primary_completion_date":"August 2007","start_date":"May 2005","last_update_posted":"March 30, 2015"},{"nctid":"NCT00117598","version_a":11,"version_b":12,"version_a_date":"2010-06-17","version_b_date":"2010-09-30","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: Duration of trial ]"}],"pom_b":[{"label":"1.","content":"Comparison of Progression free survival of subjects treated with Temsirolimus 175 mg/75 mg IV once a week and with Temsirolimus 175 mg/25 mg IV once a week, compared with the Progression free survival of subjects treated with Investigator\'s[ Time Frame: Every 8 weeks ]"},{"label":"2.","content":"choice[ Time Frame: Every 8 weeks ]"}],"first_posted":"March 6, 2012","completion_date":"January 2011","primary_completion_date":"August 2007","start_date":"May 2005","last_update_posted":"March 30, 2015"},{"nctid":"NCT00117598","version_a":21,"version_b":22,"version_a_date":"2011-12-01","version_b_date":"2012-02-02","pom_a":[{"label":"1.","content":"Comparison of Progression free survival of subjects treated with Temsirolimus 175 mg/75 mg IV once a week and with Temsirolimus 175 mg/25 mg IV once a week, compared with the Progression free survival of subjects treated with Investigator\'s[ Time Frame: Every 8 weeks ]"},{"label":"2.","content":"choice[ Time Frame: Every 8 weeks ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5) ]The period from randomization until disease progression, death or date of last contact."}],"first_posted":"March 6, 2012","completion_date":"January 2011","primary_completion_date":"August 2007","start_date":"May 2005","last_update_posted":"March 30, 2015"},{"nctid":"NCT00660504","version_a":9,"version_b":10,"version_a_date":"2010-08-05","version_b_date":"2014-06-03","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: 1.5 years after last subject first visit ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: 1.5 years after last subject enrolled ]"}],"first_posted":"July 4, 2014","completion_date":"August 2012","primary_completion_date":"February 2012","start_date":"April 2008","last_update_posted":"July 18, 2014"},{"nctid":"NCT00321464","version_a":50,"version_b":51,"version_a_date":"2008-02-07","version_b_date":"2008-03-28","pom_a":[],"pom_b":[{"label":"1.","content":"Time to first on-study Skeletal Related Event (SRE)[ Time Frame: Study is event driven. May take longer than 33 months of study duration to observe 745 first on-study SREs in study population. ]"}],"first_posted":"March 10, 2014","completion_date":"April 4, 2012","primary_completion_date":"July 20, 2009","start_date":"April 1, 2006","last_update_posted":"October 17, 2018"},{"nctid":"NCT00321464","version_a":86,"version_b":87,"version_a_date":"2010-07-01","version_b_date":"2014-01-23","pom_a":[{"label":"1.","content":"Time to first on-study Skeletal Related Event (SRE)[ Time Frame: Study is event driven. May take longer than 33 months of study duration to observe 745 first on-study SREs in study population. ]"}],"pom_b":[{"label":"1.","content":"Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)[ Time Frame: Up to 34 months ]Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented."}],"first_posted":"March 10, 2014","completion_date":"April 4, 2012","primary_completion_date":"July 20, 2009","start_date":"April 1, 2006","last_update_posted":"October 17, 2018"},{"nctid":"NCT02626455","version_a":11,"version_b":12,"version_a_date":"2016-09-26","version_b_date":"2016-10-26","pom_a":[{"label":"1.","content":"Evaluation whether copanlisib in combination with standard immunochemotherapy, is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS) - applicable to Phase III part[ Time Frame: at 45 month ]Progression free survival is defined as the time (in days) from randomization to Disease Progression or death from any cause (if no progression documented)."},{"label":"2.","content":"Determination of the recommended Phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicity s (DLTs) / adverse events (AEs) - applicable to safety run-in part[ Time Frame: at Cycle 1: 21 days or 28 days ]"}],"pom_b":[{"label":"1.","content":"Evaluation whether copanlisib in combination with standard immunochemotherapy, is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS) - applicable to Phase III part[ Time Frame: at 53 month ]Progression free survival is defined as the time (in days) from randomization to Disease Progression or death from any cause (if no progression documented)."},{"label":"2.","content":"Determination of the recommended Phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicity s (DLTs) / adverse events (AEs) - applicable to safety run-in part[ Time Frame: at Cycle 1: 21 days or 28 days ]"}],"first_posted":"No date provided","completion_date":"March 31, 2025","primary_completion_date":"February 28, 2023","start_date":"January 6, 2016","last_update_posted":"August 18, 2022"},{"nctid":"NCT02626455","version_a":37,"version_b":38,"version_a_date":"2018-10-10","version_b_date":"2018-11-08","pom_a":[{"label":"1.","content":"Evaluation whether copanlisib in combination with standard immunochemotherapy, is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS) - applicable to Phase III part[ Time Frame: at 53 month ]Progression free survival is defined as the time (in days) from randomization to Disease Progression or death from any cause (if no progression documented)."},{"label":"2.","content":"Determination of the recommended Phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicity s (DLTs) / adverse events (AEs) - applicable to safety run-in part[ Time Frame: at Cycle 1: 21 days or 28 days ]"}],"pom_b":[{"label":"1.","content":"Safety run-in_Determination of the recommended Phase-III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicities / adverse events[ Time Frame: At Cycle 1: 21 days or 28 days ]"},{"label":"2.","content":"Phase III_Evaluation whether copanlisib in combination with standard immunochemotherapy is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS)[ Time Frame: Up to 52 months ]Progression free survival is defined as the time (in days) from randomization to disease progression or death from any cause (if no progression documented)."}],"first_posted":"No date provided","completion_date":"March 31, 2025","primary_completion_date":"February 28, 2023","start_date":"January 6, 2016","last_update_posted":"August 18, 2022"},{"nctid":"NCT00703326","version_a":45,"version_b":46,"version_a_date":"2010-08-05","version_b_date":"2010-08-19","pom_a":[{"label":"1.","content":"Compare the progression-free survival of the drug combination IMC-1121B + docetaxel to placebo + docetaxel in previously untreated pts with HER2-negative, unresectable, locally-recurrent or metastatic breast cancer.[ Time Frame: 36 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: up to 36 months ]Progression-free survival (PFS) is measured from the date of randomization to the first documented date of disease progression or death from any cause."}],"first_posted":"June 17, 2014","completion_date":"November 19, 2020","primary_completion_date":"March 31, 2013","start_date":"August 6, 2008","last_update_posted":"December 6, 2021"},{"nctid":"NCT00703326","version_a":88,"version_b":89,"version_a_date":"2014-03-14","version_b_date":"2014-05-16","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: up to 36 months ]Progression-free survival (PFS) is measured from the date of randomization to the first documented date of disease progression or death from any cause."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 48 months) ]PFS was defined as time from randomization until the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions taking as reference the smallest sum longest diameter since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who neither progressed nor died were censored the day of their last radiographic tumor assessment if available or date of randomization if no post initiation radiographic assessment was available. If death or PD occurred after \u22652 missing radiographic visits, censoring occurred at date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression."}],"first_posted":"June 17, 2014","completion_date":"November 19, 2020","primary_completion_date":"March 31, 2013","start_date":"August 6, 2008","last_update_posted":"December 6, 2021"},{"nctid":"NCT00703326","version_a":101,"version_b":102,"version_a_date":"2021-02-16","version_b_date":"2021-11-03","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 48 months) ]PFS was defined as time from randomization until the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions taking as reference the smallest sum longest diameter since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who neither progressed nor died were censored the day of their last radiographic tumor assessment if available or date of randomization if no post initiation radiographic assessment was available. If death or PD occurred after \u22652 missing radiographic visits, censoring occurred at date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months) ]PFS was defined as time from randomization until the first evidence of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) or death from any cause; by Investigator assessment. Progressive disease (PD) was defined as at least a 20% increase in sum of longest diameter of target lesions taking as reference the smallest sum longest diameter since baseline, progression in non-target lesions or the appearance of 1 or more new lesion(s). Participants who neither progressed nor died were censored the day of their last radiographic tumor assessment if available or date of randomization if no post initiation radiographic assessment was available. If death or PD occurred after \u22652 missing radiographic visits, censoring occurred at date of the last radiographic visit prior to the missed visits. The symptomatic/clinical disease progression (deterioration) without documented radiologic progression did not constitute progression."}],"first_posted":"June 17, 2014","completion_date":"November 19, 2020","primary_completion_date":"March 31, 2013","start_date":"August 6, 2008","last_update_posted":"December 6, 2021"},{"nctid":"NCT03811015","version_a":21,"version_b":22,"version_a_date":"2019-08-15","version_b_date":"2019-08-16","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization to date of progression, second primary tumor from the head and neck region, or death, assessed up to 24 months ]Progression will be defined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Log rank test will be used to compare PFS and OS. Both phase II and phase III analyses will be intent-to-treat analysis, and analysis will be stratified on stratification factors collected at the time of randomization. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"2.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization to death, assessed up to 24 months ]Log rank test will be used to compare PFS and OS. Both phase II and phase III analyses will be intent-to-treat analysis, and analysis will be stratified on stratification factors collected at the time of randomization. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"3.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + radiation therapy [RT]) FDG positron emission tomography/computed tomography (PET/CT) associated with OS for patients who have a PET/CT[ Time Frame: At 12 weeks ]Logrank tests and input hazard rates will be used."},{"label":"4.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + RT) FDG PET/CT associated with PFS for patients who have a PET/CT[ Time Frame: At 12 weeks ]Logrank tests and input hazard rates will be used."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization to date of progression, second primary tumor from the head and neck region, or death, assessed up to 10 years ]Progression will be defined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Log rank test will be used to compare PFS and OS. Both phase II and phase III analyses will be intent-to-treat analysis, and analysis will be stratified on stratification factors collected at the time of randomization. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"2.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization to death, assessed up to 10 years ]Log rank test will be used to compare PFS and OS. Both phase II and phase III analyses will be intent-to-treat analysis, and analysis will be stratified on stratification factors collected at the time of randomization. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"3.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + radiation therapy [RT]) FDG positron emission tomography/computed tomography (PET/CT) associated with OS for patients who have a PET/CT[ Time Frame: At 12 weeks post therapy ]Logrank tests and input hazard rates will be used."},{"label":"4.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + RT) FDG PET/CT associated with PFS for patients who have a PET/CT[ Time Frame: At 12 weeks post therapy ]Logrank tests and input hazard rates will be used."}],"first_posted":"No date provided","completion_date":"January 1, 2027","primary_completion_date":"January 1, 2027","start_date":"June 20, 2019","last_update_posted":"September 16, 2022"},{"nctid":"NCT03811015","version_a":231,"version_b":232,"version_a_date":"2021-09-07","version_b_date":"2021-09-22","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization to date of progression, second primary tumor from the head and neck region, or death, assessed up to 10 years ]Progression will be defined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Log rank test will be used to compare PFS and OS. Both phase II and phase III analyses will be intent-to-treat analysis, and analysis will be stratified on stratification factors collected at the time of randomization. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"2.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization to death, assessed up to 10 years ]Log rank test will be used to compare PFS and OS. Both phase II and phase III analyses will be intent-to-treat analysis, and analysis will be stratified on stratification factors collected at the time of randomization. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"3.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + radiation therapy [RT]) FDG positron emission tomography/computed tomography (PET/CT) associated with OS for patients who have a PET/CT[ Time Frame: At 12 weeks post therapy ]Logrank tests and input hazard rates will be used."},{"label":"4.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + RT) FDG PET/CT associated with PFS for patients who have a PET/CT[ Time Frame: At 12 weeks post therapy ]Logrank tests and input hazard rates will be used."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From randomization to death, assessed up to 10 years ]Log rank test will be used to compare OS. As patients on the observation arm are allowed to cross-over to the nivolumab arm upon progression, an overall survival analysis using inverse probability censoring weights (IPCW, Robins et. al, 2000) will also be considered. Kaplan-Meier method and Cox regression will be used for the survival outcome analyses."},{"label":"2.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + radiation therapy [RT]) FDG positron emission tomography/computed tomography (PET/CT) associated with OS for patients who have a PET/CT[ Time Frame: At 12 weeks post therapy ]Logrank tests and input hazard rates will be used."},{"label":"3.","content":"Negative (standardized qualitative) 12 week post therapy (cisplatin + RT) FDG PET/CT associated with PFS for patients who have a PET/CT[ Time Frame: At 12 weeks post therapy ]Logrank tests and input hazard rates will be used."}],"first_posted":"No date provided","completion_date":"January 1, 2027","primary_completion_date":"January 1, 2027","start_date":"June 20, 2019","last_update_posted":"September 16, 2022"},{"nctid":"NCT02603432","version_a":69,"version_b":70,"version_a_date":"2020-10-05","version_b_date":"2020-11-23","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Up to approximately 40 months ]Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Patients last known to be alive will be censored at date of last contact."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From randomization to discontinuation from the study, death or date of censoring, whichever occurred first (maximum duration of up to 41 months at the time of final analysis) ]Overall survival was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method."}],"first_posted":"December 17, 2020","completion_date":"March 31, 2023","primary_completion_date":"October 21, 2019","start_date":"April 25, 2016","last_update_posted":"September 1, 2022"},{"nctid":"NCT04474119","version_a":2,"version_b":3,"version_a_date":"2020-09-15","version_b_date":"2021-11-16","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: up to 2 years ]PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging[ Time Frame: up to 2 years ]PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: up to 3 years ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up."}],"first_posted":"No date provided","completion_date":"August 30, 2023","primary_completion_date":"August 30, 2022","start_date":"September 14, 2020","last_update_posted":"November 24, 2021"},{"nctid":"NCT00233402","version_a":1,"version_b":2,"version_a_date":"2005-10-04","version_b_date":"2006-09-18","pom_a":[{"label":"1.","content":"\xb7To compare Hexvix cystoscopy with white light cystoscopy in the detection of histology confirmed papillary bladder cancer in patients with papillary bladder cancer."},{"label":"2.","content":"\xb7To compare early recurrence rate after Hexvix and white light transurethral resection (TURB) with white light TURB in patients with superficial bladder cancer."}],"pom_b":[{"label":"1.","content":"To compare Hexvix cystoscopy with white light cystoscopy in the detection of histology confirmed papillary bladder cancer in patients with papillary bladder cancer."},{"label":"2.","content":"To compare early recurrence rate after Hexvix and white light transurethral resection (TURB) with white light TURB in patients with superficial bladder cancer."}],"first_posted":"October 11, 2013","completion_date":"August 2008","primary_completion_date":"July 2008","start_date":"January 2005","last_update_posted":"October 11, 2013"},{"nctid":"NCT00233402","version_a":3,"version_b":4,"version_a_date":"2007-04-26","version_b_date":"2007-11-05","pom_a":[{"label":"1.","content":"To compare Hexvix cystoscopy with white light cystoscopy in the detection of histology confirmed papillary bladder cancer in patients with papillary bladder cancer."},{"label":"2.","content":"To compare early recurrence rate after Hexvix and white light transurethral resection (TURB) with white light TURB in patients with superficial bladder cancer."}],"pom_b":[{"label":"1.","content":"To compare Hexvix cystoscopy with white light cystoscopy in the detection of histology confirmed papillary bladder cancer in patients with papillary bladder cancer.[ Time Frame: 9 months ]"},{"label":"2.","content":"To compare early recurrence rate after Hexvix and white light transurethral resection (TURB) with white light TURB in patients with superficial bladder cancer.[ Time Frame: 9 months ]"}],"first_posted":"October 11, 2013","completion_date":"August 2008","primary_completion_date":"July 2008","start_date":"January 2005","last_update_posted":"October 11, 2013"},{"nctid":"NCT00233402","version_a":6,"version_b":7,"version_a_date":"2009-09-11","version_b_date":"2013-08-05","pom_a":[{"label":"1.","content":"To compare Hexvix cystoscopy with white light cystoscopy in the detection of histology confirmed papillary bladder cancer in patients with papillary bladder cancer.[ Time Frame: 9 months ]"},{"label":"2.","content":"To compare early recurrence rate after Hexvix and white light transurethral resection (TURB) with white light TURB in patients with superficial bladder cancer.[ Time Frame: 9 months ]"}],"pom_b":[{"label":"1.","content":"Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White Light[ Time Frame: Day 0 ]"},{"label":"2.","content":"Comparison of the Proportions of Patients in the White Light Cystoscopy and Hexvix Groups Who Underwent TURB for a Histologically-confirmed Ta or T1 Tumor Who Had a Recurrence ( CIS, Ta, T1 or T2-T4 Tumor) Within 9 Months.[ Time Frame: 9 months ]"}],"first_posted":"October 11, 2013","completion_date":"August 2008","primary_completion_date":"July 2008","start_date":"January 2005","last_update_posted":"October 11, 2013"},{"nctid":"NCT00434148","version_a":13,"version_b":14,"version_a_date":"2009-04-01","version_b_date":"2009-04-14","pom_a":[{"label":"1.","content":"Efficacy assessed by urinary free cortisol levels after 6 months of treatment"}],"pom_b":[{"label":"1.","content":"Efficacy assessed by urinary free cortisol levels after 6 months of treatment[ Time Frame: 6 months ]"}],"first_posted":"February 6, 2013","completion_date":"May 2014","primary_completion_date":"March 2010","start_date":"December 2006","last_update_posted":"March 8, 2016"},{"nctid":"NCT00434148","version_a":17,"version_b":18,"version_a_date":"2012-03-09","version_b_date":"2013-01-03","pom_a":[{"label":"1.","content":"Efficacy assessed by urinary free cortisol levels after 6 months of treatment[ Time Frame: 6 months ]"}],"pom_b":[{"label":"1.","content":"Proportion of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group[ Time Frame: 6 months ]A responder in the primary efficacy analysis was a patient with a mUFC\u2264ULN at Month 6 and whose dose was not increased prior to Month 6."}],"first_posted":"February 6, 2013","completion_date":"May 2014","primary_completion_date":"March 2010","start_date":"December 2006","last_update_posted":"March 8, 2016"},{"nctid":"NCT00434148","version_a":21,"version_b":22,"version_a_date":"2014-10-31","version_b_date":"2015-08-06","pom_a":[{"label":"1.","content":"Proportion of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group[ Time Frame: 6 months ]A responder in the primary efficacy analysis was a patient with a mUFC\u2264ULN at Month 6 and whose dose was not increased prior to Month 6."}],"pom_b":[{"label":"1.","content":"Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group[ Time Frame: 6 months ]A responder in the primary efficacy analysis was a patient with a mUFC\u2264ULN at Month 6 and whose dose was not increased prior to Month 6."}],"first_posted":"February 6, 2013","completion_date":"May 2014","primary_completion_date":"March 2010","start_date":"December 2006","last_update_posted":"March 8, 2016"},{"nctid":"NCT00068952","version_a":3,"version_b":4,"version_a_date":"2006-07-24","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy"}],"first_posted":"No date provided","completion_date":"March 2006","primary_completion_date":"No date provided","start_date":"August 2003","last_update_posted":"April 1, 2008"},{"nctid":"NCT02320292","version_a":3,"version_b":4,"version_a_date":"2016-01-07","version_b_date":"2016-06-15","pom_a":[{"label":"1.","content":"Complete response rate at the 6-month disease assessment[ Time Frame: 6 months ]Will be compared between the two arms. The percentage of patients in each response category (e.g., CR, partial remission, stable disease, relapse/progressive disease) will also be tabulated by arm. The proportion of patients who have a CR at 6 months will be evaluated and compared between the two treatment regimens using a two-sided alpha=0.05 continuity corrected Cochran-Mantel-Haenszel test with stratification factors."}],"pom_b":[{"label":"1.","content":"Complete response (CR) rate at the 6-month disease assessment[ Time Frame: 6 months ]Will be compared between the two arms. The percentage of patients in each response category (e.g., CR, partial remission, stable disease, relapse/progressive disease) will also be tabulated by arm. The proportion of patients who have a CR at 6 months will be evaluated and compared between the two treatment regimens using a two-sided alpha=0.05 continuity corrected Cochran-Mantel-Haenszel test with stratification factors."}],"first_posted":"No date provided","completion_date":"January 2, 2026","primary_completion_date":"January 6, 2023","start_date":"February 11, 2015","last_update_posted":"February 7, 2022"},{"nctid":"NCT03555422","version_a":2,"version_b":3,"version_a_date":"2018-06-13","version_b_date":"2019-09-19","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: 30 months after FPI ]Compare progression free survival (PFS) of the two treatment arms"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: 30 months after FPI ]Compare progression free survival (PFS) of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1."}],"first_posted":"No date provided","completion_date":"March 2023","primary_completion_date":"March 2023","start_date":"January 5, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT03555422","version_a":6,"version_b":7,"version_a_date":"2019-12-31","version_b_date":"2020-07-09","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: 30 months after FPI ]Compare progression free survival (PFS) of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled) ]Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1."}],"first_posted":"No date provided","completion_date":"March 2023","primary_completion_date":"March 2023","start_date":"January 5, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT00046683","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2006-03-28","pom_a":[],"pom_b":[{"label":"1.","content":"Campath vs. chlorambucil"}],"first_posted":"No date provided","completion_date":"June 2006","primary_completion_date":"No date provided","start_date":"July 2001","last_update_posted":"July 28, 2016"},{"nctid":"NCT00033254","version_a":10,"version_b":11,"version_a_date":"2009-08-29","version_b_date":"2012-12-21","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 6 years ]The log-rank statistic will be used."},{"label":"2.","content":"Time to tumor progression[ Time Frame: Date of randomization to documentation of progression, assessed up to 6 years ]Cumulative incidence model will be used to analyze the data. A multivariate Cox model analysis will be performed."},{"label":"3.","content":"Time to neuro-cognitive progression as assessed by the Mini Mental State Exam[ Time Frame: Up to 6 years ]Cumulative incidence model will be used to analyze the data."}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"May 2006","start_date":"March 2002","last_update_posted":"October 30, 2020"},{"nctid":"NCT00420160","version_a":2,"version_b":3,"version_a_date":"2008-07-15","version_b_date":"2015-04-10","pom_a":[{"label":"1.","content":"7-day point prevalence smoking abstinence verified by saliva cotinine taken post-intervention (8 weeks after baseline)"}],"pom_b":[{"label":"1.","content":"7-day point prevalence smoking abstinence verified by saliva cotinine taken[ Time Frame: post-intervention (8 weeks after baseline) ]"}],"first_posted":"No date provided","completion_date":"December 2008","primary_completion_date":"June 2008","start_date":"February 2007","last_update_posted":"April 14, 2015"},{"nctid":"NCT00191646","version_a":11,"version_b":12,"version_a_date":"2007-04-04","version_b_date":"2007-12-20","pom_a":[{"label":"1.","content":"- To compare the efficacy of Gemcitabine and Carboplatin +/- Paclitaxel consolidation to Paclitaxel and Carboplatin +/- Paclitaxel consolidation. Efficacy will be determined through the analysis of overall survival."}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: baseline to measured progressive disease ]"}],"first_posted":"September 9, 2010","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"October 2002","last_update_posted":"March 4, 2011"},{"nctid":"NCT00191646","version_a":13,"version_b":14,"version_a_date":"2009-08-20","version_b_date":"2010-08-12","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: baseline to measured progressive disease ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Baseline to measured progressive disease or death up to 82 months ]Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for patients who were still alive and who had not progressed."}],"first_posted":"September 9, 2010","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"October 2002","last_update_posted":"March 4, 2011"},{"nctid":"NCT00191646","version_a":14,"version_b":15,"version_a_date":"2010-08-12","version_b_date":"2010-10-13","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Baseline to measured progressive disease or death up to 82 months ]Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for patients who were still alive and who had not progressed."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Baseline to measured progressive disease or death up to 82 months ]Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for patients who were still alive and who had not progressed."}],"first_posted":"September 9, 2010","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"October 2002","last_update_posted":"March 4, 2011"},{"nctid":"NCT00191646","version_a":15,"version_b":16,"version_a_date":"2010-10-13","version_b_date":"2011-02-28","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Baseline to measured progressive disease or death up to 82 months ]Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for patients who were still alive and who had not progressed."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Baseline to measured progressive disease or death up to 82 months ]Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies."}],"first_posted":"September 9, 2010","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"October 2002","last_update_posted":"March 4, 2011"},{"nctid":"NCT00427375","version_a":1,"version_b":2,"version_a_date":"2007-01-26","version_b_date":"2007-05-29","pom_a":[{"label":"1.","content":"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after"}],"pom_b":[{"label":"1.","content":"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after[ Time Frame: 24 months ]"}],"first_posted":"No date provided","completion_date":"February 8, 2018","primary_completion_date":"December 2014","start_date":"March 5, 2007","last_update_posted":"March 14, 2018"},{"nctid":"NCT02747043","version_a":17,"version_b":18,"version_a_date":"2017-08-31","version_b_date":"2017-10-04","pom_a":[{"label":"1.","content":"Risk difference (RD) of objective response rate (ORR)[ Time Frame: Week 28 ]"}],"pom_b":[{"label":"1.","content":"Risk difference (RD) of objective response rate (ORR)[ Time Frame: Week 28 ]"},{"label":"2.","content":"Risk difference (RD) of overall response rate (ORR)[ Time Frame: Week 28 ]"}],"first_posted":"August 18, 2020","completion_date":"June 28, 2019","primary_completion_date":"June 28, 2019","start_date":"May 25, 2016","last_update_posted":"September 10, 2022"},{"nctid":"NCT02747043","version_a":52,"version_b":53,"version_a_date":"2019-10-23","version_b_date":"2020-08-07","pom_a":[{"label":"1.","content":"Risk difference (RD) of objective response rate (ORR)[ Time Frame: Week 28 ]"},{"label":"2.","content":"Risk difference (RD) of overall response rate (ORR)[ Time Frame: Week 28 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease[ Time Frame: Post treatment up to Week 28 ]Overall response within the first treatment cycle was assessed according to International Working Group - Non-Hodgkin Lymphoma criteria (IWG-NHL criteria [Cheson et al, 1999]) by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement), and bone marrow biopsy (to assess bone marrow infiltration). ORR was the percentage of participants with a best overall response of complete response (CR), unconfirmed complete response (CRu) or partial response (PR). Participants that do not meet the criteria for response were considered non-responders.CR was defined as no evidence of disease. CRu showed nodes in the original sum of the products (SPD) regressed by >75% and/or indeterminate bone marrow results.PR was a \u2265 50% decrease in SPD of the six largest dominant nodes; >=50% decrease in liver and spleen nodes, and no increase in size of other nodes nor any new sites of disease."}],"first_posted":"August 18, 2020","completion_date":"June 28, 2019","primary_completion_date":"June 28, 2019","start_date":"May 25, 2016","last_update_posted":"September 10, 2022"},{"nctid":"NCT02358031","version_a":46,"version_b":47,"version_a_date":"2016-06-21","version_b_date":"2016-08-12","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Central Radiology Review[ Time Frame: Up to 5 years ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PDL1)-Positive Expression[ Time Frame: Up to 3 Years ]"},{"label":"2.","content":"Overall Survival in Participants With PDL1-Postive Expression[ Time Frame: Up tp 5 Years ]"},{"label":"3.","content":"PFS per RECIST 1.1 by BICR in All Participants[ Time Frame: Up to 3 Years ]"},{"label":"4.","content":"Overall Survival in All Participants[ Time Frame: Up to 5 Years ]"}],"first_posted":"February 17, 2020","completion_date":"April 14, 2023","primary_completion_date":"February 25, 2019","start_date":"March 19, 2015","last_update_posted":"August 19, 2022"},{"nctid":"NCT02358031","version_a":64,"version_b":65,"version_a_date":"2019-11-26","version_b_date":"2020-02-03","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PDL1)-Positive Expression[ Time Frame: Up to 3 Years ]"},{"label":"2.","content":"Overall Survival in Participants With PDL1-Postive Expression[ Time Frame: Up tp 5 Years ]"},{"label":"3.","content":"PFS per RECIST 1.1 by BICR in All Participants[ Time Frame: Up to 3 Years ]"},{"label":"4.","content":"Overall Survival in All Participants[ Time Frame: Up to 5 Years ]"}],"pom_b":[{"label":"1.","content":"Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD.Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the Intent-To-Treat (ITT) population. PFS is reported here for all participants in the pembro combo arm and control arm. Per protocol, PFS was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record."},{"label":"2.","content":"Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) \u22651[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD.Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by immunohistochemistry (IHC) as Combined Positive Score \u22651 (hereafter referred to as CPS \u22651). Per protocol, PFS was compared separately between CPS \u22651 participants of the pembro mono arm and control arm and is presented later in the record."},{"label":"3.","content":"Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS \u226520[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD.Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as Combined Positive Score \u226520 (hereafter referred to as CPS \u226520). Per protocol, PFS was compared separately between CPS \u226520 participants of the pembro mono arm and control arm and is presented later in the record."},{"label":"4.","content":"Pembro Combo vs Control: Overall Survival (OS) in All Participants[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm. Per protocol, OS was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record."},{"label":"5.","content":"Pembro Combo vs Control: OS in Participants With PD-L1 CPS \u22651[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS \u22651. Per protocol, OS was compared separately between CPS \u22651 participants of the pembro mono arm and control arm and is presented later in the record."},{"label":"6.","content":"Pembro Combo vs Control: OS in Participants With PD-L1 CPS \u226520[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS \u226520. Per protocol, OS was compared separately between CPS \u226520 participants of the pembro mono arm and control arm and is presented later in the record."},{"label":"7.","content":"Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in All Participants[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD.Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm. Per protocol, PFS was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record."},{"label":"8.","content":"Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS \u22651[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD.Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS \u22651. Per protocol, PFS was compared separately between CPS \u22651 participants of the pembro combo arm and control arm and is presented earlier in the record."},{"label":"9.","content":"Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS \u226520[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD.Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS \u226520. Per protocol, PFS was compared separately between CPS \u226520 participants of the pembro combo arm and control arm and is presented earlier in the record."},{"label":"10.","content":"Pembro Mono vs Control: OS in All Participants[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm. Per protocol, OS was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record."},{"label":"11.","content":"Pembro Mono vs Control: OS in Participants With PD-L1 CPS \u22651[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS \u22651. Per protocol, OS was compared separately between CPS \u22651 participants of the pembro combo arm and control arm and is presented earlier in the record."},{"label":"12.","content":"Pembro Mono vs Control: OS in Participants With PD-L1 CPS \u226520[ Time Frame: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019) ]OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS \u226520. Per protocol, OS was compared separately between CPS \u226520 participants of the pembro combo arm and control arm and is presented earlier in the record."}],"first_posted":"February 17, 2020","completion_date":"April 14, 2023","primary_completion_date":"February 25, 2019","start_date":"March 19, 2015","last_update_posted":"August 19, 2022"},{"nctid":"NCT03799835","version_a":4,"version_b":5,"version_a_date":"2020-05-11","version_b_date":"2021-03-24","pom_a":[{"label":"1.","content":"Recurrence free survival[ Time Frame: 2 years ]Defined as the time from randomization to the time of first recurrence event or death. Recurrence is defined as reappearance of disease (local recurrence or occurrence of any metastasis) after the start of therapy."}],"pom_b":[{"label":"1.","content":"Recurrence-free survival[ Time Frame: 2 years ]Recurrence is defined as reappearance of disease (local recurrence or occurrence of any metastasis) after the start of therapy."}],"first_posted":"No date provided","completion_date":"February 1, 2028","primary_completion_date":"April 1, 2024","start_date":"January 17, 2019","last_update_posted":"May 31, 2022"},{"nctid":"NCT00917306","version_a":4,"version_b":5,"version_a_date":"2010-09-22","version_b_date":"2010-10-06","pom_a":[{"label":"1.","content":"To evaluate the safety of PEP005 Gel when applied to patients with actinic keratosis[ Time Frame: 57 days ]"}],"pom_b":[{"label":"1.","content":"Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)[ Time Frame: 57 days ]"}],"first_posted":"No date provided","completion_date":"September 2009","primary_completion_date":"September 2009","start_date":"June 2009","last_update_posted":"April 15, 2015"},{"nctid":"NCT02373371","version_a":2,"version_b":3,"version_a_date":"2015-08-31","version_b_date":"2019-01-09","pom_a":[{"label":"1.","content":"Percent change from baseline in total number of treated mild lesions per side at week 12[ Time Frame: Baseline and Week 12 ]Percent change from baseline in total number of treated mild lesions per side at week 12"}],"pom_b":[{"label":"1.","content":"Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12[ Time Frame: Baseline and Week 12 ]The number of lesions is assessed at baseline (before treatment) and 12 weeks later.The difference in lesions is recorded for each patient. The mean of disappeared lesions are then calculated for all patients."}],"first_posted":"April 8, 2019","completion_date":"June 1, 2018","primary_completion_date":"November 22, 2016","start_date":"March 25, 2015","last_update_posted":"April 8, 2019"},{"nctid":"NCT04211337","version_a":44,"version_b":45,"version_a_date":"2021-12-08","version_b_date":"2022-03-01","pom_a":[{"label":"1.","content":"Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)[ Time Frame: Baseline to Progressive Disease, Unacceptable Toxicity or Death from Any Cause (Estimated at up to 30 Months) ]TFFS by BICR"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) by BICR[ Time Frame: Baseline to Progressive Disease or Death from Any Cause (Estimated at up to 30 Months) ]PFS by BICR"}],"first_posted":"No date provided","completion_date":"November 13, 2026","primary_completion_date":"May 20, 2024","start_date":"February 11, 2020","last_update_posted":"September 9, 2022"},{"nctid":"NCT00127881","version_a":7,"version_b":8,"version_a_date":"2007-09-24","version_b_date":"2008-11-11","pom_a":[],"pom_b":[{"label":"1.","content":"PGA Score[ Time Frame: Duration of Study ]"}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"February 2014","start_date":"July 2005","last_update_posted":"July 26, 2012"},{"nctid":"NCT02684006","version_a":24,"version_b":25,"version_a_date":"2017-07-24","version_b_date":"2017-09-19","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: From randomization up to 30 months. ]Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) in PD-L1 positive patients[ Time Frame: From randomization up to 30 months. ]Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause."},{"label":"2.","content":"Overall Survival in PD-L1 positive patients[ Time Frame: Every 3 months up to 5 years ]OS is the time from date of randomization to date of death due to any cause."}],"first_posted":"No date provided","completion_date":"May 21, 2024","primary_completion_date":"May 21, 2024","start_date":"March 23, 2016","last_update_posted":"June 13, 2022"},{"nctid":"NCT02684006","version_a":44,"version_b":45,"version_a_date":"2020-01-28","version_b_date":"2020-02-21","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) in PD-L1 positive patients[ Time Frame: From randomization up to 30 months. ]Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause."},{"label":"2.","content":"Overall Survival in PD-L1 positive patients[ Time Frame: Every 3 months up to 5 years ]OS is the time from date of randomization to date of death due to any cause."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) in PD-L1 positive patients[ Time Frame: From randomization up to 40 months. ]Progression Free Survival (PFS) is the time from randomization to date of first documentation of objective progression of disease assessed by BICR (by RECIST version 1.1) or death due to any cause."},{"label":"2.","content":"Overall Survival in PD-L1 positive patients[ Time Frame: Every 3 months up to 8 years ]OS is the time from date of randomization to date of death due to any cause."}],"first_posted":"No date provided","completion_date":"May 21, 2024","primary_completion_date":"May 21, 2024","start_date":"March 23, 2016","last_update_posted":"June 13, 2022"},{"nctid":"NCT03780959","version_a":1,"version_b":2,"version_a_date":"2018-12-18","version_b_date":"2019-06-10","pom_a":[{"label":"1.","content":"Percentage of Participants with Disease Flare in Part 2[ Time Frame: Months 4 to 7 ]Disease flare was defined as a 30% or greater worsening in three of the six JRA Core Set Criteria and 30% or greater improvement in not more than one of the six JRA Core Set Criteria and a minimum of two active joints (swollen or limitation of movement plus pain and/or tenderness)."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Disease Flare in Part 2[ Time Frame: End of part 1 (day 90) and months 4 to 7 ]Disease flare was defined as a 30% or greater worsening in three of the six JRA Core Set Criteria and \u2265 30% improvement in one or less of the six JRA Core Set Criteria compared to day 90 and a minimum of two active joints (joints with swelling or limitation of movement plus pain and/or tenderness).The JRA Core Set criteria consisted of:Physician global assessment of disease severity assessed on a visual analog scale (VAS) from 0 (asymptomatic) to 10 (severe symptoms);Patient/parent global assessment of overall well-being assesses on a VAS from 0 (asymptomatic) to 10 (severe symptoms);Number of active joints;Number of joints with limitation of motion (LOM) and with pain, tenderness, or both;Childhood Health Assessment Questionnaire (CHAQ) disability domain;Erythrocyte sedimentation rate (ESR)."}],"first_posted":"August 2, 2019","completion_date":"July 8, 1998","primary_completion_date":"July 8, 1998","start_date":"May 1, 1997","last_update_posted":"August 2, 2019"},{"nctid":"NCT01984697","version_a":17,"version_b":18,"version_a_date":"2015-10-29","version_b_date":"2016-03-23","pom_a":[{"label":"1.","content":"HPV-9 Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) to HPV types at 4 weeks post last dose[ Time Frame: 4 weeks following the last dose of vaccine ]"}],"pom_b":[{"label":"1.","content":"Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"2.","content":"Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"3.","content":"Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"4.","content":"Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"5.","content":"Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"6.","content":"Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"7.","content":"Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"9.","content":"Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."}],"first_posted":"April 26, 2016","completion_date":"July 24, 2017","primary_completion_date":"June 19, 2015","start_date":"December 12, 2013","last_update_posted":"August 8, 2018"},{"nctid":"NCT01984697","version_a":24,"version_b":25,"version_a_date":"2017-07-28","version_b_date":"2018-06-14","pom_a":[{"label":"1.","content":"Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"2.","content":"Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"3.","content":"Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"4.","content":"Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"5.","content":"Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"6.","content":"Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"7.","content":"Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"9.","content":"Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503[ Time Frame: 4 weeks after the last dose of V503 (Month 7 or Month 13) ]Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."}],"pom_b":[{"label":"1.","content":"Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"2.","content":"Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"3.","content":"Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"4.","content":"Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"5.","content":"Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"6.","content":"Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"7.","content":"Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."},{"label":"9.","content":"Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen[ Time Frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13) ]Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL)."}],"first_posted":"April 26, 2016","completion_date":"July 24, 2017","primary_completion_date":"June 19, 2015","start_date":"December 12, 2013","last_update_posted":"August 8, 2018"},{"nctid":"NCT00128310","version_a":1,"version_b":2,"version_a_date":"2005-08-08","version_b_date":"2005-09-08","pom_a":[{"label":"1.","content":"Progression-free survival in both treatment arms."}],"pom_b":[{"label":"1.","content":"Progression-free survival in both treatment arms"}],"first_posted":"No date provided","completion_date":"January 24, 2008","primary_completion_date":"August 15, 2006","start_date":"January 18, 2001","last_update_posted":"February 21, 2019"},{"nctid":"NCT00128310","version_a":3,"version_b":4,"version_a_date":"2007-02-06","version_b_date":"2019-02-19","pom_a":[{"label":"1.","content":"Progression-free survival in both treatment arms"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: Through study completion, an average of 1 year ]Progression-free survival is calculated as the time from randomization to the first observation of disease progression or date of death (whichever occurs earlier). Progression-free survival time will be censored at the time of the most recent information for patients who are still alive at the time of the last visit."}],"first_posted":"No date provided","completion_date":"January 24, 2008","primary_completion_date":"August 15, 2006","start_date":"January 18, 2001","last_update_posted":"February 21, 2019"},{"nctid":"NCT02031432","version_a":14,"version_b":15,"version_a_date":"2016-05-10","version_b_date":"2020-01-14","pom_a":[{"label":"1.","content":"Absolute and relative frequencies of Treatment Emergent Adverse Event (TEAEs)[ Time Frame: Day 2; end of week 28 ]Any adverse event that occurs after the first intake of cebranopadol."}],"pom_b":[{"label":"1.","content":"Number of Participants With Treatment Emergent Adverse Event (TEAEs)[ Time Frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose) ]The safety of cebranopadol was assessed by the number of participants with treatment emergent adverse events (TEAEs). A TEAE was any adverse event that occurred after the first administration of investigational medicinal product (IMP), i.e., cebranopadol in this study. In addition, pretreatment adverse events which worsened during the treatment period were also considered TEAEs."}],"first_posted":"January 18, 2020","completion_date":"May 3, 2016","primary_completion_date":"April 2016","start_date":"December 18, 2013","last_update_posted":"July 15, 2021"},{"nctid":"NCT01407068","version_a":6,"version_b":7,"version_a_date":"2013-03-20","version_b_date":"2015-02-04","pom_a":[{"label":"1.","content":"Percent change from baseline in total fixed flexion[ Time Frame: Day 30 ]Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment."}],"pom_b":[{"label":"1.","content":"Percent Change From Baseline in Total Fixed Flexion[ Time Frame: Day 30 ]Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment."}],"first_posted":"February 20, 2015","completion_date":"February 2012","primary_completion_date":"February 2012","start_date":"September 2011","last_update_posted":"October 5, 2017"},{"nctid":"NCT01407068","version_a":7,"version_b":8,"version_a_date":"2015-02-04","version_b_date":"2015-04-20","pom_a":[{"label":"1.","content":"Percent Change From Baseline in Total Fixed Flexion[ Time Frame: Day 30 ]Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment."}],"pom_b":[{"label":"1.","content":"Percent Change From Baseline in Total Fixed Flexion[ Time Frame: 30 days after last injection ]Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment. Change in fixed-flexion contracture is measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees"},{"label":"2.","content":"Change in Total Range of Motion[ Time Frame: 30 days after last injection ]The total range of motion is the sum of the range of motion measurements of the two treated joints. Range of motion is defined as difference between full flexion angle and full extension angle expressed in degrees."}],"first_posted":"February 20, 2015","completion_date":"February 2012","primary_completion_date":"February 2012","start_date":"September 2011","last_update_posted":"October 5, 2017"},{"nctid":"NCT00726622","version_a":170,"version_b":171,"version_a_date":"2011-04-07","version_b_date":"2012-08-17","pom_a":[{"label":"1.","content":"Circumferential margin > 1 mm"},{"label":"2.","content":"Distal resected margin > 2 cm (or > 1 cm with clear frozen section in the low rectum)"},{"label":"3.","content":"Completeness of total mesorectal excision"}],"pom_b":[{"label":"1.","content":"Circumferential margin > 1 mm"},{"label":"2.","content":"Negative distal resected margin"},{"label":"3.","content":"Completeness of total mesorectal excision (complete or nearly complete)"}],"first_posted":"November 11, 2016","completion_date":"August 1, 2019","primary_completion_date":"October 2013","start_date":"August 2008","last_update_posted":"May 7, 2020"},{"nctid":"NCT00726622","version_a":180,"version_b":181,"version_a_date":"2013-02-07","version_b_date":"2014-05-13","pom_a":[{"label":"1.","content":"Circumferential margin > 1 mm"},{"label":"2.","content":"Negative distal resected margin"},{"label":"3.","content":"Completeness of total mesorectal excision (complete or nearly complete)"}],"pom_b":[{"label":"1.","content":"Circumferential margin > 1 mm[ Time Frame: At time of surgery ]"},{"label":"2.","content":"Negative distal resected margin[ Time Frame: At time of surgery ]"},{"label":"3.","content":"Completeness of total mesorectal excision (complete or nearly complete)[ Time Frame: At time of surgery ]"}],"first_posted":"November 11, 2016","completion_date":"August 1, 2019","primary_completion_date":"October 2013","start_date":"August 2008","last_update_posted":"May 7, 2020"},{"nctid":"NCT00726622","version_a":183,"version_b":184,"version_a_date":"2016-07-01","version_b_date":"2016-09-23","pom_a":[{"label":"1.","content":"Circumferential margin > 1 mm[ Time Frame: At time of surgery ]"},{"label":"2.","content":"Negative distal resected margin[ Time Frame: At time of surgery ]"},{"label":"3.","content":"Completeness of total mesorectal excision (complete or nearly complete)[ Time Frame: At time of surgery ]"}],"pom_b":[{"label":"1.","content":"Non-Inferiority Analysis Between Laparoscopic-assisted Resection and Open Rectal Resection for Rectal Cancer.[ Time Frame: At time of Surgery ]The primary aim is to test the hypothesis that laparoscopic-assisted resection for rectal cancer is not inferior to open rectal resection. The primary endpoint will be a composite endpoint of oncologic factors which are indicative of an adequate surgical resection based on pathologic evaluation.Primary endpoint parameters:Circumferential margin > 1 mmNegative distal marginCompleteness of total mesorectal excision (TME) A complete TME is defined as a rectal resection specimen that has an intact mesorectum and covering peritoneal envelope all the way to the level of rectal transection with no coning in of the mesorectum above the point of transection. The surface of the peritoneal covering should be smooth and shiny with no defects exposing the underlying fat. A nearly complete TME is defined as a rectal resection specimen where the mesentery is all present, without coning or missing fat. A <5 mm deep defect may be present in the envelope covering mesenteric fat."}],"first_posted":"November 11, 2016","completion_date":"August 1, 2019","primary_completion_date":"October 2013","start_date":"August 2008","last_update_posted":"May 7, 2020"},{"nctid":"NCT00726622","version_a":184,"version_b":185,"version_a_date":"2016-09-23","version_b_date":"2017-02-15","pom_a":[{"label":"1.","content":"Non-Inferiority Analysis Between Laparoscopic-assisted Resection and Open Rectal Resection for Rectal Cancer.[ Time Frame: At time of Surgery ]The primary aim is to test the hypothesis that laparoscopic-assisted resection for rectal cancer is not inferior to open rectal resection. The primary endpoint will be a composite endpoint of oncologic factors which are indicative of an adequate surgical resection based on pathologic evaluation.Primary endpoint parameters:Circumferential margin > 1 mmNegative distal marginCompleteness of total mesorectal excision (TME) A complete TME is defined as a rectal resection specimen that has an intact mesorectum and covering peritoneal envelope all the way to the level of rectal transection with no coning in of the mesorectum above the point of transection. The surface of the peritoneal covering should be smooth and shiny with no defects exposing the underlying fat. A nearly complete TME is defined as a rectal resection specimen where the mesentery is all present, without coning or missing fat. A <5 mm deep defect may be present in the envelope covering mesenteric fat."}],"pom_b":[{"label":"1.","content":"Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on Pathological Evaluation.[ Time Frame: At time of Surgery ]The primary endpoint will be a composite endpoint of oncologic factors which are indicative of an adequate surgical resection based on pathologic evaluation.Primary endpoint parameters:Circumferential margin > 1 mmNegative distal marginCompleteness of total mesorectal excision (TME) A complete TME is a rectal resection specimen that has an intact mesorectum and covering peritoneal envelope all the way to the level of rectal transection with no coning in of the mesorectum above the point of transection. The surface of the peritoneal covering should be smooth and shiny with no defects exposing the underlying fat.All three criteria must be met for a resection to be deemed adequate. Laparoscopic-assisted resection will be compared to Open rectal resection to determine if it is non-inferior."}],"first_posted":"November 11, 2016","completion_date":"August 1, 2019","primary_completion_date":"October 2013","start_date":"August 2008","last_update_posted":"May 7, 2020"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,T.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,j.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,j.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,j.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,L.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,u=n.breakpoints,c=[];r&&(c=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,u,t));var d=[];return u.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,j.Z)(c),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var u="".concat(Math.round(t/l*1e8)/1e6,"%"),c={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var p="calc(".concat(u," + ").concat(ie(d),")");c={flexBasis:p,maxWidth:p}}}i=(0,r.Z)({flexBasis:u,flexGrow:0,maxWidth:u},c)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ue=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,u=[];n&&(u=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var c=[];l.forEach((function(t){var n=e[t];n&&c.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,j.Z)(u),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],c)};return(0,k.Z)(d,te,t)},ce=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,H.Z)(m.Z).breakpoints,s=U(o),l=s.className,u=s.columns,c=s.columnSpacing,d=s.component,f=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,b=s.direction,y=void 0===b?"row":b,g=s.item,_=void 0!==g&&g,P=s.rowSpacing,T=s.spacing,k=void 0===T?0:T,C=s.wrap,x=void 0===C?"wrap":C,F=s.zeroMinWidth,A=void 0!==F&&F,E=(0,w.Z)(s,oe),N=P||k,R=c||k,M=e.useContext(X),O=v?u||12:M,L={},D=(0,r.Z)({},E);i.keys.forEach((function(e){null!=E[e]&&(L[e]=E[e],delete D[e])}));var z=(0,r.Z)({},s,{columns:O,container:v,direction:y,item:_,rowSpacing:N,columnSpacing:R,wrap:x,zeroMinWidth:A,spacing:k},L,{breakpoints:i.keys}),I=ue(z);return(0,p.jsx)(X.Provider,{value:O,children:(0,p.jsx)(le,(0,r.Z)({ownerState:z,className:(0,S.Z)(I.root,l),as:f,ref:n},D))})})),de=ce,pe=n(2065);function fe(e){return(0,T.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,L.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,pe.Fq)("#fff",he(a.elevation)),", ").concat((0,pe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),be=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,u=void 0===l?1:l,c=n.square,d=void 0!==c&&c,f=n.variant,m=void 0===f?"elevation":f,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:u,square:d,variant:m}),b=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,k.Z)(o,fe,a)}(v);return(0,p.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(b.root,o),ref:t},h))}));function ye(e){return(0,T.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,L.ZP)(be,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),u=(0,r.Z)({},n,{raised:s}),c=function(e){var t=e.classes;return(0,k.Z)({root:["root"]},ye,t)}(u);return(0,p.jsx)(_e,(0,r.Z)({className:(0,S.Z)(c.root,o),elevation:s?8:void 0,ref:t,ownerState:u},l))}));function Se(e){return(0,T.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var Pe=["className","component"],Te=(0,L.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),ke=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,Pe),u=(0,r.Z)({},n,{component:s}),c=function(e){var t=e.classes;return(0,k.Z)({root:["root"]},Se,t)}(u);return(0,p.jsx)(Te,(0,r.Z)({as:s,className:(0,S.Z)(c.root,o),ownerState:u,ref:t},l))}));function Ce(e){return(0,T.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var xe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Fe=(0,L.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,O.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Ae={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Ee={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Ne=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Ee[e]||e}(n.color),i=U((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,u=i.className,c=i.component,d=i.gutterBottom,f=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,b=void 0!==v&&v,y=i.variant,g=void 0===y?"body1":y,_=i.variantMapping,P=void 0===_?Ae:_,T=(0,w.Z)(i,xe),C=(0,r.Z)({},i,{align:l,color:o,className:u,component:c,gutterBottom:f,noWrap:h,paragraph:b,variant:g,variantMapping:P}),x=c||(b?"p":P[g]||Ae[g])||"span",F=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,O.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,k.Z)(s,Ce,i)}(C);return(0,p.jsx)(Fe,(0,r.Z)({as:x,ref:t,ownerState:C,className:(0,S.Z)(F.root,u)},T))})),Re=n(5682),Me=["component","direction","spacing","divider","children"];function Oe(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var Le=(0,L.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Re.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,V.Z)(a,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Re.NA)(o,e))};var r})))}return a=(0,Y.dt)(n.breakpoints,a)})),De=e.forwardRef((function(e,t){var n=U((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,u=n.spacing,c=void 0===u?0:u,d=n.divider,f=n.children,m=(0,w.Z)(n,Me),h={direction:l,spacing:c};return(0,p.jsx)(Le,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Oe(f,d):f}))})),ze=De,Ie=n(1774),Ze=n.n(Ie);var je=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,p.jsx)(we,{children:(0,p.jsx)(ke,{children:(0,p.jsxs)(Ne,{children:[(0,p.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,p.jsxs)(de,{container:!0,spacing:2,children:[(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsx)(ke,{children:(0,p.jsxs)(de,{container:!0,children:[(0,p.jsxs)(de,{item:!0,xs:4,children:[(0,p.jsxs)(Ne,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,p.jsxs)(Ne,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,p.jsxs)(Ne,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,p.jsxs)(Ne,{children:["Start Date: ",t.start_date]}):null]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,p.jsxs)(Ne,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,p.jsxs)(Ne,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(ke,{children:[(0,p.jsxs)(Ne,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,p.jsx)(Ne,{variant:"caption"}),(0,p.jsx)(ze,{spacing:1,children:l(t.pom_a)})]})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(ke,{children:[(0,p.jsxs)(Ne,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,p.jsx)(ze,{spacing:1,children:l(t.pom_b)})]})})}),(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsxs)(ke,{children:[(0,p.jsx)(Ne,{variant:"h6",children:"Compare the Raw Text"}),(0,p.jsx)(Ze(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Ie.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Ve(e){return(0,T.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var Be=["className","color","enableColorOnDark","position"],We=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ue=(0,L.ZP)(be,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,O.Z)(n.position))],t["color".concat((0,O.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:We(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:We(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:We(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:We(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),He=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,u=void 0!==l&&l,c=n.position,d=void 0===c?"fixed":c,f=(0,w.Z)(n,Be),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:u}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,O.Z)(t)),"position".concat((0,O.Z)(n))]};return(0,k.Z)(a,Ve,r)}(m);return(0,p.jsx)(Ue,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},f))}));function Je(e){return(0,T.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var $e=["className","component","disableGutters","variant"],Ge=(0,L.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,u=void 0!==l&&l,c=n.variant,d=void 0===c?"regular":c,f=(0,w.Z)(n,$e),m=(0,r.Z)({},n,{component:s,disableGutters:u,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,k.Z)(n,Je,t)}(m);return(0,p.jsx)(Ge,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},f))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var u=a[l][r];s[a[l][r]]=n(u)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,u=i in a,c=n[i],d=(0,e.isValidElement)(c)&&!c.props.in;!u||l&&!d?u||!l||d?u&&l&&(0,e.isValidElement)(c)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:c.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,u=t.in,c=t.onExited,d=t.timeout,f=e.useState(!1),m=(0,g.Z)(f,2),h=m[0],v=m[1],b=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),y={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return u||h||v(!0),e.useEffect((function(){if(!u&&null!=c){var e=setTimeout(c,d);return function(){clearTimeout(e)}}}),[c,u,d]),(0,p.jsx)("span",{className:b,style:y,children:(0,p.jsx)("span",{className:_})})};var ut,ct,dt,pt,ft,mt,ht,vt,bt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),yt=["center","classes","className"],gt=d(ft||(ft=ut||(ut=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ct||(ct=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,L.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),Pt=(0,L.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=pt||(pt=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),bt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),bt.child,bt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Tt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,u=void 0===l?{}:l,c=o.className,d=(0,w.Z)(o,yt),f=e.useState([]),m=(0,g.Z)(f,2),h=m[0],v=m[1],b=e.useRef(0),y=e.useRef(null);e.useEffect((function(){y.current&&(y.current(),y.current=null)}),[h]);var _=e.useRef(!1),P=e.useRef(null),T=e.useRef(null),k=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(P.current)}}),[]);var C=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,j.Z)(e),[(0,p.jsx)(Pt,{classes:{ripple:(0,S.Z)(u.ripple,bt.ripple),rippleVisible:(0,S.Z)(u.rippleVisible,bt.rippleVisible),ripplePulsate:(0,S.Z)(u.ripplePulsate,bt.ripplePulsate),child:(0,S.Z)(u.child,bt.child),childLeaving:(0,S.Z)(u.childLeaving,bt.childLeaving),childPulsate:(0,S.Z)(u.childPulsate,bt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},b.current)])})),b.current+=1,y.current=o}),[u]),x=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,u=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var c,d,p,f=u?null:k.current,m=f?f.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)c=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,b=h.clientY;c=Math.round(v-m.left),d=Math.round(b-m.top)}if(i)(p=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(p+=1);else{var y=2*Math.max(Math.abs((f?f.clientWidth:0)-c),c)+2,g=2*Math.max(Math.abs((f?f.clientHeight:0)-d),d)+2;p=Math.sqrt(Math.pow(y,2)+Math.pow(g,2))}null!=e&&e.touches?null===T.current&&(T.current=function(){C({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})},P.current=setTimeout((function(){T.current&&(T.current(),T.current=null)}),80)):C({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})}}),[s,C]),F=e.useCallback((function(){x({},{pulsate:!0})}),[x]),A=e.useCallback((function(e,t){if(clearTimeout(P.current),"touchend"===(null==e?void 0:e.type)&&T.current)return T.current(),T.current=null,void(P.current=setTimeout((function(){A(e,t)})));T.current=null,v((function(e){return e.length>0?e.slice(1):e})),y.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:F,start:x,stop:A}}),[F,x,A]),(0,p.jsx)(St,(0,r.Z)({className:(0,S.Z)(bt.root,u.root,c),ref:k},d,{children:(0,p.jsx)(st,{component:null,exit:!0,children:h})}))})),kt=Tt;function Ct(e){return(0,T.Z)("MuiButtonBase",e)}var xt,Ft=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),At=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Et=(0,L.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((xt={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(xt,"&.".concat(Ft.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(xt,"@media print",{colorAdjust:"exact"}),xt)),Nt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,u=o.children,c=o.className,d=o.component,f=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,b=void 0!==v&&v,y=o.disableTouchRipple,_=void 0!==y&&y,P=o.focusRipple,T=void 0!==P&&P,C=o.LinkComponent,x=void 0===C?"a":C,F=o.onBlur,A=o.onClick,E=o.onContextMenu,N=o.onDragLeave,R=o.onFocus,M=o.onFocusVisible,O=o.onKeyDown,L=o.onKeyUp,D=o.onMouseDown,z=o.onMouseLeave,I=o.onMouseUp,Z=o.onTouchEnd,j=o.onTouchMove,V=o.onTouchStart,B=o.tabIndex,W=void 0===B?0:B,U=o.TouchRippleProps,H=o.touchRippleRef,J=o.type,$=(0,w.Z)(o,At),G=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,H),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),G.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ue=se[1];e.useEffect((function(){ue(!0)}),[]);var ce=le&&!b&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&T&&!b&&le&&q.current.pulsate()}),[b,T,ae,le]);var pe=de("start",D),fe=de("stop",E),me=de("stop",N),he=de("stop",I),ve=de("stop",(function(e){ae&&e.preventDefault(),z&&z(e)})),be=de("start",V),ye=de("stop",Z),ge=de("stop",j),_e=de("stop",(function(e){ee(e),!1===Y.current&&oe(!1),F&&F(e)}),!1),we=(0,Qe.Z)((function(e){G.current||(G.current=e.currentTarget),X(e),!0===Y.current&&(oe(!0),M&&M(e)),R&&R(e)})),Se=function(){var e=G.current;return f&&"button"!==f&&!("A"===e.tagName&&e.href)},Pe=e.useRef(!1),Te=(0,Qe.Z)((function(e){T&&!Pe.current&&ae&&q.current&&" "===e.key&&(Pe.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),O&&O(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),A&&A(e))})),ke=(0,Qe.Z)((function(e){T&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(Pe.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),L&&L(e),A&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&A(e)})),Ce=f;"button"===Ce&&($.href||$.to)&&(Ce=x);var xe={};"button"===Ce?(xe.type=void 0===J?"button":J,xe.disabled=h):($.href||$.to||(xe.role="button"),h&&(xe["aria-disabled"]=h));var Fe=(0,Ke.Z)(te,G),Ae=(0,Ke.Z)(n,Fe);var Ee=(0,r.Z)({},o,{centerRipple:l,component:f,disabled:h,disableRipple:b,disableTouchRipple:_,focusRipple:T,tabIndex:W,focusVisible:ae}),Ne=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,k.Z)(o,Ct,a);return n&&r&&(i.root+=" ".concat(r)),i}(Ee);return(0,p.jsxs)(Et,(0,r.Z)({as:Ce,className:(0,S.Z)(Ne.root,c),ownerState:Ee,onBlur:_e,onClick:A,onContextMenu:fe,onFocus:we,onKeyDown:Te,onKeyUp:ke,onMouseDown:pe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:ye,onTouchMove:ge,onTouchStart:be,ref:Ae,tabIndex:h?-1:W,type:J},xe,$,{children:[u,ce?(0,p.jsx)(kt,(0,r.Z)({ref:K,center:l},U)):null]}))})),Rt=Nt;function Mt(e){return(0,T.Z)("MuiIconButton",e)}var Ot=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Lt=["edge","children","className","color","disabled","disableFocusRipple","size"],Dt=(0,L.ZP)(Rt,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,O.Z)(n.color))],n.edge&&t["edge".concat((0,O.Z)(n.edge))],t["size".concat((0,O.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Ot.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),zt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,u=n.color,c=void 0===u?"default":u,d=n.disabled,f=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,b=void 0===v?"medium":v,y=(0,w.Z)(n,Lt),g=(0,r.Z)({},n,{edge:i,color:c,disabled:f,disableFocusRipple:h,size:b}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,O.Z)(r)),a&&"edge".concat((0,O.Z)(a)),"size".concat((0,O.Z)(o))]};return(0,k.Z)(i,Mt,t)}(g);return(0,p.jsx)(Dt,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:f,ref:t,ownerState:g},y,{children:s}))})),It=n(2156),Zt=n(5129);n(8472),(0,G.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function jt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,p.jsx)(K,{sx:{flexGrow:1},children:(0,p.jsx)(He,{position:"static",children:(0,p.jsxs)(qe,{children:[(0,p.jsxs)(Ne,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,p.jsxs)(Ne,{component:"div",children:[t>0?(0,p.jsx)(zt,{color:"inherit",variant:"text",onClick:o,children:(0,p.jsx)(It.Z,{})}):null,t<r-1?(0,p.jsx)(zt,{color:"inherit",variant:"text",onClick:i,children:(0,p.jsx)(Zt.Z,{})}):null]})]})})})}for(var Vt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Bt=[],Wt=Q.e,Ut=Q.C,Ht=Ut.length,Jt=0;Jt<Ht;Jt++)Bt.push("");var $t=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Ut[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],u=(0,e.useState)(Bt),c=(0,g.Z)(u,2),d=c[0],f=c[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],b=h[1];return(0,e.useEffect)((function(){l(Ut[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Ht;t++){var n={};n.nctid=Ut[t].nctid,n.version_a=Ut[t].version_a,n.version_b=Ut[t].version_b,n.classification_number=d[t],n.classification_meaning=Vt[d[t]],e.push(n)}b(e)}),[d]),(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(jt,{datumNumber:r,setDatumNumber:a,numComparisons:Ht,outputData:v,batchNum:Wt}),(0,p.jsx)(z,{children:(0,p.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,p.jsx)(je,{datum:s,datumNumber:r,results:d,setResults:f})})})]})};t.createRoot(document.getElementById("root")).render((0,p.jsxs)(e.StrictMode,{children:[(0,p.jsx)(y,{}),(0,p.jsx)($t,{})]}))}()}();
//# sourceMappingURL=main.665f88dc.js.map